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Summary 
Somatic evolution in human blood and colon 
Henry Lee-Six 
 
All cancers were once normal cells. They became cancerous through the chance 
acquisition of particular somatic mutations that gave them a selective advantage over their 
neighbours. Thus, the mutations that initiate cancer occur in normal cells, and the normal clonal 
dynamics of the tissue determine a mutant cell’s ability to establish a malignant clone; yet these 
remain poorly understood in humans. One tissue was selected for the exploration of each of 
these two facets of somatic evolution: blood for clonal dynamics; colon for mutational 
processes. 
Blood presents an opportunity to study normal human clonal dynamics, as clones mix 
spatially and longitudinal samples can be taken. We isolated 140 single haematopoietic stem 
and progenitor cells from a healthy 59 year-old and grew them in vitro into colonies that were 
whole genome sequenced. Population genetics approaches were applied to this dataset, 
allowing us to elucidate for the first time the number of active haematopoietic stem cells, the 
rate at which clones grow and shrink, and the cellular output of stem cell clones.  
Colonic epithelium is organised into crypts, at the base of which sit a small number of 
stem cells. All cells in a crypt ultimately share an ancestor in one stem cell that existed recently, 
and consequently share the mutations that were present in this ancestor. We exploited this 
natural clonal unit, isolating single colonic crypts through laser capture microdissection. 570 
colonic crypts from 42 individuals were whole genome sequenced. We describe the burden and 
pattern of somatic mutations in these genomes and their variability across and within different 
people, identifying some mutational processes that are ubiquitous and others that are sporadic. 
Targeted sequencing of an additional 1,500 crypts allowed us to quantify the frequency of 
driver mutations in normal human colon. 
Together, these two studies inform on the somatic evolution of normal tissues, 
describing new biology in human tissue homeostasis and providing a window into the 
processes that govern cancer incidence. 
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Description of contributions 
 
This work was collaborative in nature. Here, I outline the contributions that others have 
made to work presented in this dissertation. I further draw attention to their contributions at 
relevant points throughout the text. 
 
Results Chapter 1: Clonal dynamics of normal blood. 
 
The general experimental design, as displayed in figure 1.1a, was formulated by Peter 
Campbell, David Kent, and Tony Green. The bone marrow aspirate was performed by Brian 
Huntly. Flow sorting of the bone marrow aspirate and culturing colonies was performed by the 
Kent lab. Subsequent peripheral blood draws and flow sorting of peripheral blood were 
performed by members of the Green and Kent labs.  
All bioinformatic analyses were performed by me, with the following exceptions: 
• Sebastian Grossman ran the Shearwater and HipSTR algorithms, and most iterations of 
the SCITE tree building algorithm. 
• Robert Osborne wrote and ran an algorithm to tabulate reads from deep sequencing of 
peripheral blood. 
• Peter Campbell wrote the mixed effects model to separate signal from noise in the 
targeted sequencing data from peripheral blood. 
 
 
My contributions to the project were the following: 
• Contributing to decisions about which peripheral blood draws should be sequenced. 
• Devising the filters to clean the whole genome sequencing data and the method of 
calling mutation. 
• Analyses of mutational signatures and embryology of blood, and the relationship 
between blood cells on the phylogeny. 
• Conceiving the method of estimating stem cell numbers by performing a capture-
recapture experiment of different peripheral blood samples. 
• With substantial guidance from Peter Campbell and Kevin Dawson, writing the 
approximate Bayesian computation for estimating the number of active haematopoietic 
stem cells. 
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• Comparing the clonal contributions to granulocytes and lymphocytes. 
 
Results Chapter 2: Mutational landscape of normal colon. 
 
The idea of using laser capture microdissection to isolate normal crypts for sequencing 
was Mike Stratton’s. Collaborators kindly provided frozen biopsies of colonic tissue. The 
organoid component of this study was set up by Sam Behjati and Sophie Roerink in 
collaboration with the Clevers lab, and the organoids were derived by the Clevers lab. A 
protocol to sequence small amounts of laser capture microdissected material was devised by 
Peter Ellis. 
My contributions to the project were the following: 
• Designing, through discussions with Mike Stratton, the experiment in terms of the 
number of crypts from each patient on which to perform targeted and whole genome 
sequencing. 
• Setting up collaborations to obtain tissue for microdissection. 
• Devising a method for fixing, staining, sectioning, and dissecting crypts. 
• Microdissecting all the crypts. 
• All analyses of the crypts and organoids, including, principally: 
o Calling mutations. 
o Driver analysis. 
o Mutational signature analysis. 
o Comparisons between normal and cancer. 
For both projects, conclusions are either entirely my own or have arisen through frequent 
discussions over three years with many lab members, but principally  Peter Campbell and Mike 
Stratton. 
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 1 
INTRODUCTION 
 
 
1. Somatic evolution 
 
One general law, leading to the advancement of all organic beings, namely, multiply, vary, let the  
strongest live and the weakest die. 
(Charles Darwin, On the Origin of Species). 
 
Darwin’s theory applies not only to whole organisms but also to the cells that constitute 
them; this is what is meant by ‘somatic evolution’. Variation and selection occur within the body 
and so evolution must follow. Cancer represents the archetype of this process, although the 
principles apply beyond the disease, and it is through the study of cancer genetics that our and 
other laboratories have approached the concept of somatic evolution more broadly. Much of this 
dissertation is framed in terms of cancer, therefore, and, for these reasons, I begin with a discussion 
of cancer genomics. 
 
2. Cancer genomics 
 
2.a. Cancer is a disease of the genome 
 
Cancer has been viewed as a disorder of cells since the nineteenth century. In 1840, 
Langenbeck stated ‘every single carcinoma cell must now appear as an organism endowed with 
life-force and developmental ability’ (cited in Bignold 2006). A series of discoveries over the 
following 150 years demonstrated that mutations were the molecular basis of cancer. 
Chromosomes were discovered in 1870, and the observation that the sum of the numbers of 
chromosomes in sperm and egg equalled that in the zygote suggested that they contributed the 
individuality of the tissue. In 1890, von Hansemann described abnormal mitoses in cancer cells 
and hypothesised that an imbalance in chromosome numbers might be important (von Hansemann 
1890). A decade later, Boveri observed that sea urchins with multipolar mitoses (due to two 
spermatozoa fertilising an egg) had developmental defects and went on to propose that cancer 
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might be due to an ‘abnormal chromosome complex’ (Boveri 1914). He further postulated the 
existence of tumour suppressor genes and oncogenes:  
 
[...] in every normal cell there is a specific arrangement for inhibiting, which allows the process of 
division to begin only when the inhibition has been overcome by a special stimulus. To assume the 
presence of definite chromosomes which inhibit division, would harmonize best with my 
fundamental idea [...] Cells of tumours with unlimited growth would arise if those ‘inhibiting 
chromosomes’ were eliminated [...] On the other hand, the assumption of the existence of 
chromosomes which promote division, might satisfy this postulate [...] If three or four such 
chromosomes meet, the whole number of chromosomes being otherwise normal, then the tendency 
to rapid proliferation would arise.  
(Boveri 1914, cited in Knudson 2001) 
 
 It was observed that mutagenic exposures (first ionising radiation (Muller 1927) and then 
chemicals such as those in coal tar (reviewed in Loeb and Harris 2008)) were frequently 
carcinogenic. The discovery of the Philadelphia chromosome (Nowell and Hungerford 1960) 
showed that a specific chromosomal alteration could be associated with cancer, providing evidence 
for the concept of driver mutations. In 1971, Knudson fitted Poisson models to the number of 
tumours found in hereditary and sporadic cases of retinoblastoma and noted that the data were 
consistent with the need for two mutations occurring at the same rate to develop the disease (of 
which one was already inherited in familial cases). Identification of the RB1 gene suggested that 
these were two inactivating hits in the same gene rather than mutations in two separate genes 
(Friend et al. 1986). This was the first tumour suppressor gene. In the same period, revival of work 
from the beginning of the century on tumour viruses indicated that specific genes carried by 
viruses, homologous to – but different from – host genes, were capable of causing cancer (Martin 
1970; Stehelin et al. 1976). Similarly, it was noted that moving DNA from cancer cells into a 
phenotypically normal cell line could transform it, indicating the existence of dominantly-acting 
oncogenes (Krontiris and Cooper 1981; Shih et al. 1981). Isolation of the causal gene (HRAS) from 
a bladder carcinoma cell line and the identification of the particular base change with oncogenic 
activity resulted in the description of the first oncogenic point mutation (Reddy et al. 1982). In the 
decades since, through first targeted and later systematic analyses of thousands of genes across 
many different cancer histologies the number of cancer driver genes has risen to a few hundred 
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(and thus 1-3% of all genes), although this is still a matter of debate (Stratton et al. 2009; 
Vogelstein et al. 2013; Forbes et al. 2017). The number of driver mutations per tumour is also 
contentious. This is discussed in the context of colorectal adenocarcinoma in Results Chapter 2. 
 
 
2.b. Mutational processes 
 
Genome sequencing has revealed that only a small fraction of mutations in a tumour are 
driver mutations. The vast majority are passenger mutations, exerting no effect (or, at least, one 
that is too weak to be selected over the lifespan of a cancer) on the fitness of the cells that carry 
them. There is substantial variability between and within different cancer types in mutation burden, 
but most adult cancers have thousands to tens of thousands of single base substitutions, tens to 
hundreds of dinucleotide substitutions (where two adjacent bases both mutate), hundreds to 
thousands of small insertions and deletions (indels), and up to a few hundred structural variants 
(Alexandrov et al. 2018; Li et al 2017). In addition, there may be insertion of viral sequences or 
reactivation of endogenous mobile elements, and most cancers display changes in their epigenome 
relative to their cells of origin, but this is beyond the scope of the present dissertation and will not 
be discussed here. 
 Although most are innocuous, these scattered mutations nonetheless represent the substrate 
for evolution. Studying their properties tells us about the processes that cause the mutations that 
do exert a functional effect and provides a window into the basis of the ‘variation’ component of 
somatic evolution. The vast numbers of somatic mutations yielded by large scale sequencing 
efforts permits a systematic analysis of the mutational processes that cause cancer. To date, 
approximately 85 million somatic mutations of all classes have been described across thousands 
of cancers (Alexandrov et al. 2018; Li et al. 2017), from which signatures of mutational processes 
(or mutational signatures) can be extracted. Here, I explain mutational signatures in the context of 
single base substitutions, but the same methodology can be applied to all mutation types. 
 The analysis of mutational signatures rests upon the idea that different mutational processes 
mutate the genome in distinct ways, such that their activity leaves a characteristic ‘signature’ in 
the genome. To begin to describe signatures, we must first classify mutations. For example, 
substitutions can be grouped according the identity of the base change, presented with the 
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pyrimidine of the mutated Watson-Crick base pair as the original base, into six classes: C>A, C>G, 
C>T, T>A, T>C, and T>G substitutions. It has long been recognised that particular mutational 
processes have a predilection for some base changes over others. For example, TP53 mutations in 
skin cancers are often C>T, while TP53 in lung cancers from smokers – but not non-smokers – 
has a large number of C>A mutations (Alexandrov and Stratton 2014). These observations have a 
molecular basis. C>T mutations in skin cancers are thought to be due to a combination of, firstly, 
ultraviolet irradiation inducing cyclobutane-pyrimidine dimers in which the C is unstable and 
spontaneously deaminates to a uracil, opposite which an A is added in replication, and secondly, 
error-prone translesion polymerase bypass of ultraviolet-induced photolesions (Ikehata and Ono 
2011). C>A mutations associated with smoking are thought to be due to bulky adducts such as 
benzo(a)pyrene metabolites binding guanines. The damaged guanine is frequently complemented 
by an adenine when replicated by the translesion polymerase POLH (Christmann et al. 2016). 
 Mutational processes with a reasonably well-characterised origin and molecular 
explanation, such as ultraviolet irradiation and smoking, were the exception rather than the rule 
before the advent of mutational signature analysis, and most somatic mutations in cancer genomes 
were of unknown cause. Even now, the aetiology of approximately half of mutational signatures 
is unknown (Petljak and Alexandrov 2016). It is not the case that the genome of one cancer 
represents one mutational process: most cancer genomes seem to have been sculpted by a number 
of co-occurring processes, which will have overlapping features (for example, there may be 
multiple processes that all cause C>T mutations). We do not know a priori the pattern of mutations 
associated with each process, nor how much each contributes to a cancer genome. The only 
information we have is the counts of mutations in every category that we have defined in each 
cancer. Remarkably, though, by comparing the mutational patterns across thousands of cancer 
samples one can deconvolute these mutations into their constituent signatures. 
 Humans can deconvolute simple cases intuitively. Imagine that three tumours have been 
sequenced, and the mutations in each tabulated. If the mutations in tumour 1 are 50% C>A, 30% 
C>G, and 20% C>T, tumour 2 only has C>A mutations, and tumour 3 has 60% C>G and 40% 
C>T mutations, we would naturally explain this with two mutational processes: process 1 is C>A 
and process 2 is C>G and C>T, and each process accounts for half of the mutations in tumour 1. 
For cancer genomes, which are far more complicated, computational methods are required. The 
most widely-applied method to date is non-negative matrix factorisation (NNMF), used to perform 
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the first comprehensive and field-defining analysis of mutational signatures (Alexandrov et al. 
2013), but many others along similar lines have arisen since (EMu (Fischer et al. 2013), signeR 
(Rosales et al. 2016), SignatureAnalyzer (Kim et al. 2016), HDP (Roberts 2018)). In this thesis, 
NNMF and a hierarchical Dirichlet process (HDP) are both used, and a brief explanation of their 
inner workings is supplied in the methods section (Methods, section 12). 
 For greater resolution of the distinction between different mutational processes, mutations 
can be divided into a larger number of biologically meaningful classes. For the analysis of 
substitutions, the base change is further subcategorised by the bases 3’ and 5’ of the mutated base, 
considering, for example, C>T in an ACG (the mutated base is underlined) context differently 
from C>T in ACC. This allows, for example, discrimination between the C>T mutations in an 
NCG context associated with the hydrolytic deamination of 5-methylcytosine and the C>T 
mutations in an NCC context associated with ultraviolet irradiation and thus the separation of these 
two processes. Depending on the richness of the dataset and the behaviour of mutational processes 
(it may be, for example, that widening the context beyond a certain point adds no extra 
information), finer categories may be defined by integrating topological features of the genome 
such as transcription strand bias or positioning relative to histones. 
 So far, using a trinucleotide categorisation of substitutions, an analysis of 4,645 whole 
genomes and 19,184 exomes has resulted in the description of 49 single base substitution 
signatures, as well as 11 doublet base substitution signatures and 17 indel signatures (Alexandrov 
et al. 2018). Similarly, nine signatures of structural variation have been characterised (Li et al. 
2017). Some signatures are of extrinsic origin (such as the one due to smoking) and some are of 
intrinsic origin (such as the spontaneous deamination of 5-methylcytosine). Particular signatures 
will be discussed at relevant points in this thesis. 
 It should be noted that mutational signatures represent sets of correlated features that need 
not be a result of a single molecular process. If two separate carcinogens that left different imprints 
on the genome were always present at exactly the same proportion in tobacco, their combined 
effect would always be extracted as one signature. They could only be separated if samples were 
found in which one process had predominated over the other. We may, therefore, expect some 
signatures to split into two as more samples are sequenced, which has indeed occurred when 
updating the TCGA analysis (Alexandrov et al. 2013) to the PCAWG analysis (Alexandrov et al. 
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2018). In due course, signatures should stabilise and their experimental validation (by, for 
example, exposing cell lines to putative carcinogens) will provide a final and robust set. 
 The exciting feature of mutational signatures is that they are a link between 
epidemiological observations and our molecular understanding of cancer. Their systematic 
exploration over time and across different tissues, people, and states of health, will be central to 
improving models of cancer and other diseases. Hopefully, mutational signatures will allow us to 
discover preventable exposures and ways to intervene in diseases of somatic evolution. For 
example, the mutational signature of aristolochic acid has been found in 47% of liver cancers in 
China, indicating that this exposure is likely to be a cause of significant morbidity (Ng et al. 2017). 
The cancer genome has – in the decade since the first cancer genomes were sequenced (Ley 
et al. 2008, Pleasance et al. 2010a, Pleasance et al. 2010b) – largely been characterised (Campbell 
et al. 2017, Alexandrov et al. 2018, Li et al. 2017, Sabarinathan et al. 2017, Dentro et al. 2018, 
Gerstung et al. 2017), and bulk sequencing of additional common tumours is unlikely to change 
our understanding of it radically. This is not to say that all questions have been resolved – far from 
it – but perhaps more is to be gained by probing deeply into cancer biology through other means. 
This involves extending our understanding of the life history of cancer and the forces that have 
shaped its evolution. 
 
 
2.c. Cancer as a multi-step branching evolutionary process   
 
Foulds made the case in 1958 that cancer was the end result of a series of qualitatively 
different changes, based on the concepts of ‘initiation’ and ‘promotion’ that came out of rabbit 
skin carcinogenesis and the fact that mammary hyperplasia often preceded frank carcinomas in 
mouse models of breast cancer (Foulds 1958). By the 1970s, the clonal origin of tumours was 
widely recognised (Nowell 1976) based on three observations: all cells from tumours had the same 
karyotype (Sandberg and Hossfeld 1970); G6PD heterozygote women only expressed one allele 
per tumour (the gene is X-linked, and so in a given cell one copy is randomly inactivated) (Fialkow 
1974); and plasma cell cancers only produced one immunoglobulin (discussed in Nowell 1976). 
Cairns related the cellular turnover of normal tissues to their acquisition of mutations, and 
discussed cancers as a product of natural selection, with sequential clonal expansions each driven 
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by a mutation (Cairns 1975). Nowell made the same argument, but explicitly added the component 
of selection, removing the least fit cells (Nowell 1976). Importantly, Nowell stated the capability 
of ‘continued variation so long as the tumour persists’, making the point that evolution has no 
endpoint. In this section, I attempt to cover succinctly the evidence for the multi-step nature and 
branching evolution of cancer, a brief discussion of mutation rates, and an acknowledgement of 
the importance of microenvironmental selection pressures. I will focus on the earliest stages of 
cancer and will not discuss metastasis or the response to therapy. 
 
 
2.c.i. Multi-step tumorigenesis 
 
 Early evidence of cancer’s multi-step nature came from the lag between carcinogenic 
exposures and the development of cancers, which suggested that other events must occur in the 
meantime, and modelling of age-incidence curves which indicated a number of rate-limiting events 
(Armitage and Doll 1954, Nordling 1953). Incidence modelling of colorectal cancer is discussed 
in Results Chapter 2. In the 1980s and 1990s, these steps were tied to a series of histopathological 
and molecular changes: the adenoma-carcinoma sequence. It was known that most adenomas arose 
from a single crypt (Ponder and Wilkinson 1986). Histopathology had shown that most carcinomas 
grew out of adenomas (Sugarbaker 1985), and their shared origin was confirmed by finding the 
same RAS mutation in both the adenoma and its linked cancer. The progression was further 
strengthened by epidemiological observations: for example, people whose adenomas were not 
removed were at greater risk of developing cancer. Once the histological progression was 
established it was possible to investigate its molecular basis. Fearon and Vogelstein’s review of 
this work is the bedrock of our understanding of multi-step carcinogenesis (Fearon and Vogelstein 
1990). Early adenomas, intermediate adenomas, late adenomas, and carcinomas were all 
sequenced, and the number of drivers in each tabulated. More drivers were found in more 
progressed lesions, with four to five (of the drivers known at the time and assayed) found in most 
frank carcinomas. Particular drivers tended to be associated with particular stages. For example, 
RAS mutations were found in the same proportion of intermediate adenomas as carcinomas, which 
suggested that RAS mutations’ main effect was to reach the intermediate adenoma stage without 
driving further progression, while loss of 17p (containing TP53) was enriched in carcinomas.  This 
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led Fearon and Vogelstein to propose the famous sequence of: 5q (containing APC) loss driving 
the formation of an early adenoma; KRAS mutations driving that of an intermediate adenoma; 18q 
(containing SMAD4) loss driving that of a late adenoma; and 17p (TP53) loss driving that of a 
carcinoma. The authors stress that it is the total sum of alterations that matters rather than their 
precise order, since this ordering of mutations is common but far from universal. Additionally, that 
certain mutations are found in more progressed lesions does not necessarily imply that they 
occurred late: TP53 would also appear mostly in carcinomas if it were, in fact, the first mutation 
but encouraged extremely rapid progression to cancer such that very little time was spent as an 
intermediate lesion. This model has been extrapolated to most other cancer types and a similar 
multi-step progression has been observed. For example, in the progression to oesophageal 
adenocarcinoma, TP53 mutations tend not to occur before high grade dysplasia and SMAD4 
mutations are not commonly found before full-blown cancer (Weaver et al. 2014). 
Pre-malignancy in blood warrants some discussion, since the clonal dynamics of blood 
make up half of the present dissertation. In childhood acute lymphoblastic leukaemia, the 
observation that monozygotic twins can both develop the disease years after birth, but their 
leukaemias share an initiating clonotypic gene fusion that must have occurred prenatally, indicates 
that extra events are required to trigger the conversion to malignancy (Greaves et al. 2003, Ford et 
al. 1993, Greaves 2018). In addition, many children harbour the initiating fusion but never develop 
leukaemia (Greaves 2018). In adult blood, the myeloproliferative neoplasms typically only bear a 
small number of known driver mutations per neoplasm (two thirds only have one known driver), 
and acquisition of certain additional driver mutations is associated with conversion to an acute 
leukaemia (Nangalia and Green 2018). Intriguingly, the order in which these first few mutations 
occur influences both the clonal dynamics of the neoplasm and its clinical manifestation (Ortmann 
et al. 2015). By assaying single cell-derived colonies from patients with myeloproliferative 
neoplasms for common driver mutations it has been shown that if JAK2 mutations occur before 
TET2 mutations, most sampled haematopoietic stem and progenitor cells had both mutations, 
whereas if TET2 occurred before JAK2, large numbers of cells with only the TET2 mutation were 
found (Ortmann et al. 2015). This indicates that TET2 mutation promotes a more rapid clonal 
expansion than JAK2 mutation does.  
More recently, much excitement has been generated by the discovery of known myeloid 
driver mutations in the blood of adults with normal blood counts and the fact that the bearers of 
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these clones are at greater risk of cancer. For such mutations to be detectable they need to be in a 
reasonable proportion of blood cells, indicating a clonal expansion, and so this phenomenon has 
been termed ‘clonal haematopoiesis’. Skewing of the proportion of cells with each X chromosome 
inactivated in women without cancer had been observed for a long time and ascribed to various 
causes, but in 2012 it was found that some of these women had TET2 mutations (Busque et al. 
2012). Of seven women followed over five years, one developed essential thrombocythaemia. A 
series of articles in 2014 based on the targeted sequencing of thousands of normal blood samples 
demonstrated that clonal haematopoiesis was widespread, with mutations in multiple leukaemia 
and lymphoma-related genes reported (Xie et al. 2014, Jaiswal et al. 2014, Genovese et al. 2014). 
The proportion of people in whom clones were detected increased with age. For example, by ultra-
deep sequencing of 15 hotspots, clonal haematopoiesis was detected in 1% of patients under 60 
and 20% of patients aged over 90 (Mckerrell et al. 2015). Importantly, the presence of mutations 
in driver genes was associated with a hazard ratio of 11.1 (95% CI 3.9-32.6) of developing a 
leukaemia, indicating that the mutant clones might be pre-malignant (Jaiswal 2014). The definition 
of clonal haematopoiesis is somewhat in flux, however. Firstly, the number of clones detected 
depends on the sensitivity of the detection methodology: when mutations could be accurately 
called down to a frequency of one in 10,000 cells, clonal haematopoiesis could be detected in 19 
out of 20 healthy people aged between 50 and 60 (Young et al. 2016). Secondly, clones have been 
found in which no known driver mutations were detected (Zink et al. 2017). It is therefore unclear 
whether clonal haematopoiesis represents a qualitatively distinct stage between normal 
haematopoiesis and cancer, or if the clones detected are merely a result of normal neutral drift that 
results occasionally in clones of a detectable size. We currently have a very limited understanding 
of the range of blood clone sizes in healthy humans. It is to be hoped that this will be resolved by 
studying further the clonal dynamics of normal human haematopoiesis. 
 
 
2.c.ii. Branching evolution 
 
Branching evolution implies that complete clonal sweeps through a tumour are infrequent. 
Experimentally, this means that if different samples are taken from a tumour, each will have a 
large number of private mutations. This can be depicted as a phylogeny with long private branches 
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leading from the samples to their coalescence into the trunk of shared, clonal mutations. This is 
frequently observed in cancers (Yates and Campbell 2012). The length of private branches is 
determined by a number of factors. Branches are lengthened by restricted movement within the 
founding clone preventing clonal sweeps (the most extreme example being that of monozygotic 
twins with concordant clonal acute lymphoblastic leukaemia), by an increased mutation rate, and 
by decreased competition for resources (such as space) between tumour cells.  
In the last few years, much has been made of a “Big Bang” model of colorectal cancer 
(Sottoriva et al. 2015). The same sub-clonal copy number changes were found in different parts of 
colorectal carcinomas. In the absence of cell migration (which is perhaps a strong assumption 
given that the ability to migrate is a hallmark of a carcinoma), this would be consistent with the 
emergence of multiple subclones and a lack of complete selective sweeps since. Subsequent work 
showed that the distribution of clone sizes across many tumours, determined based on the allele 
fraction of mutations, was not significantly different from what one would expect in the absence 
of selection (Williams et al. 2016). Conversely, it has been shown that a similar distribution of 
allele fractions can also be observed in the presence of weak subclonal selection (Tarabichi et al. 
2017). The authors of the latter study conclude that allele fractions alone are not sufficient to 
distinguish between neutrality and weak or occasional subclonal selection. Indeed, incomplete 
clonal sweeps within a tumour need not equate with neutrality: carcinomas have long been 
observed to grow out of adenomas and this has never been interpreted as neutral evolution. 
Orthogonal genetic approaches, such as dNdS (a method that compares the proportion of 
nonsynonymous and synonymous mutations in order to detect selection), have shown the presence 
of weak subclonal positive selection (Tarabichi et al. 2017). Furthermore, there is no reason that 
selection should stop operating during tumour evolution. Nonetheless, the similarity between 
observed allele fractions and simulations under a neutral model indicates that neutral drift is likely 
to play a large part in determining clone sizes in many tumours. 
 
 
2.d. Selective pressures 
 
The interactions between the tumour and its microenvironment are multifarious (Greaves 
and Maley 2012). I cannot hope to do them justice in this short section, but aim merely to 
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acknowledge their importance. The role of tissue architecture in regulating clonal competition is 
discussed in more detail below. Here, I provide a few brief vignettes on the effect of selection 
pressures in the earliest stages of cancer development.  
 Immune surveillance provides a well-established selection pressure. In aplastic anaemia, 
CD8 cytotoxic T lymphocytes attack one’s own haematopoietic stem cells, reacting against 
antigens on their surface. In 50% of people with this condition, a cell that acquires a mutation in 
the X-linked PIGA gene that results in the loss of expression of glyosylphosphatidylinositol 
anchors (such that surface antigens can no longer be tethered to the cell surface) escapes immune 
attack and proliferates to form a clone. This is paroxysmal nocturnal haemoglobinuria, which is 
associated with a low risk of transformation to leukaemia (Hoffbrand et al. 2011). Indeed, even in 
the absence of a well-described pathology such as paroxysmal nocturnal haemoglobinuria, 15% of 
people with aplastic anaemia will develop myelodysplastic syndrome or acute myeloid leukaemia 
(Yoshizato et al. 2015), indicating that these microenvironmental changes create the conditions for 
a mutant cell to outcompete its wild-type neighbours. Even when we do not understand the 
selection pressure, there is evidence that a change in environment affects clonal expansions. For 
example, in clonal haematopoiesis, mutations in spliceosome components suddenly increase in 
frequency in the elderly (Mckerrell et al. 2015). This may be due to a change in selection pressures 
associated with old age (Mckerrell and Vassiliou, 2015). 
Inflammation may provide a selective pressure that favours the outgrowth of certain clones. 
Dominant negative P53 mutations in mouse colonic crypts conferred no advantage in a 
physiological setting but did in a mouse model of colitis (Vermeulen et al. 2013). This might be – 
at least in part – because of a loss of sensitivity to cellular damage which allows the mutant cells 
to continue to proliferate while their wild-type counterparts arrest for DNA repair (Breivik 2001). 
TP53 mutations are enriched in colitis-associated neoplasia, including in non-dysplastic crypts that 
neighbour lesions (Leedham et al. 2009), and indeed, ulcerative colitis is associated with an 
increased risk of colorectal cancer. Similarly, in a model of paediatric acute lymphoblastic 
leukaemia, B cell progenitors with the ETV6-RUNX1 fusion (a common initiating lesion) 
proliferate more slowly than their wild-type counterparts in homeostasis but gain a competitive 
advantage in the presence of the cytokine TGFβ (Ford et al. 2009).  
 One experiment produced such a peculiar result that it deserves mention. Ctnnb1 mutations 
induced in small populations of cells in mouse skin were enveloped by wild-type skin, and after a 
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time, expelled from the tissue (Brown et al. 2017). When the proliferation of wild-type cells was 
inhibited, mutant cells were not expelled and were able to form large cysts. This indicates negative 
selection that is driven by wild-type cells. In a study of sequencing human skin, no negative 
selection was detected (Martincorena et al. 2015). If microenvironmental selection pressures 
arrested the growth of mutant cells, rather than eliminating them, however, no negative selection 
would be observed. The authors of the latter study did note that the range of mutant clone sizes 
detected in human skin was unexpectedly small, indicating that there may be some constraint on 
clonal expansion.  
 Clearly, there is a world of complexities of selection pressures in normal tissues that 
remains to be explored. Some have gone so far as to claim that the age incidence curves of cancer 
are due to changes in the microenvironment with age rather than the need to acquire multiple driver 
mutations (DeGregori 2017). 
 
 
2.e. Mutation rates in cancer 
 
There has been much debate over whether the mutation rates in normal tissues are sufficient 
to accumulate the number of driver mutations needed for cancer. A higher mutation rate allows for 
more rapid evolution, but it may be unnecessary and could even cause deleterious mutations. Loeb 
proposed the ‘mutator phenotype’ in 1974, based on the observation that polymerases isolated 
from acute lymphoblastic leukaemia cells replicated DNA less faithfully than those from normal 
lymphocytes. Various modelling approaches were used to determine whether an increase in 
mutation rate was necessary, some finding that it was (Loeb 1991) and others that it was not 
(Tomlinson et al. 1996). These models seem to be relatively sensitive to the number of hits that 
are necessary before the first clonal expansion and the extent of clonal expansions. Estimates of 
mutation rates were based on single gene reporter assays and so not representative of the whole 
genome.  
 The data, too, are mixed. By the 1970s, a number of studies had indicated that tumours 
made more mitotic errors than normal cells, and that the numbers increased as the tumour 
progressed (discussed in Nowell 1976). The discovery of Lynch syndrome and other genetic 
predisposition syndromes that result in an increased mutation rate certainly provides strong 
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evidence that in these circumstances an increased mutation rate is beneficial, but it is unclear 
whether this also applies to sporadic tumours where more hits would be necessary in order to 
increase the mutation rate. In colorectal cancers, it was observed that tumours that were mismatch 
repair deficient rarely exhibited chromosomal instability, and conversely tumours that were 
chromosomally unstable rarely lost mismatch repair, suggesting that there might be an advantage 
to increasing the mutation rate by whichever means (Fearon 2011). 
 With the advent of cancer genome sequencing, it has become clear that most tumours have 
tens of thousands of mutations due to a number of mutational signatures (Alexandrov et al. 2013, 
Alexandrov et al. 2018). Without sequencing normal tissues, however, one cannot know if this is 
abnormal. In one of the few tissues in which the comparison of tumour and normal has been 
performed, it was found that the mutation burden of acute myeloid leukaemia cells was not 
increased relative to healthy haematopoietic stem and progenitor cells (Welch et al. 2012). 
Nonetheless, blood cancers may represent a special case, since they are on the whole remarkably 
un-mutated and require few driver mutations. More recently, sequencing of organoids derived 
from normal colonic stem cells (discussed in Results Chapter 2 section I.4.) has shown that normal 
colonic cells have a lower mutation burden than colorectal cancers (Blokzijl et al. 2016, 
Alexandrov et al. 2018). Finally, a recent analysis shows that – with the exception of a few tens of 
genes in haploid regions which are very rarely mutated – negative selection is virtually absent in 
cancers, indicating that the mutation rates observed in cancers are not deleterious through the 
inactivation of essential genes (Martincorena et al. 2017). 
 Taken together, it seems that there is more evidence for an increased mutation rate in cancer 
than against it, in some tissues at least. While elevated mutation rates may not be necessary in 
order to acquire the sufficient number of driver mutations, an increased mutation rate may still 
increase the probability of this occurring. Definitive answers, however, can only come through the 
comparison of normal and cancerous cells. 
 
In summary, cancer is a multi-step branching evolutionary process, with ongoing clonal 
competition and complex selection pressures. Despite these great advances in our conception of 
cancer, many questions remain unanswered. Two lacunae that are of relevance to this dissertation 
stand out. First, most descriptions of tumour progression are not quantitative (with a few 
exceptions, e.g. Bozic et al. (2010), Mitchell et al. (2018)). To understand cancer evolution fully, 
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one would need to measure the selective benefit conferred by each change in the context of its 
particular microenvironment. Second, we have a limited understanding of somatic evolution before 
the advent of histological changes. 
 
 
 
3. The mutation rates and stem cell numbers of normal tissues affect cancer risk 
 
 Under a simple model of cancer, where a cell needs to acquire a defined number of driver 
mutations to become cancerous and driver mutations are independent events that occur at a 
constant rate over time, the incidence rates of cancer are closely related to the number of driver 
mutations required. If a single driver were required, the incidence rate of cancer at all ages would 
be the same, since the probability of acquiring the driver is the same in every decade. If two driver 
mutations were required, the incidence rate would increase linearly, since the probability of a cell 
having already acquired one driver increases linearly with time and the probability of acquiring a 
second driver is constant. If three drivers were required, the cancer incidence rate would increase 
proportionally to the square of age, and so on. For seven drivers: 
 
Incidence rate = k * p1 * p2 * p3 * p4 * p5 * p6 * p7 * t6 
 
where k is a constant and t is age. p1 to p7 are the rate of acquisition of each of the driver mutations, 
which in this model will be entirely dependent on the mutation rate in normal tissues. Plotting the 
logarithm of cancer incidence versus age, the slope of the line should be one fewer than the number 
of driver mutations required to cause a cancer. This is the reasoning famously applied by Nordling 
(1953) and Armitage and Doll (1954) to infer the number of rate-limiting events necessary to cause 
cancer (commonly interpreted as driver mutations) from age incidence data (Nordling used 
mortality as a proxy for incidence). Driver mutations are unlikely to be independent, since they 
may cause clonal expansions and/or increase the mutation rate. Nonetheless, at the very least, 
cancer incidence will be related to the probability of acquiring the first driver mutation (p1), which 
in turn is likely to depend approximately linearly on both the mutation rate in normal tissues and 
the number of cells at risk of transformation.  
 15 
 A higher mutation rate in normal tissues, therefore, should increase the risk of cancer. In 
support of this, many risk factors for cancer increase the mutation rate, whether genetic (biallelic 
mismatch repair deficiency, xeroderma pigmentosum, Fanconi anaemia, or polymerase proof-
reading polyposis syndrome, to name but a few examples) or environmental (such as smoking, 
ionising radiation, or aristolochic acid). Although many of these might act in other ways as well 
(such as by changing the clonal dynamics of the tissue through inducing inflammation and 
proliferation) in a study of cancers whose relative risk is elevated by smoking, the mutation burden 
of cancers from smokers was higher relative to that of cancers from non-smokers, which is 
consistent with smoking exerting its effect at least in part through elevated mutation rates 
(Alexandov et al 2016). 
 
 
3.a. Stem cells are the cell-of-origin of many adult cancers 
 
 The more cells at risk of transformation, the greater the risk of cancer. Determining which 
are the cells at risk is therefore of primary importance. Given that the capability for self-renewal 
is shared by both cancers and adult tissue stem cells, the latter have been proposed as the cell-of-
origin for a number of malignancies. Here, I will discuss the evidence for this in colon and blood. 
 Barker and colleagues inactivated Apc in cells that express Lgr5 in colonic crypts (Barker 
et al. 2009). Lgr5 is a marker expressed at the base of the crypt, and a subset of Lgr5-expressing 
cells behave as functional stem cells (to be discussed in more detail in Results Chapter 2) (Barker 
et al. 2007, Kozar et al. 2013). Loss of Apc in the stem cell compartment resulted in the rapid 
formation of large adenomas, whereas loss of Apc in the more differentiated transit-amplifying 
cells produced microadenomas that were only very rarely observed to progress into macroscopic 
lesions, and these rare cases were explained by occasional unintended Apc inactivation in stem 
cells (Barker et al. 2009). Nonetheless, in inflammation or under the influence of certain driver 
mutations, more differentiated cells within the crypt have been observed to re-express stem cell 
markers and reacquire the ability to form adenomas (Schwitalla et al. 2013). Similarly, quiescent 
Paneth cell-precursors have been shown to produce multilineage output following injury (Buczacki 
et al. 2013), and if Lgr5+ stem cells are deleted by inducing the expression of diphtheria toxin only 
in those cells, more differentiated cells seem to be able to take their place (Tetteh et al. 2016). It is 
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possible, therefore, that in some circumstances initiating lesions in more differentiated cells could 
result in cancer.   
 The evidence that haematopoietic stem cells are the cell-of-origin of certain adult blood 
cancers is less direct. The leukaemic blasts from G6PD heterozygote women with chronic myeloid 
leukaemia only expressed one isoenzyme, and B lymphocyte populations also only expressed the 
same isoenzyme (Fialkow et al. 1978, Martin et al. 1980), indicating that the cell-of-origin of the 
leukaemia had multilineage potential. It is, of course, also possible that the cell-of-origin could 
have restricted lineage potential and the driver mutations themselves alter the cell’s lineage output. 
In a model of the disease, self-renewal properties were not conferred by transduction of the 
pathognomonic Bcr-Abl fusion into progenitor cells, but they were by certain other gene fusions, 
indicating that differentiating cells could, in some cases, also act as the cell-of-origin (Huntly et 
al. 2004). In acute myeloid leukaemia, it was observed that the cells capable of causing leukaemia 
when transplanted into immunocompromised mice bore the same surface markers as 
haematopoietic stem cells (Bonnet and Dick 1997). The authors argued that for a stem cell to 
transform was more parsimonious than for a more differentiated cell to transform and reacquire 
stem-like properties and markers. Childhood acute lymphoblastic leukaemias, in contrast, may 
mostly arise from more differentiated cells, as myeloid cells are not usually found to share markers 
with leukaemic cells (Greaves 1993). 
 
 
 
3.b. Stem cell divisions and cancer risk 
 
 It was recently and controversially asserted that two thirds of the variation in cancer risk is 
a result of the “bad luck” of the random replication errors of normal cells (Tomasetti and 
Vogelstein 2015). For 31 cancer types, the authors correlated the lifetime cancer risk in the US 
against estimates of the number of stem cell divisions in the tissue of origin. A correlation of 0.8 
meant that 65% (95% CI 39% to 81%) of cancer risk was associated with stem cell divisions. 
Nothing proves that the risk associated with stem cell divisions is due to somatic mutations, but 
this is the most likely mechanism. Such a strong correlation is perhaps surprising given all the 
different factors that affect cancer development and vary across tissues: carcinogenic exposures, 
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microenvironmental and stem cell architecture differences (discussed below), the number of driver 
mutations needed by different cancers, and the proliferative advantage provided by each driver.  
 A number of criticisms can be levelled at this analysis. First, there is inaccuracy in the 
estimates of the number of stem cell divisions. The estimate of haematopoietic stem cell numbers 
is likely to be a significant overestimate (as will be discussed in Results Chapter 1), and other 
errors have been noted (Rozhok et al. 2015). Second, little attempt is made to explain some of the 
largest departures from this correlation. Most strikingly, the number of stem cell divisions in small 
intestine and colon is similar, and yet the incidence of colorectal cancer is two orders of magnitude 
higher. Third, it has been pointed out that this correlation cannot distinguish between extrinsic and 
intrinsic effects both because the effect of extrinsic mutational processes can be linked to the stem 
cell division rate if rapidly cycling cells are more likely to fix mutations, and because some 
extrinsic mutational processes might act upon multiple cell types to similar extents, thus preserving 
the correlation (Wu et al. 2016). An analysis of mutational signatures across normal tissues and 
exposures would clarify this. Even if valid, the conclusions of the Tomasetti and Vogelstein study 
were presented in an unhelpful way in terms of public health. The relative risk of cancer across 
tissues is quite different to that across people and the implications of this were not made clear 
enough in the mass media (e.g. Galagher 2015). Whatever my behaviours I will always be more 
likely to develop cancer of the colon than an osteosarcoma, but I can significantly reduce my risk 
of cancer relative to my identical twin who drinks like a fish and smokes like a chimney. The “bad 
luck” applies to my colon relative to my femur rather than to me relative to my debauched twin. 
Despite these criticisms, this study identifies those tissues that have more cancer than one would 
anticipate from the number of stem cell divisions. Similar approaches might represent an 
interesting way to explore cancer aetiology across different tissues and potentially identify 
preventable exposures, although perhaps better estimates of stem cell numbers and division rates 
are needed first. 
 A related point was raised by Tomasetti and Vogelstein’s follow-up article (Tomasetti and 
Vogelstein 2017), in which a distinction is drawn between the amount of cancer that is due to an 
exposure and the proportion of driver mutations in a tumour that are caused by it. They calculate 
that even for an exposure such as smoking, which is responsible for 90% of lung adenocarcinomas, 
still 35% of total driver mutations are likely to be due to random errors of DNA replication. This 
is perhaps unsurprising from a perspective of species evolution. Natural selection has endowed us 
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with tumour suppressive mechanisms such that cancer is unlikely during a reproductive lifespan 
with the number of drivers that are likely to occur by replication errors alone across a tissue. 
Mutagens need only tip us over the threshold of the number of driver mutations that we can tolerate 
for them to have a pronounced carcinogenic effect.  
  
 
3.c. Tissue architecture limits the selective advantage of mutant cells 
 
Cairns, after noting the potential of natural selection to promote malignancy, wrote:  
 
We may therefore expect to find fast-multiplying tissues arranged in such a way that neighbouring 
stem cells (or sets of stem cells) are restricted to limited territories so that they cannot easily 
compete with each other. 
(Cairns 1975). 
 
Going on to discuss intestinal crypts, he noted that both restricting the number of stem cells and 
restraining the competition between them would decrease the accumulation of stem cells with 
driver mutations (Cairns 1975). Here, I focus on the colon; the same mechanisms of restricting 
stem cell competition do not seem to be operative to the same extent in normal blood since, here, 
stem cells are able to recirculate (although many aspects of the haematopoietic stem cell niche are 
incompletely understood).  
 The organisation of the colonic epithelium into crypts means that even if a stem cell with 
a driver mutation manages to sweep through an entire crypt, its clone size is still limited. Clonal 
expansion cannot occur through proliferation alone: crypt fission is needed. Limiting clone sizes 
at this early stage would presumably significantly reduce the probability of another driver mutation 
occurring in the same clone. The role of driver mutations in promoting crypt fission is discussed 
in Results Chapter 2. 
 Less intuitively, the small number of competing stem cells in the intestinal stem cell niche 
strengthens the hand of chance in stem cell competition (Calabrese and Shibata 2010, Rozhok and 
DeGregori 2015). In population genetics terms, population structure decreases the effective 
population size, and the probability of fixation of a beneficial allele is related to the effective 
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population size divided by the census population size (Whitlock 2003). Stochastic factors are 
stronger in smaller niches, and so most driver mutations, even with a strong selective advantage, 
are likely to be lost from the crypt by chance. The other side of this coin, of course, is that there 
will be less negative selection as well, and colonic crypts are more likely to accumulate deleterious 
mutations than a system like blood. One can speculate that the need to balance positive and 
negative selection in tissues contributed to the evolution of different stem cell niche structures (in 
addition to obvious physiological reasons). Thus, the number of stem cells and their mutation rates 
are only one part of the story. 
 
 
4. Somatic evolution in ageing and diseases beyond cancer. 
 
Little is known about the role of somatic mutations beyond cancer, and so this section will 
necessarily be brief. The somatic mutation theory of ageing (Szilard 1959, Morley 1995) posits 
that the stochastic and progressive accumulation of mutations over life results in a loss of function 
of tissues that is responsible for ageing. It was based on observations that large scale irradiation of 
mammals seems to result in premature ageing (Henshaw  et al. 1947). Several features of Szilard’s 
model are now known to be wrong, such as the assumption that one mutation might inactivate a 
whole chromosome, but in the absence of a better explanation, the somatic mutation theory of 
ageing – with some alterations to Szilard’s model – remains attractive. 
 Progeria syndromes, such as Cockayne syndrome, are one source of evidence that somatic 
mutations play a role in ageing (Garinis et al. 2008). In these, features of the ageing process are 
accelerated, and the underlying genetic defect is frequently in a component of a DNA damage 
repair pathway (for example, transcription-coupled nucleotide excision repair is impaired in 
Cockayne syndrome). Some syndromes, such as xeroderma pigmentosum, are associated with both 
progeria and an increased risk of cancer. Furthermore, long-term survivors of chemotherapy and 
radiotherapy show signs of premature ageing (Garinis et al. 2008). A recent study of single cell 
sequencing of individual neurones (the method is discussed below) from individuals with 
Cockayne syndrome, xeroderma pigmentosum, and controls, showed that the mutation rate was 
indeed increased in somatic tissues from individuals with both diseases (Lodato et al. 2018). 
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 Nonetheless, it is questionable whether the mutation rate in normal tissues would be 
sufficient to bring about a functional defect. For example, only ~10 exonic single nucleotide 
variants are observed in a blood cell from a person in their 70s (Welch et al. 2012). Assuming a 
constant mutation rate, by age 100 a person is unlikely to have more than 20 protein-coding 
mutations per cell, which, scattered among the thousands of genes in the genome, most of which 
are diploid and non-essential, seems unlikely to have much functional effect in most cells. The 
mutation rates in other tissues are likely to be higher, but probably not high enough to cause a 
functional decline. 
 If the loss of function were associated with a selective advantage, however, an unlikely 
event affecting a small number of cells by chance could, after a period of clonal expansion, affect 
the whole tissue. Evidence of this has come from the recent discovery of clonal haematopoiesis, 
which increases the risk of all-cause mortality even after excluding malignancy (Jaiswal et al. 
2014). Much of this risk seems to come from increased cardiovascular events, seemingly through 
the aberrant expression of atherogenic cytokines by mutant cells (Jaiswal et al. 2017). Other 
diseases may be clonal in origin too. There is evidence, for example, that somatic mutations may 
play a role in autoimmune diseases such as Sjögren’s syndrome (Nocturne et al. 2013). While these 
are examples of specific diseases, the same may be true of ageing. 
 Thus, although the evidence is not yet fully convincing, the exploration of somatic 
mutations in normal tissues may reveal a somatic mutation basis for ageing and a number of 
diseases. Establishing a baseline of somatic mutation burden and processes for normal tissues from 
healthy people will provide a reference against which different disease states may be compared. 
 
 
5. Massively parallel sequencing 
 
All of the work in this thesis relies upon massively parallel sequencing in order to detect 
somatic mutations, and so a brief overview of the method is in order. Only Illumina/Solexa 
sequencing will be discussed, since it is the dominant technology and the only one used here. 
After extraction of DNA from cells, the DNA is sheared (typically by sonication, but in 
some experiments by enzymatic fragmentation (see Methods)) into fragments that are less than 
1,000 bases long. The ends of the fragments are repaired to remove overhangs, and adaptors are 
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ligated. The molecules are washed over a flow cell, where they anneal by a short sequence of the 
adaptor tail to oligonucleotides covalently bound to the surface of a glass slide. Each molecule of 
DNA is replicated by bridge amplification, resulting in the formation of DNA colonies that can be 
sequenced. 
Illumina/Solexa sequencing uses the method of sequencing by synthesis. Reversible chain-
terminating nucleotides, each coupled to a fluorophore, are washed over the flow cell. A free-
floating nucleotide binds to extend a strand of DNA along the template if it is complementary to 
the next base of the template to be copied. This terminates the reaction. On excitation by a light 
source, the fluorophore is cleaved, emitting a light signal that is detected by a camera. The colour 
of the fluorophore gives the identity of the base that has just been added. Cleavage of the 
fluorophore also unblocks the end of the molecule such that the next base can be added. The 
process continues until a read of the desired length has been achieved (150 base pairs for the XTEN 
platform which was mostly used in this study). Both ends of the DNA molecule are sequenced, 
resulting in paired-end reads. The informatic representation of the DNA sequence is then aligned 
to the human reference genome and mutations can be called (Methods). 
 
 
6. Methods for studying mutations in normal tissues 
 
The polyclonal nature of normal tissues makes them difficult to study. Standard sequencing 
protocols require hundreds of nanograms of DNA and so tens of thousands of cells. Mutations can 
only be called accurately if they are present in a substantial proportion of these cells. Unlike a 
cancer in which large numbers of mutations are shared by most cells in a biopsy sample, a biopsy 
of tens of thousands of cells from most normal tissues will reveal very few shared (and so 
detectable) somatic mutations. A number of methods have been used in recent years to tackle this 
problem: single cell sequencing; heavily error-corrected deep sequencing; in vitro clone formation; 
and microbiopsy sequencing. The latter two are used in this thesis. 
 In single cell sequencing, the DNA from single nuclei is amplified using a method such as 
multiple displacement amplification (MDA) and sequenced. Clean single cell whole genome 
sequencing would be the perfect solution to the study of normal tissues, and all the methods 
discussed below would largely be obsolete. Unfortunately, the process of whole genome 
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amplification from such a small amount of input DNA both introduces large numbers of false 
positive errors and amplifies the genome unevenly, resulting in large portions of the genome that 
are not covered (Wang and Navin 2015). Despite these caveats, it has been used to determine the 
mutation rates in single neurones (Lodato et al. 2018). In order to reduce false positives, mutations 
were only called if they were correctly phased with a germline polymorphism; the mutation burden 
was then extrapolated to the whole genome. A correlation with age was observed, indicating that 
real mutations were being called. This method, cannot, however, be used to catalogue every 
mutation in the genome of a single cell, as mutations in a high proportion of the genome cannot be 
called. 
 Heavily error-corrected deep sequencing provides a way to study a polyclonal population. 
The most successful methods have been based on the principles of ‘duplex sequencing’ (Schmitt 
et al 2012, Kennedy et al 2014), where the sequences of either strand of a DNA duplex are 
identified separately and can be compared: artefacts introduced in library preparation or 
sequencing errors are not likely to affect both strands of a duplex in the same way. One difficulty 
of this sort of approach is that recapturing both strands of a DNA duplex is unlikely. The 
probability of this was improved by a strong dilution step before the polymerase chain reaction 
(Hoang et al. 2017), and the method could then be used to call mutations in polyclonal tissues. 
Identifying and reproducing the dilution sweet-spot is technically challenging, and, even if 
achieved, the full complement of mutations in a genome cannot be identified, since the information 
of which cell each DNA molecule comes from is lost. This makes analyses of clonal dynamics 
(such as phylogenetic reconstruction) more challenging. 
 In vitro clone formation involves the isolation of single cells and their expansion in culture, 
in the presence of growth factors, into colonies that are sufficiently large to be whole genome 
sequenced. The cell’s own replicative machinery is less error prone than whole genome 
amplification methods, and the genome is naturally amplified evenly. Furthermore, the precise cell 
type of interest can be isolated prior to amplification (for example, by flow cytometry). This 
method has been used successfully for intestinal and liver cells (Blokzijl et al. 2016) and for blood 
stem and progenitor cells (Ortmann et al. 2015) amongst others. While the range of tissues for 
which this is possible is being broadened, not all cells can be expanded in this way and it seems 
unlikely that this approach will be possible for post-mitotic tissues without extensive manipulation. 
There are two other caveats of this approach: mutations can occur in vitro (although this can be 
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estimated and largely corrected: see Methods), and there is potential for positive or negative 
selection of mutations during growth (van de Wetering et al. 2015). 
 Microbiopsies exploit in vivo clonal expansions to identify mutations present in small 
numbers of adjacent cells. Microbiopsies may be blind, in which a random biopsy of a tissue is 
taken and one hopes to encounter a clone, or they may be targeted at histologically defined clonal 
units, such as a colonic crypt (discussed in greater detail in Results Chapter 2). Blind microbiopsies 
have been used successfully to identify mutations in human skin (Martincorena et al. 2015). Using 
the ‘pigeonhole principle’, which states that clones whose sum is greater than half of the biopsy 
size must be nested, it may, in some cases, be possible to infer clonal relationships, and the size of 
clonal patches can inform on selection. The technique only works for tissues in which clonal 
patches are of a detectable size, however, which may limit its use to squamous epithelia or tissues 
with a defined and large clonal unit. The mutations called are those that were present in the most 
recent common ancestor of the clone rather than those in extant cells. 
 
 
7. Blood is well suited to studying the clonal dynamics, and colon the mutational processes, 
of normal tissues 
 
 Blood and colon are both well-studied tissues, with properties that lend themselves to the 
investigation of different aspects of somatic evolution. Blood can be sampled randomly and 
longitudinally with relatively little discomfort to the patient, making the investigation of clonal 
dynamics tractable. Although haematopoietic stem cells are perhaps the best-studied adult stem 
cell, we lack the answers to basic questions in humans, such as the number of stem cells and range 
of clone sizes in healthy humans. These are important parameters to model leukaemia and other 
diseases, such as those of bone marrow failure. Furthermore, the recent discovery of widespread 
clonal haematopoiesis in the elderly associated with an increased risk of malignancy and death 
from other causes adds urgency to the need to establish a baseline for the normal clonal dynamics 
of blood in humans. 
 The colon is well-suited to the investigation of mutational processes and driver events. 
Colonic crypts form visible clonal units, permitting a microdissection approach to identifying 
somatic mutations that have occurred in colonic crypts, without the caveats of selection for or 
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against certain mutations or the acquisition of in vitro mutations. Colonic mucosa is frequently 
sampled, allowing us to investigate the range of somatic mutational processes across a range of 
people. The archetypal model of the progression from normality to cancer was defined in the colon 
(Fearon and Vogelstein 1990), and it has historically been the battleground for debates on the 
mutator phenotype (Loeb 1991, Tomlinson et al. 1996). The investigation of normal colon 
complements these studies. Finally, colorectal cancer is a common and lethal disease, with 42,000 
new cases diagnosed in the United Kingdom in 2015, and 16,000 deaths from it in 2016 (Cancer 
Research UK, accessed August 2018). Epidemiological observations (discussed in Results Chapter 
2 section I.3.) indicate that some risk is preventable. The elucidation of the mutational processes 
that cause normal cells to become cancerous can hopefully contribute to the identification of the 
causes of excess risk and indicate opportunities for early intervention, as well as contribute to our 
understanding of the pathogenesis of the disease. 
 
 
8. Thesis aims 
 
 This dissertation is divided into two chapters. The first investigates the clonal dynamics of 
normal blood, and the second the mutational landscape of normal colonic epithelium.  
The principle aim of the study of normal haematopoiesis in Results Chapter One is to 
estimate the number of haematopoietic stem cells that actively contribute to blood in one healthy 
human, and the rate at which haematopoietic stem cells replace one another. Second, it aims to 
investigate clonal relationships between the myeloid and lymphoid lineages. Third, it seeks to 
establish the mutation burden per genome and mutational processes of normal haematopoietic stem 
and progenitor cells.  
The main aim of the study of the colon in Results Chapter Two is to describe the repertoire 
of mutational processes and their mutational burden operative across different sites on the colon 
of a number of different people. Second, it seeks to establish the frequency of driver mutations in 
normal colon. Third, it investigates how the mutation rate and mutational processes change in the 
progression from normal to cancer. 
 
Background specific to each tissue is presented at the beginning of the relevant results chapter.  
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METHODS 
 
 
 
1. Samples 
 
1.a. Primary bone marrow and peripheral blood samples 
 
A bone marrow (BM) aspirate, peripheral blood (PB) sample, and a buccal swab were 
obtained in collaboration with the laboratories of David Kent and Tony Green from a 59 year-old 
man with normal blood counts and no history of blood disorders. Follow-up PB samples were 
taken every two months for the following six months, and thereafter once every six months by me, 
Carlos Gonzalez-Arias or Jacob Grinfeld. 
 
 
1.b. Colon samples for laser capture microdissection 
 
We obtained healthy colonic biopsies from four cohorts of patients. The first represents 
seven organ donors ranging in age from 36 to 67, from whom colonic biopsies were taken at the 
time of transplantation. These samples were provided by Kourosh Saeb-Parsy. The second 
represents patients aged 60 to 72 who were having a colonoscopy following a positive faecal occult 
blood test as part of the Bowel Cancer Screening Programme; we selected 16 patients who were 
not found to have either an adenoma or a carcinoma on colonoscopy, and 15 patients who were 
found to have a colorectal carcinoma (the normal biopsies that we use were distant from these 
lesions). These samples were provided by Nick Coleman. The third represents three paediatric 
patients who were having a colonoscopy for inflammatory bowel disease following suggestive 
symptoms, but in whom no diagnosis of inflammatory bowel disease was made. These samples 
were provided by Matthias Zilbauer. Finally, access to samples from one 78 year-old gentleman 
with oesophageal cancer who underwent a warm autopsy was provided by Rebecca Fitzgerald. A 
table of which samples come from which patients is provided in Appendix C. 
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1.c. Colon samples for organoid derivation 
 
Tissue material was obtained in collaboration with the Clevers lab from The Diakonessen 
Hospital, Utrecht. From the resected colon segment, both normal and tumour tissues were isolated. 
The isolated tumour tissue was subdivided into 4-5 segments. Normal tissue was taken at least 5 
cm away from the tumour.  
 
 
2. Sample preparation  
 
2.a. Isolation of haematopoietic stem and progenitor cells and peripheral blood fractions by 
the Kent lab 
 
The following work was performed by the Kent lab. Mononuclear cells (MNCs) from BM 
and PB were isolated by density gradient centrifugation (Lymphoprep; Axis-Shield, Oslo, 
Norway), and enriched for CD34 positive cells (EasySep Human CD34+ enrichment kit, 
STEMCELL Technologies, Vancouver, Canada (STEMCELL)) as per the manufacturer’s 
guidelines except that only one round of depletion in the magnet was performed. Cells were then 
stained with the following antibodies; CD38-FITC (Clone HIT2, BD Biosciences, San Jose, CA, 
USA (BD)), CD34-PerCPCy5.5 (Clone 581, Biolegend, San Diego, USA (Biolegend)), CD10-
APC-Cy7 (Clone HI10a, Biolegend), CD90-APC (Clone 5E 10, Biolegend or BD), CD45RA-
Violet450 (Clone HI100, BD) and CD135-PE (Clone BV10A4H2, Biolegend). Single 
CD34+CD38-CD90+CD45RA- cells (hereafter “HSCs”) from BM and PB were isolated for liquid 
culture using an Influx sorter (BD), equipped with the following lasers; 405nm, 488nm, 561nm, 
and 640nm, and filter sets; 530/40 (for FITC), 710/50 (for PerCPcy5.5), 750LP (for APC-Cy7), 
670/30 (for APC), 460/50 (for Violet450), and 585/29 (for PE). Bulk HSCs and 
CD34+CD38+CD90-CD135+CD45RA- (common myeloid progenitors, CMPs), 
CD34+CD38+CD90-FLK2+CD45RA+ (granulocyte-macrophage progenitors, GMPs) and 
CD34+CD38+CD90-FLK2-CD45RA- (megakaryocyte-erythroid progenitors, MEPs) from BM and 
PB were isolated for colony forming cell (CFC) assays using the same setup.  
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For liquid culture, single HSCs were sorted into 96-well plates containing StemSpan 
(STEMCELL), cc100 cytokine cocktail (STEMCELL), Penicillin/Streptomycin (Sigma-Aldrich, 
St. Louis, MO, USA (Sigma-Aldrich)), L-Glutamine (Sigma-Aldrich), 2-Mercaptoethanol (Life 
Technologies, Carlsbad, CA, USA (Life Technologies)). Ten days post-sort the medium was 
supplemented with additional recombinant growth factors (GM-CSF (Miltenyi Biotec, Bergisch 
Gladbach, Germany (Miltenyi)), G-CSF (Miltenyi), M-CSF (Miltenyi), Epo (Janssen 
Pharmaceutica, Beerse, Belgium), IL-3(Miltenyi), TPO (Miltenyi), and IL-6 (Miltenyi)). After 4-
6 weeks in culture, single-cell derived clones were harvested into PBS for subsequent DNA 
extraction.  
For colony assays, bulk HSCs, CMPs, GMPs and MEPs were sorted into 1.5ml Eppendorf 
tubes containing StemSpan before distribution and plating in MethoCult H4435 (STEMCELL). 
After 2-4 weeks in culture individual colonies were picked into PBS for subsequent DNA 
extraction. 
For longitudinal time points, PB samples were collected (40-60 ml, Lithium-Heparin tubes) 
and MNCs and granulocytes were isolated using Lymphoprep. The granulocyte fraction was 
subject to two rounds of red blood cell lysis (Ammonium chloride, STEMCELL) and defined 
numbers of cells (1,000, 10,000 and 100,000 cells/well) were plated into 96-well plates for later 
DNA extraction (stored in PBS). Bulk CD4+/CD8+ T-cells and CD19+ B-cells were sorted and 
plated in 96-well plated for later DNA extraction (1,000 cells/well).  
DNA was extracted by the Cancer Genome Project Lab core facility from cell pellets using 
DNeasy kit (Qiagen 69504) for whole genome sequencing of colonies, and using the BioRobot 
according to the protocol for dried blood samples (Qiagen 965942) for targeted sequencing of bulk 
granulocytes and lymphocytes. 
 
 
2.b. Laser capture microdissection of colonic crypts 
 
 Fresh frozen biopsies were embedded in optimal cutting temperature (OCT) compound. 30 
micrometre sections were fixed in methanol for five minutes, washed three times with phosphate-
buffered saline, and then stained with Gill’s haematoxylin for 20 seconds. Crypts were isolated by 
laser capture microdissection, with every crypt falling into a separate well. They were lysed using 
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the Arcturus PicoPure Kit (Applied Biosystems) according to the manufacturer’s instructions. 
DNA library prep then proceeded without clean-up or quantification. 
In an attempt to avoid batch effects, most plates of crypts included samples from multiple 
patients. For example, rather than dissecting all the crypts from one patient into one plate, in most 
cases the samples from a given patient were split into three groups, and crypts were cut into 
separate plates, which they shared with samples from other patients. Almost all patients had some 
samples dissected on a different day and into a different well to other samples from the same 
patient. Batch effects that affect coverage should be accounted for by statistical analysis that 
explicitly takes coverage into account. Batch contamination with DNA of another species should 
be detectable at quality control, as a low proportion of reads mapping to the genome; in other work, 
for example, Mycoplasma contamination of sequenced cell lines was detected. Batch effects 
cannot be solely responsible for the presence of any novel signature, as all novel signatures have 
been detected in crypts from multiple plates and sequencing runs. Nonetheless, we cannot exclude 
batch effects that could affect crypts from the same section of tissue, as normally these are 
processed together. 
 
 
2.c. Isolation and growth of colonic organoids by the Clevers lab 
 
 The following work was performed by the Clevers lab. Human normal and tumour colon 
organoids were established and maintained from isolated colonic epithelium. In brief, long term 
normal colonic organoid culture required Human Intestinal Stem Cell Medium (HISM) composed 
of Advanced DMEM/F12  (AdMEM) with penicillin/ streptomycin, 10 mM HEPES, 
1xGlutaMAX,1xB27 (Invitrogen) and 1 µM N-acetylcysteine (SIGMA), supplemented with 50 ng 
mL-1 human recombinant EGF (Peprotech), 0.5 µM A83-01 (Tocris), 3 µM  SB202190 (SIGMA), 
1 µM  Nicotinamide (SIGMA), 10 nM Prostaglandin E2,Wnt3A-condition medium (CM) (50% 
final concentration), Noggin-CM (10% final concentration), and R-Spondin1-CM (10% final 
concentration). Tumour organoids were cultured in medium containing only EGF, Noggin-CM, 
R-Spondin1-CM and A83-01.   
For clonal organoids from normal crypts, single crypts were embedded in 10 µl Matrigel 
and cultured in HISM medium. For clonal tumour organoid cultures, tumour cell suspensions were 
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cultured for 7-14 days in HISM without Wnt3A-CM. 10-15 individual organoids were picked and 
separately dissociated into single cells by TryPLE express (Thermo Fisher), washed and suspended 
in AdMEM containing Propidium iodide (PI). 48 single cells were sorted into tumour organoid 
medium (HISM plus 10 μM ROCK inhibitor Y-27632 (Tocris BioScience); no Wnt-CM) from 
each tumour organoid.  Sorting was based on FCS Area/FCS peak and PIneg/FCS Area using a 
Moflo machine (Beckman Coulter). Sorted cells were spun down at 1000 g and 4°C for 5 minutes, 
after which single cells were each embedded into 10 µl of Basement Membrane Extract (BME, 
Amsbio) and seeded into 96 well-plates at a ratio of 1 cell/well. The gel was left to solidify in a 
37°C incubator after HISM (no Wnt3A-CM) was added. Y-27632 was added to the medium for 
the first a week after sorting. For each original tumor organoid, a single clonal organoid was 
selected and expanded for further study.  
 DNA was extracted from frozen tissue samples or organoid cultures using AllPrep 
DNA/RNA minikit (Qiagen 80204). 
 
 
3. Library preparation and sequencing 
 
3.a. Library preparation 
 
Libraries for the blood study and for the colonic organoids were prepared by the Sanger 
Institute Core Pipelines. Library preparation of low-input microdissected crypts was performed by 
Peter Ellis and Chris Alder. Two library preparation methods were used for low-input material: 
initially, sonication was used to fragment DNA, and later, an enzymatic fragmentation method was 
implemented as it could make libraries from even lower input. Comparison of the two methods 
showed no difference in mutation calls once post-processing filters (described below) had been 
implemented. For sonication libraries, 20ul of LCM lysate was sheared with focused acoustics and 
DNA isolated with magnetic beads. End preparation and A tailing was performed and duplexed 
adaptors were ligated. After another bead-cleanup and 12 PCR cycles, a final bead-cleanup was 
performed and sequenced on the HiSeq X platform (Illumina). For enzymatic libraries a magnetic 
bead separation was performed up-front. DNA was not washed off beads, but a bead/DNA slurry 
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was incubated with Ultra II FS buffer and Ultra II FS enzyme (New England BioLabs). DNA that 
was fragmented and A-tailed was ligated with duplex enhancers and processed as for sonication. 
 
 
3.b. Sequencing 
  
 For whole genome sequencing, paired end sequencing reads (150bp) were generated using 
Illumina XTEN® machines. For targeted sequencing, sequencing reads (75bp) were generated 
using Illumina HiSeq2000® machines. Sequences were aligned to the human reference genome 
(NCBI build37) using BWA-MEM for 150bp reads and BWA-align for 75bp reads by the Sanger 
Institute Core Informatics team.  
 
 
4. Bait-set design for targeted sequencing of peripheral blood 
 
Very deep sequencing of every single substitution detected in the clones would be cost-prohibitive. 
We therefore selected mutations to be included in the bait-set according to the following criteria: 
• All mutations called by the Shearwater algorithm (see below) in two or more samples 
• Mutations called in at least one clonal sample and also in at least one polyclonal sample 
• We aimed to sample approximately 20 mutations private to each colony (for both clonal 
and polyclonal). These were selected in the following way: 
o Mutations were ranked according to their sequencing error rate from whole genome 
sequencing of a large panel (approximately 1000 tumours and normal samples). 
The Shearwater algorithm was used to calculate the error rate. 
o We then picked the 10 mutations on the X chromosome with the lowest error rate, 
since mutations on the X chromosome should provide greater sensitivity as our 
patient is male. 
o We then picked the 10 mutations from elsewhere in the genome with the lowest 
error rate. 
o When selecting mutations private to polyclonal colonies, we prioritised mutations 
with the highest VAF, that were likely to be in the dominant clone.  
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• We also included 100 mutations that are known hotspot mutations found in clonal 
haematopoiesis of indeterminate potential (CHIP) and leukaemias in order to detect CHIP 
should it arise. 
   
We performed custom RNA bait design following manufacturer’s guidelines (SureSelect®, 
Agilent®, UK). Of the 19336 mutations selected, only 9175 could have a high-quality bait 
designed for them (some mutations are not suitable for bait design because, for example, they fall 
in a repetitive region of the genome). Driver mutations that had been included to allow us to detect 
clonal haematopoiesis of indeterminate potential could not, of course, be assigned to the tree, and 
neither could mutations that were present in polyclonal samples and not in any clonal samples. 
After final data curation and re-assessment of mutation assignment to the tree, 7116 mutations 
could be assigned to the tree of 140 clonal samples unambiguously and used for analysis. 
 
 
5. Mutation calling 
 
5.a. Substitutions 
 
For all studies, substitution calling was broken down into three steps: mutation discovery; 
post-hoc filtering to produce a list of clean sites; and, finally, genotyping, where the presence or 
absence of every mutation in every sample is evaluated. Mutations were initially discovered using 
the Cancer Variants through Expectation Maximisation (CaVEMan) algorithm (Jones et al. 2016). 
CaVEMan uses a naïve Bayesian classifier to derive the probability of all possible genotypes at 
each nucleotide. CaVEMan copy number options were set to major copy number 5 and minor copy 
number 2 for normal clones, as in our experience this maximises sensitivity, but for analysing 
tumour organoids the tumour copy number profile from ASCAT (see below) was used. For all 
studies, the algorithm was run using an unmatched normal in order to be able to derive 
phylogenies: had another sample from the same individual been treated as a matched normal, early 
embryonic mutations would have been treated as germline and discarded, resulting in incorrect 
trees. Some post-processing filters were used in all studies. These included filtering against a panel 
of 75 unmatched normal samples to remove common single nucleotide polymorphisms, and two 
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filters (only applied to whole genome sequencing data) designed to remove mapping artefacts 
associated with BWA-MEM: the median alignment score of reads supporting a mutation should 
be greater than or equal to 140, and fewer than half of these reads should be clipped. After these 
filters, a pileup of all the samples from a given patient was constructed, counting the number of 
mutant and wild type reads in every sample over every site that had been called in any sample 
from that patient. Only reads with a mapping quality of 30 or above and bases with a base quality 
of 30 or above were counted. 
 
 
Different post-processing filters were applied depending on the dataset. 
 
 
5.a.i. Substitution calling in blood colonies 
 
To build a phylogeny from 140 colonies sequenced at low coverage requires a stringent set of 
mutation calls. To minimise the number of false positive mutations, the following post-processing 
filters were included in addition to those detailed above: 
 
• To remove germline:  
o We knew from initial manual tree building that there was an early split in the tree 
into two sample groups with more than 20 clonal colonies in either group. 
Therefore, if a mutation had mutant reads in greater than 120 out of 140 clonal 
colonies we considered it as germline. 
• To remove false positives, or mutations that would be uninformative for tree building: 
o Mutations that fell within 10 base pairs of each other or within 10 base pairs of 
indels were removed. 
Mutations 
called against 
unmatched 
normal with 
CaVEMan 
algorithm
Filtered against 
75 unmatched 
normals
Post processing 
filters as 
described in 
Nik-Zainal et al 
2012
Median 
alignment score 
of reads 
(ASMD) >=140
Fewer than half 
the reads 
should be 
clipped 
(CLPM=0)
Pileup: count 
mt and wt reads 
in all samples 
for subs called 
in any sample
Dataset-specific 
filtering
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o Mutations that had a sequencing coverage in a given sample of less than 6 reads for 
autosomes and less than 3 reads for sex chromosomes were given a status of NA in 
that sample. Mutations with this NA status in more than 5 samples were removed. 
o We observed that mapping artefacts could cause a mutation to be seen at low VAF 
in multiple samples. We therefore applied the following filters 
▪ the mean VAF for a mutation, across all samples in which there are any 
mutant reads at all, should be greater than 0.3. 
▪ exclude sites where more than 10% of the samples in which there are any 
mutant reads have a VAF of less than 0.1 
 
This resulted in 134,411 sites that were carried forward for further evaluation using the Shearwater 
algorithm (Gerstung et al. 2014), which was run by Sebastian Grossmann. This algorithm 
compares allele frequencies of variants to a background error model derived from sequencing 
thousands of samples from unrelated studies on the same platform. Sequencing errors are known 
to occur at different frequencies across different sites of the genome. By obtaining a 
comprehensive view of the number of variant calls at each position in unrelated normal genomes, 
we built an error model for each nucleotide change for each position. This method has previously 
been employed to find variants supported by small numbers of reads (Gerstung et al. 2014; 
Martincorena et al. 2015). For this study, the position-specific error probabilities were inferred 
from 234 whole genome sequences from unrelated normal samples from various donors and 
tissues. The ShearwaterML model to compare observed variant frequencies with the background 
error model is described in the R-package deepSNV-1.21.4 (Gerstung et al. 2014). After correcting 
for multiple testing with the Benjamini-Hochberg procedure, only variants were kept that were 
significantly mutated over the error model, using a corrected p value cutoff of 0.05. Although most 
true variants largely exceed this threshold, this procedure maximizes the chance of retaining 
variants on a relatively low number of reads but that occur in parts of the genome that suffer from 
few false positive calls. As a further stringent filter to minimise false positive calls, variants had 
to be supported by at least 3 mutant reads to be considered by the algorithm. In this way, every 
mutation called in an individual was genotyped as being present or absent in each sample.  
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5.a.ii. Substitution calling in colon microbiopsies 
 
 In addition to the filters described in section 5.a., additional filters were designed by 
Mathijs Sanders to remove artefacts associated with low-input library construction. The library 
preparation protocol for microbiopsies produced shorter library insert sizes than standard methods. 
It was, therefore, common for paired-end reads from microbiopsy libraries to overlap, resulting in 
double counting of mutant reads. Mathijs Sanders therefore generated fragment-based statistics to 
prevent the calling of variants supported by a low number of fragments. Variants were annotated 
by ANNOVAR (Wang et al. 2010) and fragment-based statistics (fragment coverage, number of 
fragments supporting the variant, fragment-based VAF) were calculated for each variant after the 
exclusion of marked PCR duplicates. In the rare event of a disagreement in the called base at the 
variant position between overlapping paired-end reads, the base with the highest quality score was 
selected. Fragment-based statistics were calculated separately for all fragments, only counting 
those with alignment score t 40 and base scores t 30. Variants supported by at least 3 high quality 
fragments were retained and used for the next stage of variant filtering. 
Examination of variants called in microbiopsies demonstrated that an excess was present 
within inverted repeats capable of forming hairpin structures, that they were supported by reads 
with very similar alignment start positions (i.e., not marked as PCR duplicates), and were primarily 
located close to the alignment start within the supporting reads. These variants were frequently 
within 1-30 base pairs of another variant. Filtering based on variant proximity alone would also 
remove actual kataegis events, and so could not be used. In silico modelling of the potential hairpin 
revealed that the variants called in the same read were aligning to each other in the stem of the 
structure, but could not form a base pair (i.e., mismatched), while all other bases could. Careful 
consideration indicated that the artefacts were the consequence of erroneous processing of 
cruciform DNA (existing either prior to DNA isolation or formed during library preparation) by 
the enzymatic digestion protocol applied. Mathijs Sanders considered modelling the hairpin 
structures to filter these variants, but given the fact that read clustering (i.e. similar alignment 
position) serves as a strong hallmark for these artefactual variants, he opted to use the proximity 
of the variant to the alignment start, and the standard deviation (SD) and median absolute deviation 
(MAD) of the variant position within the supporting reads, as features for filtering. These statistics 
were calculated separately for positive and negative strand aligned reads. In case the variant was 
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supported by a low number of reads (i.e., 0-1 reads) for one of the strands, the filtering was based 
only on the statistics generated for the other strand. Per variant, if one of the strands was supported 
by too few reads, it was required for the other strand that either: (I) there should be d 90% of 
supporting reads to report the variant within the first 15% of the read starting from the alignment 
start, or (II) the statistics MAD > 0 and SD > 4. Per variant, if both strands were supported by a 
sufficient number of reads it was required for both strands separately that either: (I) there should 
be d 90% of supporting reads to report the variant within the first 15% of the read, (II) the statistics 
MAD > 2 and SD > 2, or (III) that the other strand should have the statistics MAD > 1 and SD > 
10 (i.e., the variant is retained if the other strand demonstrates strong measures of variance). The 
proposed strategy reduced the number of artefactual variants while retaining all other variants, as 
assessed by running the last filtering step on WGS data from non-LCM experiments. 
After applying these filters, mutations were genotyped based on the number of mutant and 
wild type reads at each locus. Mutations were called based on a variant allele fraction (VAF) > 
0.2, a depth > 7, and at least 4 mutant reads. If the depth over a locus was less than seven in a given 
sample, or if there was more than one mutant read but the other criteria were not met, the genotype 
was set to NA for tree construction purposes. Loci that were set to NA in more than one third of 
the samples were removed for construction of the phylogeny. Positions were called as germline if 
they were either called as present or NA in all of the samples from a given patient. 
 
 
5.a.ii. Substitution calling in colonic organoids 
 
As organoids were sequenced with normal library preparation methods at higher coverage than 
other samples, they were fully clonal, and there were fewer samples from each patient (which 
makes phylogeny construction easier), less stringent filtering was required. However, a calling 
method had to be developed that allowed the detection of a pre-malignant clone that could contain 
both the normal organoids (which were derived from >5cm away from the tumour) and the tumour 
(a field effect). For each patient, the only germline reference available was healthy colorectal tissue 
>5cm distant from the tumour, consisting of epithelial and connective tissue. We reasoned that if 
there were a field effect the somatic mutations in this tissue should not be fully clonal. We therefore 
deducted germline mutations on the basis that they were fully clonal in the bulk normal, while 
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mutations that were subclonal in the bulk were not removed from the analysis. To define a mutation 
as subclonal in the bulk, the probability of finding the observed number of mutant reads or fewer 
given the sequencing coverage had to be less than 0.005, based on the binomial distribution with 
a probability of 0.5 for autosomes. Mutations that failed to meet this criterion were considered to 
be germline and were removed. Mutations were then genotyped using the Shearwater algorithm, 
as for blood colonies. The Shearwater algorithm was run by Sebastian Grossmann. 
 
 
5.b. Small insertions and deletions (indels) 
 
As for substitutions, calling of indels was broken down into mutation discovery, filtering, 
and genotyping. Mutations were called with the Pindel algorithm (Raine et al. 2015) using an 
unmatched normal. Post processing filters were applied as in Nik-Zainal et al. (Nik-Zainal et al. 
2012), and the number of mutant and wild-type reads was tabulated as above. The same dataset-
specific filters were applied as for substitutions. Indels were then genotyped based on a VAF>0.2, 
a depth of at least 10, and support of at least 5 mutant reads. 
 
 
5.c. Short tandem repeats (STRS) 
 
 Short tandem repeats were called only for the blood colonies in order to test the robustness 
of the tree. The HipSTR algorithm to call them was run by Sebastian Grossmann (Willems et al. 
2017). HipSTR was run using de novo stutter estimation and STR calling with de novo allele 
generation as per the author’s recommendation. The calls were filtered on a calling quality of at 
least 0.95 and at least six reads per sample spanning STR loci on autosomes and at least three reads 
on sex chromosomes. Calls were also filtered if more than 15% of the reads were affected by PCR 
stutter or featured indels in the STR flanking regions. If STR calls were removed in more than five 
samples, the locus was flagged for all samples.  
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5.d. Structural variants 
 
 Genomic rearrangements were called using the BRASS algorithm (Li et al. 2017, 
https://github.com/cancerit/BRASS). Abnormally paired read pairs from WGS were grouped and 
filtered by read remapping. Read pair clusters with t50% of the reads mapping to microbial 
sequences were removed, as were rearrangements where the breakpoint could not be reassembled. 
Candidate breakpoints were matched to copy number breakpoints defined by ASCAT within 10kb. 
Only structural variants where the two breakpoints were more than 1000 base pairs apart were 
considered. Blood colony structural variants were called against another colony, colonic 
microbiopsies against a matched normal when available and against another crypt when not, and 
colonic organoids against bulk normal epithelium. 
 
 
5.e. Copy number changes 
 
Copy number changes were called using the Allele-Specific Copy number Analysis of 
Tumours (ASCAT) algorithm (Van Loo et al. 2010, Nik-Zainal et al. 2012, 
https://www.crick.ac.uk/peter-van-loo/software/ASCAT). The same matched normal sample was 
used as for calling structural variants. For additional validation of copy number changes in normal 
colon, the QDNAseq algorithm (Sheinin et al. 2014) was run. ASCAT uses both the read depth 
and ratios of heterozygous single nucleotide polymorphisms to determine an allele-specific copy 
number, while the QDNAseq relies solely on variations in sequencing depth. To call amplifications 
and deletions in the colonic microbiopsy cohort, only those that were called by ASCAT and 
showed a clear departure from the background on QDNAseq were retained.  To call copy neutral 
loss of heterozygosity in this cohort, all such events called by ASCAT were checked visually on 
Jbrowse (Buels et al. 2016) to verify an imbalance of parental snps. 
 
6. Construction of phylogenies 
 
Phylogenies were constructed using the matrix of genotypes (with samples as columns and 
mutations as rows) derived for every patient.  
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6.a. Derivation of the phylogeny of blood 
 
The phylogeny of blood was built using the maximum likelihood implementation of SCITE 
(Jahn et al. 2016), a tree-inference algorithm that uses Markov chain Monte Carlo sampling with 
an error model that takes potential false positives and false negatives into account for tree scoring. 
The SCITE algorithm was run by Sebastian Grossmann. The false positive error rate was known 
as the probability of every mutation being real is provided by Shearwater. False negative error 
rates were estimated by visual inspection using jBrowse of over 1,000 sites that had been provided 
to Shearwater but not called as present. We ran five independent Markov chain Monte Carlo 
simulations with one million iterations to test for robustness of the obtained phylogeny that all 
resulted in the same tree. Furthermore, the results were consistent with manual tree building 
attempts on a subset of clonal colonies.  
 To test the robustness of phylogeny, we bootstrapped the substitution input matrix for 
SCITE 1,000 times and ran SCITE 1,000 times to generate bootstrapping p values for each node 
in the tree (figure 1.4a). Furthermore, we took the following steps to rebuild our tree using different 
data and/or different tree building methodology: 
1. We repeated tree building from the same matrix of substitution calls by maximum 
parsimony, bootstrapping 100 times.  
2. We repeated tree building from a combined matrix of substitution and indel calls by 
maximum parsimony, bootstrapping 100 times. 
3. We used the HipSTR algorithm to call STRs and built a tree with neighbour joining, 
bootstrapping the input matrix of mutation calls 100 times. 
4. We built the tree using all variants combined (substitutions + indels + STRs) using 
neighbour joining, bootstrapping 100 times.  
5. We built the tree using substitutions and non-STR indels using maximum parsimony, 
bootstrapping 100 times.  
 
 These are detailed below, and the results of each tree-building approach are shown in figure 
1.4. SCITE and HipSTR were run by Sebastian Grossmann, and all other work performed by me. 
It should be noted that the shape of our tree, with multiple short branches that are ancestral to many 
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cells, makes bootstrapping conservative. As some of the earliest splits in the tree are supported by 
a single mutation which may be omitted in a bootstrap replicate (a given mutation will be present 
on average in 630 out of 1000 replicates), some of the earliest splits may not be supported by a 
particularly high proportion of replicates, even though the mutation calls are highly confident 
(based on multiple colonies carrying 5-10 reads reporting the variant, while being completely 
absent from other colonies). Indeed, shorter branches have lower p values. 
 When comparing trees, the quantity of interest is whether high-confidence nodes from 
other datasets and tree-building methods agreed or disagreed with our tree. For the purpose of this 
analysis, we define a high confidence node as one that created the same split of samples into two 
groups in >=70% of bootstrap replicate trees built with a given method. 
 
1. Substitutions using maximum parsimony and bootstrapping. 
The input matrix of substitution calls was bootstrapped 100 times and trees were built with each 
bootstrap replicate using maximum parsimony. We used the mix programme from the phylip 
(Felsenstein 1989) suite of tools, using the Wagner method. Ignoring terminal nodes (which are 
uninformative), 58 out of 139 nodes had >70% support. The fact that such a low proportion of 
nodes was well-supported is most likely due to the fact that many of the branches at the top of the 
tree are supported by no mutations (hence the polytomies in our original tree) or a small number 
of mutations, which need not be present in every bootstrap replicate. Of the 58 well-supported 
nodes, 56 were present in our tree, and two were absent. The differences only involve a minor 
reordering of branches within a clade. The discrepancies are not supported by many mutations in 
the SCITE tree. 
 
2. (Non-STR) Indels using maximum parsimony and bootstrapping 
There are only 228 shared indels outside of short tandem repeats (STRs), and so it is not surprising 
that a tree built only from these should have a high degree of uncertainty and several polytomies. 
Only 22 nodes (out of 126 this time because of polytomies in the parsimony tree) are supported by 
>70% confidence. Two of these 22 disagree with our original SCITE tree. As with the 
substitutions, these two differences are minor departures from the original SCITE tree. 
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3. STRs with neighbour joining bootstrapping results 
Short tandem repeat indels were called with HipSTR (see above). The phasing quality was low 
and so the sum of alleles at a given locus was used, ignoring the parental origin. Trees were built 
with neighbour joining using the absolute distance between cells. We bootstrapped the matrix of 
calls 100 times, recalculating the distance matrix each time. The resultant consensus tree was 
uncertain, with multiple polytomies and only 2 nodes supported by 70% of the trees.  Of these two 
high confidence nodes, one agreed with our original SCITE tree and one disagreed. This discordant 
node sits at the top of one clade with 10 descendants in the STRs NJ tree. In our original SCITE 
tree, however, these cells are scattered around the tree. Some of these cells share large numbers of 
substitutions with cells not contained in the STRs NJ clade (such as BMH97 (inside the STR NJ 
clade), which shares ~500 mutations with BMH73 (outside the STR NJ clade)), which leads us to 
trust the substitution tree over the STR tree.  
 
4. Combined substitutions, indels, and STRs using neighbour joining 
We tried neighbour joining on the combined dataset of STRs, substitutions, and indels, 
bootstrapping the matrix of mutation calls 100 times. As there were 92,661 shared STRs, 9,982 
substitutions, and 228 indels, the STRs dominate each bootstrap replicate. As with the tree built 
only from STRs using neighbour joining, few nodes are well-supported. Of 27 nodes that were 
present in 70% or more of the trees, 23 were present in our original SCITE tree and 4 were 
discordant. Three of these 4 nodes were nested inside each other, and so really represent only two 
discordant clades. 
 
5. Combined substitutions and indels analysis using maximum parsimony 
Because of the lack of consistency among trees built by neighbour joining from bootstrap 
replicates of STRs, we performed an analysis on combined substitutions and indels, excluding 
STRs. We used maximum parsimony, as different false positive and false negative rates for 
substitutions and indels meant that SCITE would not have been appropriate. Of 59 nodes that were 
present in 70% or more of the trees, 56 were present in our original SCITE tree and 3 were 
discordant. The arrangements of the nodes in these three discordant clades is similar to their 
arrangement in the original SCITE tree.  
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 In summary, the vast majority of high confidence nodes found using other data types and 
tree building methods support the tree that we built originally with SCITE. Furthermore, with the 
exception of a couple of overlaps between maximum parsimony substitution and indel trees 
compared to maximum parsimony on combined subs and indels (i.e. the same tree building method 
on nested datasets), the disagreements between our tree and those built with different datasets or 
tree-building methods were not recurrent: different disagreements were found with each 
alternative tree. We are therefore confident that the tree that we have provided is the best tree that 
we could have built. 
 
The accuracy of the reconstruction of the tree matters principally for four findings:  
1. The uneven contribution to the embryo of the first division that we can reconstruct. 
2. The relationship between different cell types (stem cell vs progenitor, and peripheral blood-
derived stem cell vs bone marrow-derived stem cell). 
3. The timing of branch points throughout life for phylodynamic inference (both for the stem 
cell population size trajectory and the estimation of the number of stem cells contributing 
actively to granulopoiesis). 
4. Timing when in life mutations occur, such that we can assign our mutations to the tree. 
This is important both in terms of estimating stem cell pool size and for the analysis of 
stem cell clone contribution to different mature blood cell types. 
 
For the embryology analysis, since mutations were checked manually we are confident that the 
uneven split into two groups at the top of the tree is correct. For the latter three points, the most 
important features of the tree are later branchpoints. The precise arrangement of short branches 
right at the top of the tree is less informative than the branches that we observe later in molecular 
time. These branches are necessarily supported by more mutations shared by a small number of 
colonies, and so we are very likely to reconstruct them correctly. Indeed, none of these later 
branch-points were called into question by our different tree-building analyses. 
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6.b. Derivation of the phylogeny of colonic microbiopsies 
 
 Derivation of a phylogeny of colonic crypts was less challenging than that of blood because 
there were fewer samples per patient, and accuracy in the precise arrangement of short early 
branches was less important because we perform no analyses of the relatedness of different crypts. 
All that phylogenies are used for in this analysis is for timing mutations. The most informative 
branches in this case are the long branches shared by a small number of crypts, which are very 
robust to all tree construction methods. For this reason, trees were built using maximum 
parsimony, as for the validation of the blood phylogeny. The tree was bootstrapped 100 times and 
the consensus taken.  
 
  
6.c. Derivation of the phylogeny of colonic organoids 
 
Phylogenies were constructed by maximum parsimony, as detailed in the validation of the 
phylogeny of blood. The SCITE (Jahn et al. 2016) and Sifit (Zafar et al. 2017) algorithms were 
run for validation and produced the same results (data not shown). 
 
 
7. Assignment of mutations to the phylogeny 
 
Phylogeny inference programmes provide the topology of the tree but not the assignment 
of mutations. Mutations from the input matrix of genotypes therefore have to be re-assigned to 
branches. In order to assign a set of mutation calls with no false negative and no false positives to 
a tree, each branch of the tree would be considered in turn. If a mutation was called in all the 
descendants of a given branch, and in no samples that were not descendants of the branch, 
mutations would be assigned to that branch. However, the complexity of the phylogeny and the 
number of false positive and false negative calls in the mutation matrix affect how many mutations 
fit the tree perfectly. Because of differences in the datasets, slightly different approaches were 
taken to assign mutations to each tree. 
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7.i. Assignment of mutations to the phylogeny of blood 
 
 Given the size of the phylogeny of blood, its shape, and non-zero false negative and false 
positive rates of mutation calls, we expected that a proportion of mutations would not fit our tree 
perfectly. Consider a mutation that is truly present in 50 colonies. With 15x coverage over the site 
in every sample, if we simulate resampling of mutant reads from the binomial distribution (with 
size of 15 and probability of 0.5), 17% of the time the mutation will have fewer than the 3 reads 
required to call it in at least one sample. Variation in sequencing depth and sequencing errors 
would further decrease the probability of calling the mutation perfectly in every sample. Mutations 
were therefore assigned in the following way: 
 
• Private mutations, only called in a single sample, could be assigned perfectly to the branch 
ancestral just to that sample.  
• 6,819 out of 9,982 mutations called in more than one clonal sample fit the tree perfectly. 
These were assigned to the branch of the tree that was ancestral to all the colonies that bore 
the mutation to none of the colonies that did not bear the mutation. 
• The 3,163 mutations that did not fit the tree perfectly were assigned in a probabilistic 
manner.  
o True positive and true negative rates of 0.99 were chosen. 
o For every node, the probability that a mutation that was truly present in that node 
given the number of positive and negative calls in the descendants of the node and 
in all of the colonies that do not descend from that node, was calculated. 
o The mutation was assigned to the node which had the highest probability of the 
mutation being there. 1,306 mutations that had ambiguous placements (they fit two 
or more nodes in the tree equally well) were not assigned. 
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7.ii. Assignment of mutations to the phylogenies of colonic microbiopsies 
  
Colonic microbiopsies also suffered from low coverage, and, what is more, some stromal 
contamination. For this reason we did not expect mutations to fit the tree perfectly. Unlike in the 
phylogeny of blood, where assignment of mutations to branches mattered for the recapture phase, 
here mutations were only assigned to the tree in order to determine the mutational processes active 
at a particular time. We reasoned, therefore, that it was preferable to assign only mutations that fit 
the tree perfectly, and rather adjust the branch lengths based on the power to call mutations at a 
given branch. Using the clonality and coverage of all descendants of a branch, the proportion of 
true substitutions or indels on the branch that would be first discovered (whether by CaVEMan or 
Pindel) and then genotyped as present according to the criteria described above was calculated. 
The observed branch length was then adjusted by dividing by this proportion. This was done for 
both substitutions and indels, but not for structural variants and for larger copy number changes 
due to a lack of data: most branches have no large variants and so could not be extended 
appropriately.  Rearrangements and copy number changes were assigned to phylogenies manually. 
 
 
7.iii. Assignment of mutations to the phylogenies of colonic organoids 
 
 The colonic organoid data was high coverage (~30X) and fully clonal, and with relatively 
small numbers of samples per patient. Ignoring private mutations, which necessarily fit any tree, 
97.7% of shared mutations fitted the tree structure from patient 1 perfectly, 89.7% fitted the tree 
from patient 2 perfectly, and 88.1% fitted the tree from patient 3 perfectly. The lower concordance 
with the tree for patients 2 and 3 reflects the increased copy number changes that have occurred in 
these phylogenies. Examination of the copy number state at loci where there were discordant 
mutations showed that the majority could be explained by deletions of those mutations in a 
subclone. Substitutions that did not fit the tree perfectly were therefore assigned to the most recent 
common ancestor of the samples in which they were called.  
 The approach for assigning rearrangements was slightly different, as the same 
rearrangement may be called in related samples with slightly different breakpoints. To identify 
rearrangements that had been sequenced in related clones as the same, both the upstream and the 
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downstream breakpoints had to fall within 500bp of each other. The majority of rearrangements 
fitted the tree.  Visualisation of discordant rearrangements using IGV 
(http://www.broadinstitute.org/igv) showed that often an overlapping rearrangement meant that 
the rearrangement was lost in a clone.  
 
 
8. Analysis of relationships in phylogeny for blood 
 
 Testing for differences in the relatedness of cell types on the tree was carried out by analysis 
of molecular variance (AMOVA (Bird et al. 2011; Excoffier et al. 1992)), comparing stem cells 
derived from the bone marrow with those from peripheral blood, comparing stem cells relative to 
progenitors, and different progenitor types relative to one another. The phylogeny was first made 
ultrametric by extending private branches to the maximum branch length of 1210 mutations. Then 
the mutational distance between two samples (i.e. the number of mutations over which you would 
have to walk to go from one cell to another on the tree) was calculated for all sample pairs. Within-
population and between population sum of squared distances were calculated, divided by their 
degrees of freedom, and used to estimate the fraction of total variation explained by differences 
between cell populations (the F statistic). To calculate p values, the population labels of cells were 
randomly re-assigned 30,000 times, and the same statistic was calculated. The p value is the 
proportion of random re-assignments that has an F statistic more extreme than the observed value.  
 
 
9. Analysis of population size trajectory for tree of blood 
 
Analysis of population size trajectory was performed using the Phylodyn package (Karcher et al. 
2017, Lan et al. 2015), using a phylogeny made ultrametric by extending private branches to the 
maximum branch length of 1210 mutations, and with 70 grid points. 
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10. Targeted sequencing mutation analysis of peripheral blood 
 
 A stringent error-correction method of counting the number of mutant and wild type reads 
over a locus was devised and executed by Robert Osborne. BAM files were annotated with read 
coordinate (rc), mate coordinate (mc) and optical (od) auxiliary tags using biobambam2 (Tischler 
and Leonard 2014). Reads were included for analysis if they were marked as proper-pairs, had a 
minimum mapping quality ≥ 30, < 3 mismatches and were not marked as optical duplicates, 
supplementary, QC fail, unmapped or secondary alignments. We also restricted analyses to bases 
with base quality ≥ 30. Overlapping reads can result in double-counting of a base. If the base calls 
on read 1 and read 2 were not identical then the call was discarded. If the base calls on reads 1 and 
2 matched then the call was assigned to the read with the highest base quality score. If the call on 
reads 1 and 2 matched and the base quality scores on both reads was identical then the call was 
randomly assigned to one or other reads. Instead of discarding PCR duplicate molecules, we 
generated consensus calls by grouping calls from reads with the same fragmentation breakpoints, 
read orientation and read number. A consensus base was called if >90% of the reads shared the 
same base. There were no minimum number of reads (if the group contained only one read then 
its call was retained). 
  For plotting purposes, signal was then separated from noise by using data from control cord 
blood from two individuals using a Bayesian generalised mixed effects Poisson model which was 
written by Peter Campbell, with minor amendments by me. The input data comprise the observed 
number of reads reporting each variant in the control sample and the corresponding total depth 
across that base; and the same for each test sample from our subject. A Poisson model was fitted 
in which the dependent variable was the number of reads reporting the variant, including an offset 
for log(total depth) (so that we are really estimating the fraction of reads). Random effects were 
included for the branch in the test sample (allowing for the VAF of mutations on the same branch 
to be correlated); the mutation (allowing for variable error rates among different mutations); and 
the interaction term of specific mutation by test sample (allowing for the test sample to have excess 
reads reporting the variant than the control sample). Parameter estimates and residuals are assumed 
to be drawn from a multivariate normal distribution with uninformative conjugate priors on the 
covariance. The model was fitted with the R package ‘MCMCglmm’, with 300,000 iterations, a 
burn-in of 10,000 iterations and thinning to 1/1000 iterations. Mutations were called as ‘detected’ 
 47 
if more than 90% of iterations of the MCMC chain after burn-in estimated a positive term for the 
test sample. 
 
 
11. Detection of driver mutations and positive selection 
 
11.a. Detection of driver mutations and positive selection in blood 
 
 We searched both for particular mutations that could confer a selective advantage (driver 
mutations), and for global signals of positive selection in colonies that had undergone whole 
genome sequencing.  
 First, we first took all coding mutations called by CaVEMan or Pindel, but without 
applying post processing filters beyond those detailed in Nik-Zainal et al (2012) in order to 
maximise our sensitivity. We also searched for copy number changes and rearrangements that 
might affect known myeloid cancer genes. We then intersected this with a list of 348 genes that 
are found to be mutated in at least 10 haematopoietic and lymphoid neoplasms from the COSMIC 
database, found to be mutated in CHIP (Jaiswal et al. 2014; Genovese et al. 2014, Xie et al. 2014, 
Mckerrell et al. 2015), in AML (Cancer Genome Atlas Research Network et al. 2013), or in the 
COSMIC cancer gene census (Forbes et al. 2017). Any mutations in genes in our list were visually 
inspected on jBrowse as a form of verification, and we used prior knowledge of the gene’s function 
and the ways in which it is mutated to decide whether the mutation that we observed was a likely 
driver mutation. 
 Second, we tested for positive and negative selection of mutations using dNdScv 
(Martincorena et al. 2015, Martincorena et al. 2017). In brief, this algorithm compares the number 
of synonymous and non-synonymous mutations in coding regions, adjusting for the pattern of 
mutational processes in the sample and local mutation rates, to detect if there is an excess or paucity 
of non-synonymous mutations relative to what is expected by chance under a neutral model. An 
excess of non-synonymous mutations indicates positive selection, while a paucity indicates 
negative selection. This method of driver detection is therefore independent of prior knowledge. 
This allowed us to search both for genes that might be under positive selection, and to see the 
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global dNdS of all the mutations, which tells us whether there is any excess of non-synonymous 
over synonymous mutations in the whole dataset. 
 Finally, 100 of the most frequent mutation hotspots in clonal haematopoiesis of 
indeterminate potential were included in the bait-set for targeted sequencing of peripheral blood, 
allowing us to detect driver mutations that may not have been present in the clones that were 
originally whole genome-sequenced (Appendix A).  
 
 
11.a. Detection of driver mutations and positive selection in colonic microbiopsies 
 
 Again, driver mutations were detected both through an unbiased dNdS method and through 
manual annotation. For these analyses, the CaVEMan and Pindel calls were used without post-
processing filters in order to maximise our sensitivity. All putative driver variants were visually 
inspected using Jbrowse (Buels et al. 2016), and so we could afford a higher false positive rate in 
the mutation discovery phase. 
 dNdScv (Martincorena et al. 2015, Martincorena et al. 2017) was used to conduct three 
tests: first, using only the whole genome sequencing data, an analysis of selection over all genes; 
second, using combined whole genome and targeted sequencing data, over all the genes covered 
by the bait-set; and finally, using again this combined dataset, over 90 selected cancer genes 
(Appendix B). 
 Manual annotation of driver variants based on prior knowledge complemented this. A list 
of 90 colorectal cancer genes (Appendix B) curated from the literature, that were also covered by 
the bait-set were intersected with the list of substitutions and indels from combined whole genome 
and targeted sequencing. Mutations were annotated as putative drivers if they were either missense 
mutations that fell in an oncogene hotspot (based on visualisation of the distribution of mutations 
in the gene on COSMIC (Forbest et al. 2017)), or if they were nonsense mutations that fell in a 
tumour suppressor gene. 
 Finally, structural variants that might act as drivers were assessed by intersection of genes 
involved in each structural variant with the twelve genes involved in gene fusions that have been 
reported in colorectal cancer in COSMIC (VTI1A, TCF7L2, TPM3, NTRK1, PTPRK, RSPO3, 
ETV6, NTRK3, EIF3E, RSPO2, C2orf44, and ALK). No fusion genes were found. The genes 
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involved in structural variants in our data did not overlap with the list of 90 cancer genes used for 
assessing substitutions and indels, and nor were there any genes that were affected by more than 
one structural variant. 
 
 
11.a. Detection of driver mutations and positive selection in colonic organoids 
 
 Driver analysis in colonic organoids was performed by Sophie Roerink. To classify driver 
events in substitutions, indels and rearrangements the following criteria were used: 1) deleterious 
mutations in genes identified in CRC by TCGA (Cancer Genome Atlas Research Network et al. 
2012) 2) all other known oncogenes carrying a canonical activating mutation 3) tumour suppressor 
genes with loss of function, and/or carrying two deleterious mutations.  
 
 
12. Adjusting crypt mutation burden by the callable proportion of the genome 
 
Whole genome sequences from crypts have variable coverage and clonality, which affect 
the proportion of the genome that can be called. In order to compare crypts, crypt mutation burdens 
throughout the text are adjusted for their coverage and clonality. The read depths for 1,000 sites 
were sampled from each crypt in order to capture the variability in its coverage. For each site, a 
mutation was simulated. Numbers of mutant reads over a given simulated position were drawn 
from a binomial distribution with probability equal to the clonality of the crypt, and the number of 
trials equal to the coverage that has been sampled for that site. The proportion of simulated sites 
for which mutations are callable serves as an estimate of the callable proportion of the genome. 
Raw mutation burdens per crypt are divided by this proportion to estimate the total mutation 
burden per crypt. 
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13. Extraction of mutational signatures 
 
13.a. Categorisation of mutations 
 
 Mutations were categorised following the method used by the Mutational Signatures 
working group of the Pan Cancer Analysis of Whole Genomes (Alexandrov et al. 2018). Single 
base substitutions were categorised into 96 classes according the identity of the pyrimidine mutated 
base pair, and the base 5’ and 3’ to it. Doublet base substitutions were categorised into 78 classes 
according to the identity of the reference and alternative bases. Indels were classified according to 
whether they were an insertion or a deletion, the identity of the inserted/deleted base, the length of 
the mononucleotide tract in which they occurred, or the degree of homology with the surrounding 
sequence into 83 classes (figure 2.1). 
 
 
13.b. Non negative matrix factorisation (NNMF) 
 
 Consider a matrix, with the name of every sample along one side, the name of every 
mutation category that we have defined (e.g. C>A in ACA) on the other. The matrix is populated 
by the counts of mutations in each sample of each category. NNMF considers this observed matrix 
to be the product of a matrix of signatures and a matrix of exposures, plus some noise (Alexandrov 
et al. 2013b). The matrix of signatures is made up of the categories on one side, and the names of 
the signatures on the other, and populated by the proportion of a signature that is in a particular 
context. The matrix of exposures is made up of the samples on one side, the signatures on the 
other, and the amount that each signature contributes to each sample populates the matrix. The 
numbers that populate the matrices of signatures and of exposures are unknown. They are learnt 
by trying different combinations of numbers in these two matrices, and measuring the similarity 
of their product with the observed set of counts. In the classical version of the algorithm written 
by Ludmil Alexandrov, the distance metric used is the Frobenius norm (Alexandrov et al. 2013, 
Alexandrov et al. 2013b). The number of signatures that are used is not learnt from the data. 
Different numbers of signatures are tried, and a measure of the stability of the solution (calculated 
by bootstrapping the input data) and how well it approximates the observed data is used to select 
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the optimal number of signatures. With more signatures, the observed counts are approximated 
more accurately but the reconstruction is less stable. 
 
 
13.c. Hierarchical Dirichlet Process 
 
 The use of a Hierarchical Dirichlet Process to extract mutational signatures was developed 
by Nicola Roberts (Roberts 2015, Roberts 2018). A Dirichlet Process is a non-parametric 
clustering method that takes as input a probability distribution and produces as output a more 
discretised probability distribution over the same domain. Signatures are treated as a multinomial 
probability distribution of the set of mutation classes (e.g. the trinucleotide context). The mutation 
counts per category in a sample are considered to be the result of draws from a sample-specific 
mixture of a shared set of signature probability distributions. The hierarchical nature comes from 
the fact the samples are put in groups (for example, in my analysis all samples from one patient 
were put in a group), and the amount that each signature contributes to a sample is drawn from 
parent node of the group; this has the effect that samples within a group are considered to be more 
similar to each other than samples from different groups.  
 Signatures are learnt by Gibbs sampling (Teh et al. 2006). A set of clusters is initialised 
with random counts in each category, all contributing randomly to every sample. In every iteration 
of the chain, mutations are shuffled between clusters. They are more likely to be drawn into clusters 
that resemble them (i.e. that have a high proportion of mutations in the same class). With some 
low probability, mutations can also form their own clusters, which means that the number of 
signatures in the dataset can be learnt rather than having to be specified. Averaging over posterior 
samples over the chain produces the number of signatures, their identity, and their contribution to 
each sample. 
 The algorithm can be conditioned on known signatures by including nodes of “fake data” 
that containing pseudocounts in the category distribution of a known signature. Mutations from 
the real datat that are similar to these known signatures are likely to be drawn into their clusters. 
Mutations that are not similar to any of the preconditioned clusters, however, can still form their 
own clusters, allowing simultaneous matching to known signatures and discovery of new ones. 
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14. Timing copy number changes in colonic microbiopsies 
 
If substitutions are assumed to occur at a constant rate, the copy number of mutations over 
a particular copy number segment allows us to time when the copy number change occurred. For 
example, if one chromosome copy is amplified (i.e. a change from 1+1 to 2+1, where the number 
indicates the number of copies of each parental chromosome), then mutations that occurred on the 
amplified chromosome prior to its amplification will be on two copies, whereas those that occurred 
after the amplification will only be on one copy. Mutations were timed using the MutationR 
package (Gerstung et al. 2017, https://github.com/gerstung-lab/MutationTimeR), which accounts 
for lower detection sensitivity of mutations at lower copy number. To maximise reliability only 
copy number changes with that contained 100 substitutions at good coverage were timed. 
Trinucleotide profiles of substitutions estimated to occur before and after the copy number change 
were inspected and found to be very similar, suggesting that there has been no change in the 
mutational processes operative since the copy number change, and so supporting our assumption 
of a constant mutation rate. 
 
 
15. Timing mutations relative to a whole genome duplication 
 
A whole genome duplication (WGD) was observed in the trunk of the tumour for patient 2 
in the organoid study. Timing as many mutations as possible relative to this allowed the 
investigation of the evolution of mutational processes.  
 
 
15.a. Timing substitutions relative to the whole genome duplication 
  
 For every truncal substitution in every tumour clone from patient 2, the copy number 
segment (as called by ASCAT) in which that mutation fell was defined. Mutations could only be 
timed in samples in which there was a minor copy number of 0 and a major copy number greater 
than 1. Fortunately, because of the extensive copy number changes in this tumour, all mutations 
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fell in a region that met these criteria in at least one sample. For a given mutation that fell in such 
a copy number segment in a given sample, the VAF in that sample of known germline single 
nucleotide polymorphisms that fell in that segment (that necessarily occurred before the WGD) 
and the VAF of somatic mutations assigned to branches further down the tree (that necessarily 
occurred after the WGD) was examined. If, in a given sample, a mutation had a VAF greater than 
90% of the VAFs of the mutations that were known to occur further down tree it was considered 
to have occurred before the WGD, whereas if it had a VAF less than 90% of the VAFs of the SNPs 
it was considered to have occurred after the WGD. If there was any overlap between the 90th 
percentiles of the SNPs and the later mutations, or if the mutation fitted neither of these criteria, it 
was considered uninformative and was not used in the signature analysis. This accounted for 9,094 
mutations (out of a total of 12,623 assigned to the trunk), that were not used in signature analysis. 
There is no reason to believe that mutations that were excluded for these reasons should be 
attributable to different mutational signatures than those that could be included, and indeed their 
trinucleotide mutation contexts are similar (data not shown). For each mutation, then, the number 
of samples in which it had been counted before and after the WGD was tallied. If a mutation was 
called as occurring before the WGD in some samples and after the WGD in others, the mutation 
was designated as conflicting and excluded from the analysis. 82 mutations fell into this category, 
and the remaining 3,447 could be timed unambiguously relative to the WGD and used in the 
signature analysis. In figure 1 we extrapolated the preWGD and postWGD fractions and their 
relative signature components to all mutations identified in the clonal trunk of P2.  
 
 
15.b. Timing driver mutations relative to the whole genome duplication 
 
 Driver mutations in TP53 and APC were timed relative to the WGD in patient 2. The TP53 
mutation was at VAF 1 in a region that was 2+0 in all samples, indicating that it occurred before 
the WGD. There were mutations in both alleles (which we will call mutation 1 and mutation 2) of 
APC. P2.T4.2 and P2.T5.1 both had the APC locus called as 2+2, and both mutations were at VAF 
0.5. P2.T1.1, P2.T1.3, and P2.T6.2 were 2+1 in the APC region. Mutation 1 was at VAF 0.67 and 
mutation 2 at 0.33. In P2.T2.5 the region was also called as 2+1, but mutation 1 was at VAF 0.33 
and mutation 2 at VAF 0.67. This shows biallelic inactivation of APC prior to the WGD. 
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15. Placing a lower bound on the age at which cells acquired aberrant mutational processes 
 
 The onset of signature 18 was timed in each patient relative to the rate of signature 1 (see 
Results Chapter 2, section R.7.b.). Calculations are found in table M.1. 
 
 
  patient 1 patient 2 patient 3 
branch to calculate ratio of 
signature 1 : signature 18  
Ancestor of 
all clones 
except for 
PD21928c6 
Segment after 
WGD but before 
the most recent 
common ancestor 
Average of 
the two 
branches 
after the 
trunk 
signature 1 mutations in branch 2088 975 2043 
signature 18 mutations in 
branch 
2926 410 2571 
signature 1:signature 18 in 
branch 
0.7 2.4 0.8 
signature 18 mutations in trunk 1054 934 1617 
signature 1 mutations in trunk 2508 3509 3050 
estimate of signature 1 
mutations after signature 18 
onset 
752 2221 1285 
estimate of signature 1 
mutations before signature 18 
onset 
1756 1288 1765 
estimated years since signature 
18 onset 
24 20 22 
 
 
Table M.1. Calculations to estimate the onset of signature 18. 
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RESULTS CHAPTER 1 
CLONAL DYNAMICS OF NORMAL BLOOD 
 
Introduction to this chapter 
 
I.1. Haematopoietic stem cells 
 
 In adult homeostasis, hundreds of billions of blood cells must be produced every day, in 
the correct proportion of many specialised cell types, over the whole of life.  Mature blood cell 
types include erythrocytes that transport oxygen, platelets that control haemostasis, and a battalion 
of cells with complementary immune functions: neutrophils, basophils, eosinophils, dendritic 
cells, macrophages, natural killer cells, B lymphocytes, T lymphocytes, and innate lymphocytes. 
Many of these have multiple subtypes. All mature blood cells ultimately derive from 
haematopoietic stem cells (HSCs). The conceptual definition of an HSC, therefore, is that it should 
have the potential to produce all blood cell types and to self-renew, producing daughters that have 
equal potential for the lifespan of the organism. In between stem cells and their mature progeny in 
the hierarchy of differentiation are progenitor cells, with a weaker capability for self-renewal and 
a more restricted set of possible differentiation fates. A progenitor will typically undergo multiple 
cell doubling and differentiating divisions to produce large numbers of functional mature blood 
cells. 
 The term Stamzelle was coined by Ernst Haeckel in 1868 as the first organism from which 
all life stemmed, in line with his Darwinian views (Haeckel 1868, Laurenti and Gottgens 2018). 
He later used it to describe the fertilised egg, from which all cells in the organism derive. Thus, as 
explained by Laurenti and Gottgens, the term stem cell has always had the connotation of being at 
the root of a phylogeny, whether germline or somatic (Laurenti and Gottgens 2018). Bone marrow 
cells that could generate mature blood cells were described independently by Bizzozero and 
Neumann (Bizzozero 1868, Neumann 1868) and a cell type that might give rise to all of blood was 
proposed in the late nineteenth century, when it was suggested that red and white blood cells might 
have a common ancestor (Pappenheim 1896). This idea remained controversial (Cooper 2011) 
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until 1945, when Owen noted that fraternal twin cattle that had shared a placenta also shared the 
blood cell types of both calves for life, thus providing evidence of a long-lived cell type that could 
be the source of blood (reviewed in Weissman and Shizuru 2008). Owen wrote: 
 
Since many of the twins in this study were adults when they were tested, and since the interchange 
of formed erythrocytes alone between embryos could be expected to result in only a transient 
modification of the variety of circulating cells, it is further indicated that the critical interchange is 
of embryonal cells ancestral to the erythrocytes of the adult animal. These cells are apparently 
capable of becoming established in the hemopoietic tissues of their co-twin hosts and continuing 
to provide a source of blood cells distinct from those of the host, presumably throughout his life. 
(Owen 1945) 
 
 In the 1950s, transplantation studies provided the means to begin to characterize these cells. 
Bone marrow was shown to be the site of residence of HSCs, as lethally irradiated mice could be 
saved by injecting them with bone marrow from other animals (Lorenz, 1951). Although regrowth 
of haematological tissues was observed in the salvaged mice, it was initially believed that this was 
due to a humoral factor in the marrow stimulating autochthonous regeneration. In 1956, however, 
a chromosomal (Ford et al. 1956) or enzymatic (Nowell et al. 1956) marker was shown to be shared 
by mature blood cells from both the donor and the recipient, indicating that cells themselves were 
transferred and that the restoration of haematopoiesis might be cellular. The approach described 
in this results chapter of using mutational markers to track stem cell clones traces its origin to these 
original experiments.   
 In a series of seminal experiments in the 1960s, Till and McCulloch showed the existence 
of multipotent stem cells. They induced chromosomal markers in one mouse by irradiation and 
transplanted them into a second mouse. Spleen colonies in the recipient were clonal for a given 
marker, indicating that a single cell could make all the cells in a colony (Becker et al. 1963). Re-
transplanting cells from suspensions of spleen colonies into secondary recipients showed the 
capacity of some cells to self-renew through multiple rounds of transplantation and produce 
multilineage output (Siminovitch et al. 1963). Some chromosomal markers were found in both 
myeloid and lymphoid tissues (Wu et al. 1968), from which the authors concluded:  
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These findings […] indicate that hematopoietic colony-forming cells, erythroblasts, granulocytes, 
thymic cells, and the cells of lymph nodes may all belong to the same clone. Our studies, however, 
do not allow us to determine precise parent-progeny relationships within such a clone. For example, 
we do not know whether or not some or all hematopoietic colony-forming cells can differentiate to 
give rise to both myeloid and lymphoid descendants or, alternatively, if colony-forming stem cells 
and lymphoid cells have a common, as yet unidentified, precursor. The resolution of this problem 
will require further detailed analysis of patterns of differentiation within large hematopoietic 
clones. 
(Wu et al. 1968) 
 
These questions are still not fully answered. 
The invention of multi-parameter flow cytometry in the late 1970s provided new tools to 
study HSC behaviour. In the 1980s, the field moved to the prospective isolation of HSCs by flow 
cytometry on cell surface markers, assaying the potential of different populations to make the 
various mature cell types by in vitro colony assays or transplantation experiments (Visser et al. 
1981, Visser et al. 1984). This work led to the hierarchy of stem cell differentiation found in most 
textbooks today (reviewed in Weissman and Shizuru 2008). Crucially, in 1988 it was shown that 
functional stem cells could be isolated (Spangrude et al. 1988).  
The current working experimental definition of a stem cell has not moved on very far: a 
cell is generally accepted to be a stem cell if it can give rise to cells of both the myeloid and 
lymphoid lineages for at least 16 weeks within an irradiated host (Bryder et al. 2006), although a 
more rigorous test is whether its progeny can do the same when re-transplanted into a secondary 
recipient (Eaves 2015). In the intervening decades, multiple properties of stem cells have been 
characterised: for most of the time they should be quiescent (Wilson 2008, Foudi 2009, Cabezas-
Wallscheid 2017), glycolytic (Simsek et al. 2010, Ito and Suda 2014), rely on autophagy (Warr et 
al. 2013, Ho et al. 2017), and not synthesise as many proteins as their descendants (Signer et al. 
2014). None of these is absolute, and most of the time functional assays are required to show 
stemness. 
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I.2. The embryological origins of blood 
 
 Our study permits us to examine retrospectively the ancestry of adult blood cells, and so a 
very brief discussion of the embryology of blood aims to put this in context. The first blood cells 
in the developing embryo appear in the yolk sac (Sabin 1920). Primitive erythrocytes derived from 
the yolk sac assure oxygen transport in the developing fetus. They derive from a progenitor that is 
shared with the endothelial cells of the yolk sac’s blood islands, and consequently called a 
haemangioblast (Choi et al. 1998). Based on shared surface markers, haemangioblasts are thought 
to originate in the posterior region of the primitive streak (Huber et al. 2004). Yolk sac-derived 
cells, however, are not the ancestors of most adult haematopoietic tissue. This was elegantly 
demonstrated by grafting quail embryo bodies onto chicken yolk sacs before development of 
vascular connections between the chicken body and yolk sac (Dieterlen-Lievre 1975). Quail cells 
have a prominent nucleolus, which could be used as a lineage marker. Blood from these chimaeras 
was shown to derive exclusively from quail cells in 16 out of 17 animals. The site of development 
of the cells that go on to provide life-long haematopoiesis was established by transplanting various 
parts of the mouse conceptus into adult irradiated recipients (reviewed in Dzierzak and Speck 
2008). The aorta-gonad-mesonephros (AGM) region and the vitelline and umbilical arteries 
contained cells with the capability of long-term multilineage reconstitution. Haematopoietic 
clusters were seen to emerge from the ventral aspect of the dorsal aorta only three days after the 
beginning of yolk sac haematopoiesis, which indicates that the AGM and yolk sac haematopoietic 
precursors are unlikely to be particularly closely related. Haematopoietic cells made in the AGM, 
the yolk sac, and the placenta, all migrate to and reside in the fetal liver for the duration of 
embryogenesis, where they proliferate (reviewed in Mikkola and Orkin 2006). They colonise the 
bone marrow around the time of birth. 
 
 
I.3. Estimates of the numbers of active HSCs 
 
 One of the aims of this thesis is to estimate the number of active HSCs in a healthy human. 
Estimates have varied widely over the past few decades. Here, I review important contributions to 
the field. 
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I.3.a. Animal models 
 
 A feature of studies that aim to determine the identity and output of stem cells is the need 
to label cells such that their progeny can be traced. The induction of labels generally involves 
genetic manipulation, which is not feasible in humans. Most studies, therefore, have relied upon 
animal models.  
 
 
I.3.a.i. Transplantation studies in animal models 
 
Transplantation studies carry a triple benefit for tracking cells: first, the cell type of interest 
can be isolated by flow cytometry; second, it is easier to label these cells outside the body than 
inside it; and third, transplantation into a recipient allows an assay of stem cell function, based on 
the concept that stem cells are able to reconstitute long term multilineage haematopoiesis. These 
studies, however, bear two major and linked disadvantages: first, they provide an assay of stem 
cell potential rather than fate (cells that behave as stem cells physiologically may not do so in 
transplant and vice versa); second, the stress of  cell labelling and transplantation affects stem cell 
dynamics.  
 Initial studies of transplanting retrovirally-barcoded cells into genetically anaemic or 
irradiated mice indicated that one to three haematopoietic stem and progenitor cells (HSPCs) were 
responsible for the majority of the blood produced in the salvaged animal (Dick et al. 1985, Keller 
et al. 1985). Barcodes could be found in all lineages and after secondary transplantation, proving 
that the cells capable of reconstitution were from high up the differentiation hierarchy (Lemischka 
et al. 1986). Remarkably, transplantation of even a single cell was sufficient to reconstitute long-
term multilineage haematopoiesis (Osawa et al.1996).  
 More quantitative approaches have relied upon limiting dilution transplantation 
experiments in mice to determine the frequency of four to eight HSCs per 100,000 nucleated 
marrow cells (Abkowitz et al. 2000). As mentioned in the General Introduction in the context of 
determining the clonality of tumours, measuring the expression of an allele on the X chromosome 
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(X chromosome inactivation or XCI skewing) of female heterozygote mammals can be used to 
detect an imbalance in clone sizes: because of random X chromosome inactivation early in 
embryogenesis, under a stable polyclonal model of haematopoiesis half of cells should express the 
paternal allele and the other half the maternal one. This approach was used to estimate stem cell 
numbers in cats. Following autologous transplantation with different numbers of stem cells, the 
degree of XCI skewing was used to estimate the frequency of feline stem cells in the bone marrow 
(Abkowitz et al. 1996). Combining frequency estimates with counts of nucleated marrow cells per 
animal (determined from the distribution of radioactive transferrin) resulted in the estimate of 
11,000-22,000 HSCs per mouse and 6,000-16,800 HSCs per cat (Abkowitz et al. 2002). 
 Transplantation studies of an animal model closer to humans physiologically and 
genetically have also suggested the existence of thousands of stem cells. Autologous 
transplantation of irradiated macaques with large numbers of retrovirally-marked HSPCs 
suggested that at least 1,000 HSPCs contributed to multilineage haematopoiesis in the first year 
following transplantation (Kim et al. 2000). Longer-term follow-up of macaques has suggested 
that the first year post-transplantation is one of clonal instability (Kim et al. 2014). Nevertheless, 
follow-up for years still supports highly polyclonal long term multilineage haematopoiesis, with 
hundreds to thousands of unique markers detected (Kim et al. 2014, Koelle et al. 2017). It should 
be noted that long-term clonal marking assays will all underestimate the total number of cells 
contributing to haematopoiesis due to sequencing detection thresholds (a 0.05% detection 
threshold is reported in Koelle et al. 2017): small clones are missed, and a detectable one is counted 
as a single clone rather than the hundreds of stem cells that may descend from it. 
 
 
I.3.a.ii. Studies of native haematopoiesis in animal models 
 
Due to the disadvantages of transplantation studies outlined above, recent work has 
exploited advances in inducible genetic labelling to mark cells in vivo, allowing assays of actual 
stem cell fate rather than stem cell potential.  
In 2014, the Camargo group used an inducible sleeping beauty transposon system to label 
HSPCs indiscriminately at one time-point (Sun et al. 2014). Four months later (allowing the 
shortest-lived cells to exhaust), they searched for tags among different blood fractions. They found 
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that over 90% of granulocyte tags were only ever found at one timepoint for up to 12 months of 
chase. The authors ascribe this result to a model of clonal succession, where stem cell clones are 
recruited successively to drive haematopoiesis and then exhaust (Kay 1965). For a label to be 
detectable by their semi-quantitative method, it probably needs to be present in a number of stem 
cells, given that they estimate the sensitivity of their assay to be ~0.1% and there are likely to be 
thousands to tens of thousands of active stem cells. If this is indeed the case, then the model of 
clonal succession would require a number of closely related stem cells to enter synchronously into 
a phase of doubling and differentiating cell divisions to fuel blood production, until they all exhaust 
at the same time. The coordination of multiple stem cell members of a clone seems implausible, 
and such a conceptualisation of haematopoiesis is perhaps a consequence of the experimental 
approach of labelling cells at one particular time-point. This separates a large branching phylogeny 
into distinct clades (or clones) by drawing a horizontal line at the time of labelling and suggests 
that a clone is a meaningful biological entity. If labelling had occurred earlier, clones would have 
contained more stem cells, and if later, fewer; there is no reason for all members of a clone to share 
a pattern of behaviour when the level of grouping is so arbitrary. The original hypothesis of clonal 
succession (Kay 1965), proposed that coordination of clones might be spatial or involve a positive 
feedback loop. Little evidence of these feedback loops has emerged in the fifty years since the 
hypothesis was formulated. In the absence of this evidence it is hard to reconcile clonal succession 
with polyclonal haematopoiesis. 
Sun and colleagues found that only 7% of bone marrow granulocyte tags were shared with 
nascent pro/pre-B cells, which was interpreted to mean that haematopoiesis was largely driven by 
unipotent progenitors. There are, however, other plausible interpretations of this finding. Firstly, 
analysis of their results is complicated by the fact that both stem and progenitor cells are labelled: 
tags from unipotent progenitors will necessarily be short-lived and lineage-restricted, and will far 
outnumber tags in stem cells and multipotent progenitors. Putting that aside, as a long chase period 
was allowed, these results can be explained by the polyclonality of blood without the need to 
invoke clonal succession or consign the bulk of steady-state haematopoiesis to lineage-restricted 
populations. Let us suppose that 15,000 stem cells are present in a mouse (Abkowitz et al. 2002). 
Allowing for some neutral drift of the population over the chase period, these might retrace their 
ancestry to perhaps 12,000 stem cells at the time of labelling. The labelling strategy tags ~30% of 
HSCs, so ~4,000 clones are tagged. Sun et al. generally recapture a few hundred tags, so let us say 
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that 400 tags from granulocytes and another 400 from B lymphocytes are captured. Assuming that 
these are derived from HSCs that make exactly equal proportions of B lymphocytes and 
granulocytes, these each represent independent samples of 10% of the labelled stem cell clones, 
and we would only expect a 1% overlap between the two of them. This 1% of the total pool of 
labelled clones represents 10% of the labelled granulocyte clones that were captured, and so the 
authors would present this finding as showing that only 10% of tags from granulocytes were 
recaptured in B lymphocytes – a number not dissimilar from the 7% that they found. The same 
argument can be used for why granulocyte tags are infrequently recaptured. The overlap could be 
further reduced if the number of stem cells were larger (which it could quite conceivably be), some 
stem cells were even slightly biased towards one lineage or another, there were an imbalance in 
the number of tags recaptured from different samples, or if there were a degree of transposon 
reactivation during the chase period. Indeed, the transposon was found to have remobilized in the 
absence of induction in one of 24 secondary colonies derived to test the leakiness of their assay. 
Nonetheless, this study remains an elegant demonstration of the vast polyclonality of blood in 
unperturbed haematopoiesis. 
 Busch et al. took the alternative lineage-tracing approach of permanently inducing the 
expression of yellow fluorescent protein (YFP) in 1% of immunophenotypic HSCs and all their 
descendants (Busch et al. 2015). The population is studied as a whole: individual cells are not 
marked and consequently any stem cell heterogeneity is missed. By limiting dilution, they 
estimated that ~30% of immunophenotypic HSCs contributed to haematopoiesis over most of a 
mouse’s adult life. As most strategies for isolating HSCs also mark some progenitors, this 
proportion could well be higher: it is conceivable that all stem cells contribute. No attempt was 
made to estimate the number of HSCs, but rather this proportion was combined with estimates 
from limiting dilution transplantation experiments of ~17,000 stem cells to derive a lower bound 
of ~5,000 HSCs actively contributing to haematopoiesis in the investigated time period. Slow 
equilibration between the proportion of the label in the stem cell and progenitor compartments was 
taken to mean that the bulk of haematopoiesis must be sustained by cells downstream of the most 
undifferentiated HSCs. Finally, YFP+ cells were transplanted into recipients in order to investigate 
the differences between in vivo and transplant haematopoiesis. They found very variable 
engraftment, with a mean of one in 33 engrafting. This helps to explain some results of oligoclonal 
haematopoiesis from transplantation experiments and strengthens the case for in vivo studies. 
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 A similar study was performed by Sawai et al. (2016), where a different system was used 
to lineage-trace a high proportion (80-90%) of HSCs with the least differentiated phenotype and 
slowest proliferation rate. Longitudinal analysis allowed a precise timing of when the label 
appeared in different compartments and the kinetics of differentiation. Broadly, their results agree 
with those of Busch et al. and Sun et al. on the large numbers of stem cell clones contributing to 
haematopoiesis, although they find that the rate of transition from stem cell to mature blood cell 
types is faster, estimating that 3-8% of the labelled HSCs enter differentiation every day. This 
supports a more traditional model in which progenitors are less long-lived. 
 Finally, a polylox recombination system which marks cells uniquely by randomly excising 
and inverting ten cassettes was used by Pei et al. (2017) to mark embryonic cells in mice at the 
emergence of HSCs. 10 months after birth, barcodes were detected, showing that the adult HSC 
compartment is a mosaic of hundreds of embryonic clones, ranging in size from 0.2-3.8%, mostly 
with multilineage output. Since adult clones are nested within embryonic clones, the number of 
embryonic clones forms an extreme lower bound for the number of active stem cells. 
 In summary, all studies of in vivo unperturbed haematopoiesis in mice support a polyclonal 
model of haematopoiesis where large numbers of adult stem cells, likely in the thousands, 
contribute to haematopoiesis. It could be argued that they have not changed our understanding of 
haematopoiesis dramatically relative to transplantation studies, but they do at least demonstrate 
similar findings in a more physiological model. It should be noted that even in animal models there 
are no direct estimates of the number of active stem cells at steady state. 
 
 
I.3.b. Estimates of human HSC numbers 
 
65 million years of evolutionary divergence, coupled with the long lifespan and large size 
of humans indicate that – even if we had good estimates from mice – it may not be sufficient to 
extrapolate from mouse studies to estimate human stem cell numbers and dynamics. Mice are 
typically studied under pathogen-free conditions, the proportion of peripheral blood cells that are 
myeloid in humans is larger, and there are many known differences between HSCs from the two 
species, including immunophenotypic definition, cytokine requirements, and differences in the 
HSC niche (Doulatov et al, 2012, Abkowitz et al.1996, Catlin et al. 2011, Larochelle 1996). Below, 
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I discuss experiments that aim to estimate stem cell numbers in humans, first by transplantation 
into mice or other humans, and then in unperturbed haematopoiesis by necessarily indirect means. 
 
 
I.3.b.i. Xenotransplantation of human cells into animals 
 
 Xenotransplantation studies face all the caveats of autologous and allogeneic 
transplantation, with the added complication of differences between the human niche and that of 
the recipient immunosuppressed animal. Furthermore, they have produced varying results, with 
the estimate of the number of stem cells varying from 250,000 (Wang et al. 1997) to ~7,000 
(discussed in Bystrykh et al. 2012). It is unclear how to reconcile these experiments, although 
differences in the degree of immunocompromise of the animal, the transplantation regimen, and 
the amount of ex vivo manipulation of stem cells may all be important. 
 
 
I.3.b.ii. Transplantation of human cells into humans 
 
 The advent of gene therapy over the last few decades has allowed analysis of unique gene 
insertion sites as a side-product of clinical trials. Although initial attempts were leukaemogenic 
through insertional mutagenesis (Hacein-Bey-Abina et al. 2003), more recently it seems that 
insertion of the genes acts as a neutral tag. In addition to the caveat that transplantation measures 
potential rather than fate, these patients are by definition unwell. Despite the fact that analysis of 
viral insertion sites is only semi-quantitative, counting the number of unique insertion sites 
detected years after transplantation provides a lower bound on the number of active stem cells in 
this non-physiological setting. At least hundreds (Cartier et al. 2009) or thousands (Biasco et al. 
2016) of stem cells contributed to long term multilineage haematopoiesis in these patients. 
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I.3.b.iii. Indirect methods of studying native human haematopoiesis 
 
Methods for studying native human haematopoiesis have been based on the detection of 
markers that vary naturally between different somatic human cells.  Firstly, in women 
heterozygous for an X-linked marker gene, detection of the proportion of cells that have inactivated 
either X chromosome (X chromosome inactivation or XCI skewing) provides insights into 
population dynamics. Early work inferred from the small degree of XCI skewing in most women 
that the number of active stem cells must be at least 400, based on binomial statistics (Buescher et 
al. 1985). A more recent study (Catlin et al. 2011), used the proportion of women with XCI 
skewing as a proxy for the rate of clonal drift. The rate of clonal drift is determined jointly by the 
population size and the rate of symmetric cell divisions (see below); knowing any two of these 
three terms allows the third to be inferred, but one is insufficient. Catlin et al. assumed that humans 
had the same number of stem cells as had been inferred in mice and cats by limiting dilution 
transplantation experiments (discussed above) and used that to infer the rate of symmetrical stem 
cell divisions. Furthermore, this study predates the description of clonal haematopoiesis (General 
Introduction), which may be responsible for a proportion of the skewing observed, particularly in 
the older of the two cohorts used. Finally, the model of how XCI skewing occurred is unusual: it 
was assumed to be due to hemizygous selection of one X allele over the other, with the parameter 
for the strength of the selective advantage drawn from a distribution based on the strength of 
hemizygous selection in Safari cats (cats that are the offspring of the distantly-separated South 
American and Eurasian breeds). There is little evidence of hemizygous selection in humans beyond 
the observation of skewed XCI. This Catlin et al. article is often cited in relation to the number of 
human stem cells despite the fact that no attempt is made to estimate it there (for example, Welch 
et al. 2012, Laurenti and Gottgens 2018, Young et al. 2016). 
Secondly, analysis of telomere length distributions over the life of patients (Werner et al. 2015) 
provides a window into tracking unperturbed haematopoiesis. Telomerase is expressed in HSCs, 
but at insufficient levels to stop telomere attrition completely over the course of life (Lansdorp 
2008). Werner et al. compared simulations to observed telomere data to infer the proportion of 
symmetric to asymmetric stem cell divisions over life. The underlying principle is that, under a 
model of purely asymmetric stem cell divisions, the telomeres shorten in all stem cells at the same 
rate, resulting in a Poisson distribution of telomere lengths over the population of cells, where the 
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lambda of the distribution decreases linearly with age. In contrast, in a model with mostly 
symmetric stem cell divisions, some stem cells have been through many more cell divisions than 
others. More stem cells are held in reserve, without cycling, and the decay in telomere length is 
logarithmic. Analysis of telomere data from a range of patients of different ages showed that the 
decrease in telomere length in the first decade of life is logarithmic and becomes linear later, 
indicating many symmetrical stem cell divisions and an increase in population size in childhood 
which then plateaus in adolescence. This, incidentally, argues against a model of clonal succession 
in adulthood. 
 
Taken as a whole, this large body of work across humans and animal models suggests that the 
more physiological the model, the greater the evidence for a large number of multilineage clones 
driving blood production at steady state. Nonetheless, no studies have estimated ab initio the 
number of stem cells in humans, due to the ethical contraints on inducing clonal markers in healthy, 
unperturbed humans. 
 
 
I.4. HSC clone lineage biases 
 
 Over the past fifteen years or so a number of findings have challenged the textbook model 
of haematopoiesis, in which a homogeneous pool of stem cells – through a rigid series of 
progenitors with defined lineage restrictions – produces the right balance of all cell types. In 
particular, the introduction of assays of single cells, whether colony-forming assays (Doulatov et 
al. 2010), transcriptomic analyses (Paul et al. 2015), or single cell barcoding experiments (Perie et 
al. 2015) have suggested alternative patterns of progressive lineage restriction and generally 
pointed towards lineage priming occurring higher up the hierarchy than anticipated by the original 
model, which was derived from observations of bulk populations that shared a surface marker 
(Laurenti and Gottgens 2018). However, this work is not the focus of the present chapter:  the 
discussion here is restricted to assays of the cell types that descend from clones of stem cells (rather 
than the precise series of progenitors that lie between an individual stem cell and its mature 
progeny) as that is of greater relevance to the results presented below. 
 
 67 
 
 
I.4.a. Transplantation studies in animals 
 
 Transplantation experiments in mice have shown that cells that meet the criteria for 
stemness can be further stratified based on their surface markers into those with greater or lesser 
self-renewal potential (Kent et al. 2009), indicating intrinsically-determined HSC heterogeneity. 
Furthermore, immunophenotypic HSCs can be biased towards producing one mature cell type or 
another (reviewed in Copley et al. 2012, and in Schroeder 2010). Some HSCs have been found to 
be biased towards the myeloid or lymphoid lineage (Muller Sieburg et al. 2004, Dykstra et al. 
2007, Challen et al. 2010, Muller-Sieburg et al. 2012), and some towards the megakaryocyte-
erythrocyte lineage (Sanjuan-Pla et al. 2013). Interestingly, HSC biases are recapitulated upon 
their transplantation, suggesting that this is a somatically heritable phenotype, although it may 
additionally be modulated by extrinsic signals such as growth factors (Muller-Sieburg et al. 2004, 
Dykstra et al. 2007, Challen et al. 2010). 
 
 
I.4.b. In vivo studies in animals 
 
 As previously discussed, transplantation experiments and colony assays determine a cell’s 
potential rather than its fate had it remained in its host under physiological conditions. HSCs in 
vivo could therefore be more or less biased than is suggested by ex vivo experiments, including the 
experiments that built the classical roadmap of haematopoiesis in the 1980s and 1990s. As 
described in the section on estimating stem cell number above, it has recently become possible to 
induce unique and heritable tags in haematopoietic stem and progenitor cells such that their clonal 
output can be determined in homeostasis. In a study that used the same sleeping beauty transposon 
system as Sun et al. (2014), after eight weeks of chase many tags were shared across all lineages 
except for megakaryocyte precursors, suggesting most stem cells are ancestral to multiple cell 
types, with the exception of megakaryocytes (Rodriguez-Fraticelli et al. 2018). Conversely, a large 
number of tags were found only in megakaryocytes, indicating that in unperturbed haematopoiesis 
a reasonable proportion of stem cells make megakaryocytes and negligible numbers of other cell 
 68 
types. Importantly, some of these megakaryocyte-restricted HSCs produced multilineage output 
when transplanted into a recipient, highlighting the suggestibility of these biased HSCs.  
 
4.c. Observations and transplantation studies in humans 
 
 In humans, it has been observed that with increasing age a myeloid bias develops (Pang et 
al. 2011). Two explanations have been put forward: stem cells represent one congruent population 
without bias in youth, but a bias towards the myeloid lineage develops with increasing age; or the 
stem cell pool represents at least two groups, one of which has a myeloid bias and one a lymphoid 
bias, and over the course of life the myeloid-biased group gradually predominates over the other 
(Schroeder 2010). Which of these is the case remains to be determined. Gene therapy studies have 
provided the opportunity to track transplanted cells in humans using the site of vector integration 
as a unique clonal mark. In a study of four patients with Wiskott-Aldrich syndrome who were 
transplanted with autologous genetically-modified HSPCs, integration sites were frequently shared 
between myeloid and lymphoid cells (unfortunately, no separate analysis of B and T lymphocytes 
was reported) showing the existence of multipotent stem cell clones (Biasco et al. 2016). In 
contrast, in one B-thalassaemia patient who received a genetically modified HSPC transplant, a 
long-lived (33 months) B and T lymphocyte-deficient clone was observed, suggestive of a myeloid 
biased stem cell (Cavazzana-Calvo et al. 2010). Intriguingly, the lentiviral vector in this clone had 
integrated into and increased the expression of HMGA2, a known regulator of HSC self-renewal 
durability (Copley et al. 2013). Its behaviour may therefore reflect normal biology or be due to 
insertional mutagenesis. 
 
 In summary, there is compelling evidence for some degree of HSC lineage bias, although 
most stem cell clones in humans and unperturbed mice still seem to have multipotent output. Very 
little is known about biases in unperturbed human haematopoiesis. What bias there is in animal 
models seems to be both cell-intrinsic and flexible in the case of stress. One can conjecture that 
the ability of HSCs to modulate output based on environmental stressors might be advantageous 
in evolutionary terms, given that the haematopoietic system is faced with the challenge of 
massively amplifying the production of one cell type – such as granulocytes in acute infection or 
platelets in haemorrhage – without necessarily scaling up the production of other cell types. 
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I.5. Spontaneous somatic mutations as natural barcodes 
 
 To track the clonal dynamics of stem cells in a healthy unperturbed human requires a label 
that occurs naturally in cells at a high rate, persists over life, and can be reliably detected. Somatic 
mutations provide such a marker. Induced mutations were famously used by Till and McCulloch 
to study normal haematopoiesis, and spontaneous mutations have been used to track the clonal 
dynamics of tumours (Ding et al. 2010, Ding et al. 2012, Tsao et al. 1999). We build on this work 
to use spontaneous somatic mutations to study normal blood.  
In blood, all available evidence – limited though it is – indicates that the mutation rate over 
life is relatively constant. Welch and colleagues cultured and whole exome sequenced three single 
HSPCs from each of seven healthy individuals spanning in age from birth to the eighth decade of 
life (Welch et al. 2012). Although the total number of mutations per exome is low, these data show 
a linear accumulation of mutations. Furthermore, in acute myeloid leukaemia the mutation burden 
increases linearly with the age of diagnosis (Welch et al. 2012, Alexandrov et al. 2015). More 
noise is present in analyses of blood cancers, most likely due to a combination of occasional 
aberrant mutational processes in some cancers which inflates the mutation burden and a variable 
time to the most recent common ancestor (MRCA) of the tumour (a longer time to the MRCA 
decreases the number of mutations called since many subclonal mutations will not be detected). 
Not only does the mutation rate seem constant, but the mutation burden is sufficient for us to detect 
large numbers of potential clonal markers per cell. Welch et al.’s normal HSPC exomes acquired 
mutations at a mean of 0.13 exonic mutations per year of life. Assuming that approximately 1% 
of mutations occur in coding regions, this translates to 13 mutations per genome per year, or 780 
in a 60 year-old. Most AMLs have approximately 400-500 mutations per genome (Cancer Genome 
Atlas Research Network et al. 2013, Welch et al. 2012). Thus, by sequencing 100-200 normal 
blood genomes in a 60 year-old, one could hope to detect over 100,000 nested clonal barcodes. 
Such an approach has become feasible in recent years because of the falling costs of sequencing 
and reliable methods of culturing single HSPCs into large colonies amenable to whole genome 
sequencing.  
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I.6. Population genetics models for studying stem cells 
 
 In this study, we use methods from the field of population genetics to study the clonal 
dynamics of blood. We conceive of blood stem cells as a population of asexually-reproducing 
individuals. It is therefore necessary to introduce briefly the population genetics models that we 
apply: the neutral Moran model and the neutral Wright-Fisher model, and the associated coalescent 
process. 
The population of stem cells can be thought of as behaving like the neutral Moran model 
of population genetics (Moran 1958, Gladstein 1978).  In this model, in every generation two 
different individuals (or stem cells, in our case) are chosen from the population at random; one 
dies (or differentiates), and the other reproduces (a symmetrical doubling stem cell division), 
leaving two daughter individuals which carry the set of mutations carried by the parent individual. 
The waiting time from the birth of an individual until it next gives birth or dies, in the Moran 
model, is equivalent to the waiting time from the origin of a stem cell (in a symmetrical cell 
division) until the first time its stem cell descendant undergoes a new symmetrical cell division. 
We are blind to asymmetric cell divisions, as they do not change the genotype composition of the 
stem cell population. 
Associated with the Moran model, which evolves forwards in time, is a genealogical 
process, where a sample of individuals from the population retrace their ancestry backwards 
through time. Here, in every generation back in time, a coalescent event may or may not occur 
among the ancestors of the sample. The occurrence of coalescent events is independent in each 
generation, and therefore the number of Moran model generations (going backwards) until a 
coalescent event has a geometric distribution, just as the number of coin tosses until a head is seen 
follows a geometric distribution. Kingman’s coalescent is a stochastic process that generates 
genealogies, for any specified sample size, exactly as if the forward time process is a neutral Moran 
model (Kingman 1982). The timings of the coalescent events and the random pairing of lines of 
descent together determine the topology of the phylogenetic tree and the branch lengths. 
When the population size N is large, N/2 generations of the Moran model closely 
approximates to one generation of the Wright-Fisher model (Fisher 1922, Wright 1931), which is 
more convenient to simulate forwards in time. In every generation of the Wright-Fisher model, the 
genotypes of individuals are obtained by sampling with replacement from the parent generation. 
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As with the Moran model, a reverse time genealogical process is associated with the forward time 
Wright-Fisher model, where every cell in one generation is assigned to a parent in the previous 
generation, independently of other cells; thus, a coalescence is generated when two cells happen 
to be assigned to the same parent.  
For a sample of cells from a given population, the probability of two cells picking the same 
parent in the preceding generation is dependent on the population size. If we only have two cells 
in our sample, and a population size of N, the probability that both will pick the same common 
ancestor in the preceding generation is 1/N. When the population size is large relative to the sample 
size, either zero or one coalescent event will occur in a given generation; that more than two cells 
should happen to pick the same common ancestor out of a large pool becomes very unlikely, 
making the model more similar to the Moran model. As with the Moran model, the number of 
generations until a coalescent event follows a geometric distribution. The probability of two cells 
not coalescing in a Wright-Fisher generation is (1-(1/N)). Therefore, the probability of coalescing 
G generations ago is the probability of not coalescing for (G-1) generations, and then of coalescing 
in the Gth generation: P(G) = (1-(1/N))G*(1/N). 
It follows that if the population size is 10 times larger, the probability of two cells picking 
the same parent is 10 times smaller, and 10 times more generations are required to achieve the 
same probability of a coalescent event. This means that the pattern of branch points in a phylogeny 
derived from a certain population size having gone through a certain number of generations will 
be the same as that from a population 10 times as large having gone through 10 times as many 
generations. 
It can be shown mathematically that the mean waiting time from the birth of an individual 
until it next gives birth or dies is the same as the generation time of the Wright-Fisher model (as 
shown by Kevin Dawson in the technical appendix of Lee-Six et al. (2018)). This in turn is 
equivalent to the mean time between symmetric cell divisions along a given line-of-descent. 
Because of this equivalence, we can simulate stem cell population drift using the Wright-Fisher 
model, which is computationally more convenient because fewer generations are required and each 
is of a fixed chronological duration.  
 
 
 
 72 
Results 
 
R.1. Experimental design 
 
 Here follows a brief overview of the experimental design. In order to exploit the somatic 
mutations of normal stem cells as clonal markers, our experiment was designed in two phases: a 
‘mutation discovery’ phase, in which somatic mutations were discovered by whole genome 
sequencing of colonies derived from single HSPCs from one individual; and a ‘mutation 
quantification’ phase, in which the mutations that we had discovered by whole genome sequencing 
were detected and accurately quantified in mature blood fractions from the same individual, telling 
us the output of the clones that we had discovered. These data were then analysed with methods 
adapted from population genetics and ecology, effectively treating each stem cells as an individual 
within a population. An outline of the experimental workflow is provided in figure 1.1a. 
 
 
R.2. Mutation discovery phase: HSPC isolation, clonal amplification, and sequencing 
 
 A bone marrow aspirate was performed (by Brian Huntly) on one healthy 59 year-old male 
volunteer with normal blood counts and no past history of blood disorders. Peripheral blood was 
taken on the same day. We also obtained a buccal swab as a germline control. An individual of 
this age was picked because he would be sufficiently old to have acquired a workable number of 
mutations (assuming the mutation rate reported by Welch and colleagues (2012)) but was young 
and healthy enough to allow, potentially, decades of longitudinal follow-up. Studying a male was 
advantageous because he would have only one copy of the X chromosome such that the allele 
fraction of X chromosome mutations could be evaluated more accurately. On a diploid 
chromosome, even a perfectly clonal mutation can still fluctuate in allele fraction because of 
binomial sampling of mutant and wild type reads, complicating the estimation of the true allele 
fraction, whereas a homozygous clonal mutation should be present on every single sequencing 
read. 
 Cells obtained from the bone marrow and peripheral blood harvest were sorted by flow 
cytometry. This served the dual purpose of isolating the immunophenotypic cell populations of 
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interest based on their cell surface markers and of obtaining single cells. Cells were cultured in 
methylcellulose or liquid culture for 2-6 weeks until colonies were derived that were sufficiently 
large to be whole genome sequenced.  Overall, we harvested 285 stem cell-derived colonies and 
390 progenitor-derived colonies, split across common myeloid progenitors (CMPs), granulocyte 
macrophage progenitors (GMPs), and megakaryocyte erythroid progenitors (MEPs). Progenitor 
cells that produced a colony with a different morphology to their immunophenotypic definition 
were not picked. All of the colony derivation work was performed by David Kent, Mairi Shepherd, 
Nina Friesgaard-Oebro, and Miriam Belmonte, with advice on culturing conditions from Elisa 
Laurenti. 
 When we began this study, whole genome sequencing required large amounts of DNA 
(~100ng), and not all colonies could be expanded to such a large size. This imposed a selection 
bias on the colonies that we sequenced towards colonies from less differentiated cell types that 
have greater expansion potential. It is also possible that colonies with certain mutations may not 
amplify well under normal culturing conditions relative to their wild-type counterparts, as has been 
observed for cancer-derived organoids from a number of tissues (van de Wetering et al. 2015). We 
chose to whole genome sequence at ~15X the 100 stem cell-derived colonies with the largest 
amount of DNA, and the 98 progenitor-derived colonies with the largest amount of DNA. 
 
 
R.2.a. Quality control of colony whole genomes 
 
 The clonal origin of each HSPC colony was determined by visual examination of 
histograms of their mutant allele fractions. In a colony that is truly single cell-derived, somatic 
mutations should only be present on one of two copies of an autosome, and so their allele fraction 
should be binomially distributed around 0.5. For the X chromosome of our male individual, allele 
fractions should be exactly 1. For 140 colonies, this was indeed the case. However, for the 
remaining 58, the allele fractions were lower, indicating that these colonies were derived from one 
or more cells (figure 1.1b). This is probably a result of colonies growing into one another in 
methylcellulose. Because some of the stem cells were grown in liquid culture, while all progenitors  
 
 
 
 
 
 
 
 
 
Figure 1.1. Experimental design and quality control. a, The 
experimental workflow. Following bone marrow aspiration, 
single haematopoietic stem cells (HSCs) and haematopoietic 
progenitor cells (HPCs) were isolated by fluorescence-activated 
cell sorting (FACS) and expanded in liquid culture or 
methylcellulose into colonies that could be whole genome 
sequenced. Somatic mutations discovered by sequencing were 
used to construct the phylogeny. This is the mutation discovery 
phase. In the mutation quantification phase, peripheral blood 
samples underwent deep targeted sequencing to quantify 
mutations that had been found in the discovery phase. b, 
histograms of the variant allele fraction (VAF) of mutations were 
used to identify whether colonies were derived from one cell or 
more. An example clonal sample (BMH66) and polyclonal 
sample (BMP12) are shown. In a clonal sample, the VAF of 
autosomal mutations should be distributed around 0.5, and that 
of sex chromosomes should be 1. For a subclonal sample it 
should be lower. Occasionally, even in a clonal sample lower 
VAFs are seen due to the failure to detect a mutation on a read, 
or a read from another locus being aberrantly mapped to the 
locus in question and lowering the apparent coverage, or a 
mutation acquired in vitro.  c, histograms of the burden of 
substitutions and indels across all 140 clonal samples. d, the 
distribution of mutations from all 140 clonal samples around the 
genome, shown as a circos plot. The outermost ring of the circos 
plot depicts the karyotypic ideogram. Moving inwards, base 
substitutions are shown as rainfall plots where the height of the 
dot in the substitution ring is proportional to log10 of the 
distance to the next mutation and with the colour of the dot 
illustrating the base change, as shown in the key. (c) a 
comparison of the substitution burden between stem cells and 
progenitor cells. There were not significantly more mutations in 
progenitors than stem cells (p=0.14, Wilcoxon Rank Sum test). 
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were grown in methylcellulose, the stem cells were less affected than the progenitors. Furthermore, 
MEPs grow as more compact balls than CMPs and GMPs, and so were relatively spared. For these 
reasons, after removal of 58 polyclonal colonies we were left with 63 bone marrow-derived HSCs, 
16 peripheral blood-derived HSCs, 38 MEPs, five CMPs, and eight GMPs. 
 We could also use allele fractions to assess what proportion of mutations might have 
occurred in vitro during the process of colony derivation. Unless a selective sweep occurred in 
vitro (which seems unlikely), only mutations that were present in the sorted founder cell will be 
fully clonal in a colony. The proportion of mutations that are subclonal within a colony with a 
VAF peak at 0.5 informs on the mutation rate. Because of binomial sampling of mutant and wild 
type reads combined with the low sequencing depth, it can be difficult to tell if a mutation on an 
autosome is truly subclonal. This is further complicated by sequencing false negative artefacts, 
and more frequently mismapping of reads to this location in the genome and appearing as a wild 
type read. Mismapping events are relatively frequent with Illumina HiSeqX-sequenced and BWA-
mem-mapped data. The bottom left-hand panel of figure 1.1d demonstrates two X chromosome 
mutations with a VAF below 1. Visual inspection of these mutations shows that one is present on 
4 out of 8 reads. This mutation is in a relatively low complexity part of the genome and could 
represent either a sequencing artefact or a mutation acquired in vitro. The other mutation is present 
on 12 out of 13 reads. The read that does not support the mutation maps uniquely to that position 
in the genome, and so probably represents a sequencing error. The variant, however, is likely to 
be a true clonal mutation. Thus, even true clonal mutations on the X chromosome may not have a 
VAF of 1, but the mutation is likely still to be present on a large proportion of the reads. Variants 
acquired in vitro, however, should be present in half of the cells in a clone or fewer. Therefore, a 
more informative metric of the proportion of variants that might have occurred in vitro is the 
proportion of X chromosome variants at variant allele fraction of 0.5 or less (assuming equal 
amplification of both daughters of the first cell division). Considering only positions with depth 
10 or above, at which the allele fraction can be estimated accurately, and considering only colonies 
with more than five high coverage X chromosome mutations called, the mean percentage of 
mutations per colony at a variant allele fraction of <0.5 is 5.6%.  
An additional source of evidence that in vitro mutations do not contribute substantially to 
our mutation catalogue is that two colonies share 1,115 substitutions and have only 51 and 87 
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private mutations respectively. In vitro mutations will typically be private, so fewer than 7% 
(87/(87+1115)) of the total mutations called in these colonies could have occurred in vitro. 
 
 
R.2.b. Genomics of normal blood cells 
 
 A mean of 1,023 (range 815-1,210) single base substitutions and 20 small insertions and 
deletions (indels) (range 2-37) were observed across the 140 colonies (figure 1.1c). No copy 
number changes or structural variants were detected. Progenitor cells had slightly more 
substitutions than stem cells (mean of 1,038 for progenitors and 1,024 for stem cells), but the 
difference was not statistically significant (p=0.14 by Wilcoxon rank sum test) (figure 1.1e). This 
result does not necessarily mean that progenitors do not have an increased mutation rate over stem 
cells, as the line-of-descent to any given progenitor will have spent nearly all its time as an HSC. 
Imagine that a progenitor that we sampled exited the stem cell compartment one month before 
sampling, and over that last month acquired mutations at a 10-fold greater rate than in stem cells. 
In this scenario, the progenitor would only have 10-20 more mutations than its stem cell cousins.  
Comparison of the mutation burden that we detect in normal HSPCs and that reported in 
acute myeloid leukaemia (AML) supports at the level of the whole genome the findings by Welch 
et al. that AML exomes do not have more mutations than normal HSPC exomes. Indeed, many 
AML genomes have a lower mutation burden than that reported here: the mean number of 
mutations per AML genome in a cohort with a mean age of 55 was just over 400 (Cancer Genome 
Atlas Research Network et al. 2013). Some of this difference may be due to different sequencing 
platforms and mutation calling algorithms. In addition, in some patients, contamination of the 
matched normal tissue with leukaemic blasts (such that somatic mutations may appear to be 
germline) could result in a significant underestimation of the mutation burden. Another – and 
biologically interesting – component is that the most recent common ancestor of the leukaemia 
may have existed a long time ago; if a single leukaemic cell were sequenced, it might have the 
same mutation burden as a single normal cell, but bulk sequencing misses a large proportion of 
the subclonal mutations in the tumour. Depending on the strength of the effect of the first three 
factors, comparison with our data would indicate that the MRCA of many AMLs occurred years 
to decades before diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Trinucleotide context of mutations in normal 
blood. a, the counts of substitutions in each of 96 trinucleotide 
contexts from all 140 clonal samples combined. b, c, the same 
figure for representative individual progenitor colonies (b) and 
stem cell colonies (c). d, Non-negative matrix factorisation of 
the blood trinucleotide context along with a panel of blood 
cancers deconvoluted the substitutions in the our samples into 
two signatures. Signature A accounted for 30% of mutations and 
bears a strong resemblance to signature 1 (see text). Signature B 
accounted for 70% of mutations and was novel. e, trinucleotide 
context of mutations from three blood cancers, chosen for their 
similarity to the trinucleotide context of normal blood colonies. 
f, results from mutational signature decomposition of a panel of 
cancers. The mutations burden attributable to each signature 
from each sample of a given cancer type is shown. Signatures 
that are not signature A or B are all coloured grey. CLLE, 
chronic lymphocytic leukaemia; COAD, colorectal 
adenocarcinoma; DLBC, diffuse large B cell lymphoma; KIRP, 
kidney renal papillary cell carcinoma; LAML, acute myeloid 
leukaemia; MALY, malignant lymphoma; MDS, 
myelodysplastic syndrome; MPN, myeloproliferative 
neoplasms; MM, multiple myeloma; PBCA, paediatric brain 
cancer. 
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 The somatic mutations in blood stem cell genomes that we observed were mostly C>T and 
T>C transitions, particularly in a context of NCT (the mutated base is underlined) (figure 1.2a). 
The trinucleotide spectrum of mutations in all of our samples was similar (figure 1.2b and 1.2c). 
A similar spectrum has been observed in a study of clonal haematopoiesis (Zink et al. 2017). Visual 
inspection of all blood cancer genomes included in the Pancancer Analysis of Whole Genomes 
study revealed that it was present in some cancers (figure 1.2e). A mutational signature (General 
Introduction) extraction was run with the combination of our samples and all of these cancers. The 
trinucleotide context of our sample was deconvoluted and found to be ~30% a signature that 
similar to signature 1, a known signature present in all tissues that is discussed in Results Chapter 
2, and ~70% a novel mutational process (signature B in figure 1.2d). Quantification of the 
contribution of this mutational process to all blood cancer genomes analysed indicates that it is 
present at some level in most blood cancers. It is responsible for a large proportion of mutations 
in myeloproliferative neoplasms, myelodysplastic syndrome, and AML, which have relatively 
quiet genomes and, as discussed above, for the most part have not departed significantly from the 
somatic mutational landscape of normal blood (figure 1.2f). In more mutated cancers, such as 
certain lymphomas, the signature is obscured by a vast excess of additional process, which may 
explain why it has not been reported previously. The signature contributed proportionately less to 
solid tumour genomes included as a negative control, although it was detected in kidney cancers 
and paediatric brain cancers. The cause of this signature, as with many mutational signatures, 
remains unknown. 
 The mutations were scattered across the genome (figure 1.1d), with <1% causing non-
synonymous changes in protein-coding genes. We searched our 140 genomes for driver mutations, 
(which would affect our interpretation of clonal dynamics in this experiment) in two ways: first, 
by manual annotation of known cancer genes, and second, using a dNdS approach which detects 
the enrichment of non-synonymous mutations in a gene above what would be expected by chance, 
indicating positive selection (Martincorena et al. 2017). The dNdS approach therefore does not 
rely on prior knowledge of which mutations are drivers. dNdS also allows us to estimate a global 
measure of selection across all the mutations in the dataset. The global dNdS across all 140 blood 
genomes is 1.0010 (95% CI 0.889-1.127), with values greater than one indicating positive selection 
and values less than one negative selection. No genes were found to be under positive selection by 
dNdS, and no known driver mutations were found by manual curation of known drivers of myeloid 
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neoplasms. Finally, in the second phase of the experiment in which we performed targeted 
sequencing, we included 100 common hotspot mutations frequently observed in clonal 
haematopoiesis and myeloid malignancies, and no drivers were detected despite deep sequencing. 
We cannot exclude the presence of as-yet undiscovered drivers that are rare in our dataset, but all 
the evidence that we have gathered indicates that this individual’s blood is evolving neutrally. 
 
 
R.2.c. Construction of a phylogeny of HSPCs 
 
 A phylogeny of HSPCs was constructed based on the sharing of somatic mutations across 
the 140 colonies. Our confidence in each of the branch-points was quantified by Felsenstein’s non-
parametric bootstrapping method (Felsenstein 1989), with 1,000 bootstrapping replicates. The tree 
was constructed independently based on indels and on short tandem repeats and using all types of 
data combined, using bootstrapping in all cases. We applied all three of a maximum likelihood, 
maximum parsimony, and neighbour joining methods (although not all on every dataset, as some 
are not appropriate for certain data types (Methods)). In general, the structure of the tree was 
supported with high confidence: few branch-points that were supported with high confidence using 
different methods disagree with the tree that we present (figure 1.4) (Methods). Tree-building was 
performed with substantial help from Sebastian Grossman (distribution of the work-load described 
in Methods). 
 The phylogeny that was reconstructed had a deep branching structure, with most mutations 
private to a given cell: of 129,582 substitutions on the tree, 8,676 were shared amongst different 
colonies (figure 1.3a). The construction of a phylogeny allowed us to perform multiple analyses: 
we could time mutations relative to one another (mutations on a branch shared by two colonies 
necessarily occurred before those on a branch private to one of those colonies); determine the 
relationship of all cells to one another; and apply phylodynamic models that were developed in the 
fields of population genetics and epidemiology to our data. These are explored below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Inferences from the phylogeny. a. phylogeny of 
140 single haematopoietic stem and progenitor cells showing the 
relationship between cell types. At each tip of the tree is a 
colony. Branches connect colonies to each other to form a family 
tree.  Branch lengths are proportional to the number of somatic 
mutations: thus, a branch that is ancestral to two colonies and 
100 substitutions long reflects the fact that these two colonies 
share 100 substitutions that are not present in any of the others. 
Symbols at the tips of the branches represent the phenotype of 
the cell. b, the same phylogeny as in a, but showing only the first 
10 mutations of molecular time. c, the number of descendants of 
each node for the first 10 mutations of molecular time, used to 
estimate the embryonic mutation rate (Methods). d, 
phylodynamic inference of the population size trajectory of the 
stem cell pool reveals changes in the effective population size of 
stem cells over life based on the timing of coalescences (branch-
points) in our observed phylogeny. Shading illustrates different 
credibility intervals. The y axis is shown in units of ‘population 
size multiplied by generation time’ (cell-years) because the same 
distribution of coalescences can be generated from a population 
of 10 times the size with 10 times as many generations. 
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Figure 1.4. Construction of the phylogeny using different 
methods. a, the phylogeny of cells, presented with p values next 
to every node, derived by bootstrapping the substitution matrix 
1000 times, building a tree using SCITE for each replicate, and 
counting the proportion of the bootstrapped trees that support 
each node. b-f, phylogenies constructed using different datasets 
and methods. In each case the phylogeny was constructed using 
100 bootstraps of the data, and the p value for each node shown 
underneath it. Branches are coloured by whether a branch 
ancestral to exactly the same descendants is also present in the 
SCITE tree, and are drawn with a thicker line if the branch is 
recovered in >=70% of bootstrap replicates. b, substitution and 
indel datasets combined, building the tree by maximum 
parsimony. c, substitution, indel, and neighbour joining datasets 
combined, building the tree by neighbour joining. d, 
substitutions, tree build by maximum parsimony. e, indels, tree 
built by maximum parsimony. f, Short tandem repeats, tree built 
by neighbour joining.  
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R.2.d. Embryological insights 
 
R.2.d.i. The ontogeny of blood 
 
 As one looks up the phylogeny, one is looking back in time into the somatic history of the 
haematopoietic system. The probability of capturing the most recent common ancestor of a 
population with a sample of size n for a randomly bifurcating tree is equal to (n-1)/(n+1); in our 
case, assuming that ours is a random sample of blood, 197/199=0.99. The earliest branch-point on 
our phylogeny therefore in all likelihood represents the cell division of the most recent common 
ancestor of blood. It partitions the tree into two uneven groups, one with one third of the cells 
(52/140) referred to as ‘clade A’ and the other with two thirds (88/140) referred to as ‘clade B’. 
All cells in clade A all share one mutation (‘mutation A’) which is absent from clade B, and, 
conversely, those in clade B share a mutation which is absent from clade A (‘mutation B’). We 
searched for these early embryonic somatic mutations in whole genome sequencing of the buccal 
swab sample. Strikingly, mutation A was found in the buccal epithelium at a clonal fraction of 1/3 
(on 6 out of 30 reads) and mutation B at a clonal fraction of 2/3 (on 11 out of 33 reads). Mutation 
B was sequenced more deeply using a bait-set (discussed below), and found to occur on 124 out 
of 414 read (0.30%). It is possible that the buccal swab has some blood contamination, but it seems 
very unlikely that it should be made up exclusively of blood with no epithelial contribution at all. 
These data therefore indicate that the most recent common ancestor of blood is shared with the 
most recent common ancestor of buccal epithelium. Thus, at no point in embryogenesis is there a 
cell that is fated to produce all of blood and only blood. Furthermore, since blood is mesoderm-
derived and buccal epithelium ectoderm-derived (Rothova et al. 2012), this common ancestor must 
precede gastrulation. Indeed, it seems likely that it existed very early, perhaps as one of the first 
cells in the embryo. 
 
 
R.2.d.ii. Early embryonic mutation rates 
 
 Beyond this first branch-point, we observed a number of short branches, supported by 0-4 
mutations (figure 1.3b). We were able to use the structure of the phylogeny to estimate the mutation 
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rate for the first 10 mutations of molecular time, presumably reflecting the first days or weeks of 
life. Firstly, the rate of branching in our tree informs on the upper bound of mutation rate per cell 
division. By 10 mutations of molecular time, we observe 33 lines-of-descent in our tree. Therefore, 
at least 33 cells must have existed in the embryo by this stage of molecular time. With doubling 
divisions, in the absence of cell death, it would take at least five generations to grow to this number 
of cells (25 = 32). Under this simplified scheme, the mutation rate is likely to be under 2 mutations 
per generation (10 mutations divided by 5 generations). Two principal caveats complicate this 
model: first, cell loss (either death or contribution to extraembryonic tissues exclusively, such that 
no descendants contribute to the adult); and, second, we may not have sampled every embryonic 
clone. Both cell loss and incomplete sampling of embryonic clones would mean that more 
generations need to have elapsed for us to obtain 33 lines-of-descent in our tree. Therefore, both 
would lower our estimate of the mutation rate per cell division. Thus, we can use an upper bound 
of 2 mutations per cell division.  
The number of polytomies (or multifurcations) in this early embryonic tree also informs 
on the mutation rate per cell division. Polytomies in the tree can only occur if no mutations were 
acquired in a cell division. The lower the mutation rate, the more cell divisions are associated with 
no mutations and the more polytomies appear in the tree. Cell loss can make a true polytomy 
appear as a dichotomy, but not the other way around, and so increasing cell loss decreases the 
number of polytomies seen. The number of polytomies, therefore, also provides an upper bound: 
a combination of increased cell loss and decreased mutation rate would result in the same number 
of polytomies.  
In the absence of cell loss, the following calculations allow us to estimate the mutation rate 
per cell division. In the first 10 mutations of molecular time of our phylogeny we observe 18 
dichotomies, two trichotomies, and two hexachotomies (figure 1.3b,c). In the absence of cell loss, 
a trichotomy means that two cell divisions occurred, creating four branches, and one out of the 
four was associated with no mutations. Similarly, a hexachotomy means that five cell divisions 
occurred, creating 10 branches, and four of them were associated with no mutations. In total, the 
32 cell divisions required to make 33 lines-of-descent created 64 branches, 10 of which  were 
associated with no mutations, one for each of two trichotomies and four for each of two 
hexachotomies. From the Poisson distribution, the maximum likelihood of 10 branches with no 
mutations is 1.86 mutations per division (-log(10.64)), with a 99% confidence interval of 1.19 to 
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2.80. We can therefore conclude that in the absence of cell loss, mutation rate per cell division in 
the early embryo is likely to fall between 1.2 and 2 mutations per cell division, a rate that overlaps 
with estimates from human neural progenitor clones (Bae et al. 2018) and de novo germline 
mutations (Rahbari et al. 2016). With more cell loss, the mutation rate could be lower. 
 
 
R.2.e. Phylogenetic relationships between different cell types 
 
 The mapping of phenotypes (as defined by surface markers and colony morphology) onto 
our phylogeny provides us with the opportunity to study clonal relationships. A statistical test for 
clustering on the phylogeny (Analysis of Molecular Variance, or AMOVA (Methods)) allows us 
to perform three comparisons: bone marrow-derived versus peripheral blood-derived stem cells; 
stem cells versus progenitors; and different kinds of progenitors versus one another.   
 First, no clustering of bone marrow-derived stem cells was observed relative to their 
circulating counterparts (p=0.14). This shows that there is no detectable geographic clustering of 
related cells in the marrow and, as far as we can tell, our sample from iliac crest is representative 
of the bone marrow throughout the body of this individual. This is consistent with two 
explanations: 1) a large polyclonal group of stem cells seeds the iliac crest marrow (and probably 
other marrow locations) around the time of birth, and no local clonal sweep occurs thereafter; or 
2) stem cells must regularly recirculate and redistribute sufficiently often that the population in the 
iliac crest is a reasonably random sample of the whole stem cell pool.  If neither of these scenarios 
were occurring, we would expect to see marrow-specific clades of the phylogenetic tree. 
 Second, the degree of clustering of progenitors relative to stem cells informs on the 
proportion of stem cells contributing to blood. If only a small proportion of stem cells were 
contributing to blood, and we had sequenced the entire haematopoietic phylogeny, we would see 
clades of progenitors clustering around their parent stem cells, and large numbers of stem cells 
with no nearby progenitor. Even if the parent stem cell were not sequenced, clustering of its 
progenitor daughters would be observed. In contrast, if all stem cells were contributing equally, 
stem and progenitor cells should be distributed around the tree. We were not able to detect 
clustering of stem cells relative to progenitors (p=0.12), indicating that more than a few clones are 
generating progenitors. The test that we use to show that progenitors are not clustered relative to 
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stem cells does not have an intuitive statistic, and it is hard to encapsulate the relationships on the 
tree with a few numbers. We can say, for example, that of the 51 progenitors, 37 are more closely 
related to another progenitor than to a stem cell. This or a more extreme value occurs 8% of the 
time in a randomisation test. However, this does not tell us when the common ancestor of the pair 
of cells existed, which is important for establishing whether currently active progenitors derive 
from a small number of stem cell ancestors. Perhaps a more useful statement is that the 51 
progenitor colonies distribute across 47 different lines-of-descent extant at 100 mutations of 
molecular time, compared to 89 stem cells across 76 lines-of-descent. Thus, the progenitors we 
sequenced are not drawn from a substantially more restricted set of historic lines-of-descent than 
the stem cells. 
Third, we were not able to demonstrate any clustering of different types of stem or 
progenitor cells on our tree. For example, MEPs were no more likely to be closely related to one 
another than they were to GMPs or CMPs (p=0.10), although the small numbers of GMPs and 
CMPs reduce the power of this analysis. These data are consistent with either a model whereby 
stem cell clones provide multilineage replenishment of progenitor cells with individual 
commitments, or a model with unilineage priming but such a large pool of ancestors that the cells 
of the same type that we have sampled were unlikely to descend from the same clone.  
All of the above analyses have limited power. It is possible that by sequencing more stem 
and progenitor cells we would have been able to detect clustering of these various cell types. It is 
difficult to quantify the effect size that we would have been powered to detect, as this will depend 
on the size of the stem cell pool and the clonal dynamics of the tissue, both of which we are 
exploring here largely for the first time. These results should be revised by future studies.  
Nevertheless, the observation that stem and progenitor cells are interspersed on the tree is 
useful to our analyses. Taken in conjunction with the relative paucity of recent branch-points, it 
implies that the phylogeny is dominated by events that occurred in stem cells. Progenitors can be 
thought of as random samples of stem cell clones and can therefore be treated in the same way as 
stem cells. Furthermore, since progenitors have short life-spans, if one were to retrace their life 
history they would rapidly coalesce with a stem cell. Branch-points that occur more than a few 
tens of mutations up the tree, and so more than a few years ago, necessarily represent symmetrical 
cell divisions where one stem cell has divided to give rise to two daughter stem cells. We know 
that both daughters are stem cells since we have sampled their progeny years to decades later. It 
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does not matter that some of the branch-points that we observe in our phylogeny we might have 
discovered through sequencing two progenitors, since our data indicate that we are sampling the 
descendants of two different stem cells. In analogy to this, in studies of mitochondrial inheritance, 
male samples can be treated as proxies for their mothers (Griffiths and Tavaré 1994). Therefore, 
for the analyses that follow, which rely upon the pattern of branch-points in our phylogeny, we 
can treat progenitors as stem cells, and, indeed, hereafter we refer to them as such. 
 
 
R.2.f. Population size trajectory over life 
 
 While most branch-points are observed at the top of the phylogeny, a sizeable number also 
occur later. As explained above, these represent symmetrical cell divisions of adult stem cells. The 
pattern of branch-points throughout the tree is remarkably informative on how the size of the 
population of stem cells has changed over life. This has been extensively studied in population 
genetics and epidemiology, where, for example, the seasonal rises and falls of influenza virus 
populations can be reconstructed through an analysis of the branching pattern of the phylogeny 
(Lan et al. 2015;  Karcher et al. 2017). These approaches are based upon Kingman’s coalescent 
(Kingman 1982), which is discussed briefly above. Essentially, under a constant population size, 
the time intervals between coalescent events on a phylogeny should follow independent geometric 
distributions (with means determined by the number of lines of descent which traverse each inter-
coalescent interval). Deviations from this statistical pattern of coalescences indicate changes in the 
size of the population. By comparing the pattern of coalescences before and after each time point, 
fluctuations in the population size can inferred. 
 The population size trajectory was computed using an established Bayesian method (Lan 
et al. 2015, Karcher et al. 2017) (figure 1.3d). We observe almost logarithmic growth early in life, 
for the first 100 mutations of molecular time, as one might expect given that the population must 
expand from one cell in the early embryo to an adult stem cell pool size. At this point, however, 
the population size stabilises. Assuming a constant mutation rate over life, 100 mutations of 
molecular time represents approximately 6 years of age. We cannot be quite this precise with great 
certainty, since the mutation rate may be higher in the embryo and perhaps in early childhood. If 
this were the case, the inflexion point would occur at a younger age. It would be possible to draw 
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a straight horizontal line through the 95% confidence interval on the population size trajectory 
from mutation 100 right until the end of life, such that we cannot reject the null hypothesis of a 
constant population size in adulthood. In humans, the number of immunophenotypic HSCs 
increases in life (Pang et al. 2011). Here, we are assaying the effective population size – that is to 
say, stem cells that are still able to reproduce – and so our results are a readout of stem cell function. 
It should be noted too that our individual is only 59 years old, whereas most studies of stem cell 
ageing look at older people.  
The stability of the stem cell pool indicates a degree of homeostasis: the symmetric stem 
cell divisions – where one stem cell begets two others – that we observe as branch-points in our 
tree must be counterbalanced by death and/or differentiation of a number of cells equal to that 
created. It is unknown at which level this control is exercised. It could be provided by a niche of 
limited size beyond which stem cells are forced to die/differentiate (Zhang et al. 2003), by 
stochastic fate decisions that are balanced at the population level, as has been observed in 
epithelium (Alcolea et al. 2014), or even through a deterministic model. 
The absolute size of the stem cell pool cannot be estimated through this approach without 
knowing the generation time of the population of stem cells, which is equivalent to the average 
time between symmetrical stem cell divisions. As explained in the introduction to this chapter, the 
same expected pattern of coalescences in a phylogeny is generated by a population that is 10 times 
as large as another going through 10 times as many generations: they are confounded. Very little 
is known about the generation time of stem cells in humans, and so we could not simply use an 
estimate from the literature. Instead, the next phase of our experiment allowed us to learn both at 
the same time. 
 
 
R.3. Mutation quantification phase: estimating the number of human stem cells 
 
R.3.a. Targeted sequencing of peripheral blood 
 
 In this phase of the experiment, we aimed to quantify the frequency in peripheral blood of 
the clonal markers that we had discovered by whole genome sequencing. All 129,582 mutations 
assigned to branches of the tree were potential clonal markers. To design a bait-set for and perform 
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high depth-targeted sequencing of all of these mutations would have been extremely costly. We 
therefore designed a bait to as many of the 8,676 mutations present in more than one colony as 
possible and aimed to target approximately 10 mutations per private branch of the tree. When 
selecting private mutations, we picked sites in the genome with the lowest sequencing error rate 
possible, based on a panel of ~1000 genomes (Methods). Not all mutations are suitable for bait 
design (because, for example, they fall in a repetitive region of the genome), resulting in a bait-set 
of 7,116 mutations, of which 6,317 were shared and 799 were private. 
 With this bait-set, we performed targeted sequencing of granulocytes taken at 4-month 
(mean coverage 776X), 9-month (mean coverage 4,669X), and 14-month (mean coverage 268X) 
time-points after the bone marrow aspirate. Different samples were sequenced with different levels 
of coverage as a range-finding exercise. In addition, a negative control of two cord bloods from 
unrelated individuals (kindly provided by Grace Collord) was sequenced (mean coverage 5,305X). 
An algorithm for counting mutant and wild type reads with stringent error correction, written and 
run by Robert Osborne, was used to generate mutation counts over every bait. Further error 
correction was performed statistically, using a Markov chain Monte Carlo generalised linear mixed 
model that used the site-specific error rate from the control DNA to estimate the true VAF in test 
samples, written by Peter Campbell (with minor amendments by me). Reassuringly, mutations on 
higher branches were at higher VAF than mutations on lower branches. 96.5% of mutations had 
no mutations on lower branches with a higher allele fraction. The VAFs of mutations were stable 
across the three time-points (figure 1.7). This is reassuring from a quality-control point of view, 
but also of biological interest, demonstrating clonal stability (at this level of the phylogeny, at 
least) over a 10-month period. 
 Most mutations further down the phylogeny were not detectable (figure 1.5). In contrast, 
mutations on the majority of embryonic and early childhood branches were detectable, as indicated 
by multiple black or red branches at the top of the phylogeny in figure 1.5. Every clade with 
detectable mutations represents a clone whose descendants are making blood nowadays. The 
picture we observe, therefore, is one of polyclonal haematopoiesis, with contributions from stem 
cells dispersed on the phylogeny of blood. A total of 47 non-nested clones have mutations that are 
detectable in the 9-month granulocytes (not all of these can be seen in figure 1.5, as a VAF cut-off 
is used to allow comparisons between different timepoints, but they can be seen in figure 1.8 where 
no cut-off is used). As with the Rodewald group’s embryonic clonal marking strategy (Pei et al. 
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2017, section I.3.a.ii. of this chapter), the number of early clones that we observe actively 
contributing represents an extreme lower bound on the total number of actively contributing stem 
cells. Furthermore, if we make the assumption that stem cells make equal numbers of granulocytes, 
the distribution of VAFs itself suggests that thousands of stem cells are ancestral to today’s 
granulocytes. If only 500 stem cells made blood, we should hardly ever see mutations at a VAF 
much below one in 1,000. Over some sites, the coverage is sufficiently high and the error rate in 
controls is sufficiently low that we can detect mutations at VAFs of the order of 1 in 3,000-4,000. 
We observe VAFs right down to our detection limit, suggesting that at least 2,000 stem cells are 
contributing to the granulocyte pool. 
 
 
R.3.b. Capture-recapture approach for estimating stem cell number 
 
 We hypothesised that the actual number of stem cells might be estimated through a capture-
recapture (also known as ‘mark and recapture’) approach that is typically used in ecology. The 
total number of animals in a population, N, can be estimated by marking n animals on one visit 
and recapturing K animals on a second visit. The number of recaptured animals that have been 
marked, k, tells us the size of the population through the formula: N=(K*n)/k. In our study, ‘stem 
cells’ can be substituted for ‘animals’, and ‘mutations’ for ‘markers’: by taking multiple blood 
samples from one time-point, lysing and sequencing them separately, and comparing the overlap 
between the mutant alleles found in one sample and those in another sample, one could begin to 
estimate the size of the population.  
 In our study, however, this is complicated by several factors. First, mutations are not 
discovered by sequencing of peripheral blood, but have rather been discovered previously by 
whole genome sequencing; the question is if they are recaptured in different peripheral blood 
samples. Second, we separated our blood sample into six subsamples, rather than two, for greater 
resolution. To adapt the analysis for these first two factors only requires minor amendments.  
More challenging, however, is the fact that a mutation does not mark a single stem cell, but 
rather a clone of stem cells. For this to be most informative we need to know when the MRCA of 
the clone existed (i.e. when the clonal mutation occurred). Although we know on which branch a  
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Quantification of mutations by targeted 
sequencing. a, the phylogenetic tree of cells is shown as in 
Figure 1.3a, but information from targeted sequencing of 
peripheral blood granulocytes from the 9 month time-point is 
overlaid. This is shown more clearly in the inset (b), which 
zooms in on a portion of the tree. The underlying structure of the 
tree is shown in grey. On top are placed horizontal bars, one for 
every mutation in the bait-set for targeted sequencing. The bars 
are coloured according the proportion of cells in the sample that 
carry the mutations (obtained by multiplying the variant allele 
fraction for autosomal mutations by two), indicated in the colour 
scale. Undetectable mutations are coloured grey and shown as 
smaller bars. Mutations are assigned to a branch based on which 
colonies they are present in. We cannot know the ordering of 
mutations along a branch other than from the targeted 
sequencing of peripheral blood; mutations have therefore been 
spaced evenly along a branch according to their mean VAF from 
targeted sequencing of all granulocyte and lymphocyte time-
points combined. Small fluctuations in the estimated VAF due 
to random sampling of mutant reads mean that sometimes a 
mutation might be at a higher allele fraction in one particular 
sample than the mutation placed above it; this explains why 
sometimes a mutation at a low allele fraction in a particular 
sample is placed higher up the tree than a mutation which is at 
lower allele fraction in that sample. A higher density of baits was 
designed for branches shared by more than one colony. On these 
branches the mutations are so close together that they can appear 
as one continuous bar. c, This schematic explains that the VAFs 
of mutations decline down branches because of undetected 
coalescences with stem cells that were not whole genome 
sequenced but that are producing granulocytes. 
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given mutation falls, we do not, from the whole genome sequencing alone, know the ordering of 
mutations along that branch. Targeted sequencing of peripheral blood informs on this: the VAF of 
mutations should decline down a branch, since they represent nested clones. To obtain a point 
estimate of their molecular time, therefore, we can spread mutations evenly down a branch in order 
of decreasing VAF. By performing a capture-recapture experiment on mutations from a given slice 
of molecular time, one could estimate the number of cells that existed at that time with extant 
descendants (i.e. the number of clones). 
The rate of decline of VAFs down the tree is governed by the same coalescent process that 
determines the pattern of branchpoints in the phylogeny. Indeed, the VAFs decline because of 
undetected coalescences (figure 1.5c), and so this rate largely measures the same quantity as the 
rate of observed branching, albeit more sensitively. Recall that this defines the relationship 
between stem cell number and generation time but does not allow one to be calculated without 
knowledge of the other. 
 Extra information, however, comes from the mutations found at the very bottom of the 
tree, which occurred in the last few generations of stem cells: those that are ancestral to our 
granulocyte sample with few intermediate stem cells. The number of ‘clones’ at this level of the 
tree is essentially the same as the number of active stem cells. We had lysed and sequenced 
separately six different granulocyte samples from the same time point. Based on flow-sorting, each 
sample contained ~90,000 cells, and each position in the bait-set was sequenced in each sample at 
a mean depth of 800X.  
Imagine the extreme case where only 10 stem cells make granulocytes at any one time. In 
this scenario, each of the six granulocyte samples will contain descendants from all of the 10 stem 
cells, and the VAFs of mutations in all six peripheral blood samples will be very similar to each 
other. In contrast, imagine a scenario in which one billion stem cells are making granulocytes at 
any one time. In this case, different samples of granulocytes will contain cells that descend from 
different ancestral stem cells: a sample of 90,000 granulocytes will not contain descendants from 
all stem cells. The VAFs of mutations will therefore differ more between different granulocyte 
samples than in the scenario of a small number of contributing stem cells. This is the information, 
in conjunction with the pattern of branchpoints in the tree and the rate of VAF decline, that we set 
out to use to estimate the total number of stem cells in the population.  
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R.3.c. Approximate Bayesian Computation to estimate stem cell numbers 
 
Because of the complexity of using these multiple sources of information at the same time, 
it was not possible to solve this problem analytically. In future, it would be possible to apply a 
fully Bayesian approach, but because computation of the likelihood function involves integration 
of a large number of possible phylogenies, such an approach is impractically slow.  In contrast, an 
Approximate Bayesian Computation (ABC) can be parallelised and run within the timescale 
available. 
The concept of an ABC is simple: a model is simulated many times, varying the parameters 
of interest; for each simulation, summary statistics that capture the features of the data of interest 
are computed; simulated summary statistics are compared to the same statistics calculated on the 
observed data; and the values of the parameters of interest that produce summary statistics similar 
to the observed are deemed to be more likely than those that produce very different summary 
statistics (Tavaré et al. 1997; Beaumont et al. 2002; Bertorelle et al. 2010). The b simulations 
(where b is a number to be determined, but typically around 1,000) that are most similar to the 
observed are chosen and the values of the parameters in these simulations can be treated as a 
credibility interval. Finally, a regression step on a given parameter may be performed (Blum and 
Francois 2010, Csillery et al. 2012), regressing the value of the parameter against a measure of the 
dissimilarity between observed and expected summary statistics, thus finding the parameter value 
that would most closely approximate the observed data. 
In our case, a simple model of haematopoiesis (explained below) was simulated thousands 
of times, varying the number of active stem cells and the generation time, and the whole 
experiment was repeated in silico on every simulation, from whole genome sequencing of the 
colonies, to design of the bait-set, to estimating the VAFs of mutations in peripheral blood. Such 
an approach allows us to recreate the uncertainties in our data: for example, we can pretend in the 
simulation that we do not know the true ordering of mutations, and rather reconstruct it by ordering 
mutations down a branch according to their estimated VAF (which need not be equal to their true 
VAF, since it is calculated from the binomial resampling of mutant and wild-type reads), just as 
in the real experiment. Similarly, we can use the observed sequencing depths from our data to 
generate a slight unevenness in coverage, making the simulation more realistic. Summary statistics 
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were chosen to include a measure of the pattern of branch-points on the tree and to reflect a capture 
recapture approach, by looking at how many mutations were shared between different blood 
samples. A more detailed description of each step of the method follows. 
Please note that while I wrote the ABC code, I received extensive guidance from Kevin 
Dawson and Peter Campbell. 
 
 
R.3.c.i. The model of haematopoiesis 
 
R.3.c.i.1.  Overview of model 
 
Haematopoiesis is complex, and to model it requires a number of assumptions. We 
therefore opted for a simple model of haematopoiesis: individual stem cells within the population 
of total stem cells replicate stochastically over life and their clonal dynamics approximate neutral 
drift. Stem cells were simulated with a forward-in-time Wright-Fisher model, varying the number 
of stem cells and generation time. Because of uncertainty in the clonal dynamics of growth to 
adulthood, we commence our simulations at the point where the adult stem cell pool has reached 
a constant size, at 100 mutations of molecular time (figure 1.4d). In each cell division, each stem 
cell acquired a number of somatic mutations drawn from the Poisson distribution. The mean of the 
Poisson distribution is chosen such that the mean number of mutations per stem cell after the 
requisite number of generations in that simulation would equal the observed mean of 1,023. 
It should be noted that we are using the term ‘stem cell’ to refer to cells that have self-
renewed over the 59 years of life of our subject and are ancestral to circulating granulocytes. This 
population of cells may not translate directly to the standard definition of haematopoietic stem 
cells as those capable of long-term multi-lineage reconstitution when transplanted into 
immunocompromised mice. Nevertheless, our ‘stem cells’ meet the conceptual definition of a stem 
cell since they have self-renewed for so long, and in addition to producing granulocytes are likely 
also to have produced B lymphocytes (figure 1.8, discussed in section R.4.). We only concern 
ourselves with the stem cells that have given rise to cells actively making blood. In this 
experimental set-up, we are blind to long-term dormant stem cells (i.e., years of not making any 
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sort of long-lived multi-lineage progeny) and to stem cells that exclusively produce other mature 
blood cell types but no granulocytes.  
 
 
R.3.c.i.2. Assumptions 
 
First, we model stem cells with active contributions from their progeny as belonging to one 
population. There is evidence that there may, in fact, be different pools of stem cells cycling at 
different rates (Wilson et al. 2008), but it is currently unclear whether this applies to humans, how 
big each pool is, whether cells move from one pool to the other during homeostasis and if so at 
what rate, and what the relative contribution of each pool to circulating granulocytes is. We 
therefore chose to model the pool of stem cells actively contributing to granulopoiesis as one 
population. It is also important to note that while all stem cells share the same probability of 
dividing in a given window of time, our model in effect allows them to behave stochastically, as 
in previous models of haematopoiesis (Abkowitz  et al. 1996, Catlin et al. 2011).  
Second, we assume that the size of this stem cell pool is constant over the period of 
adulthood studied (figure 1.4s, Werner et al. 2015). We do not concern ourselves with the 
dynamics of how the population grew to be this size: all our summary statistics only use 
information from after 100 mutations of molecular time, when we see that the stem cell population 
size has stabilised. We thus have a population of stem cells of constant size that we allow to 
replicate stochastically over the course of adult life. 
Third, we make the assumption that there is no selection in the stem cell pool. This is based 
upon our inability to detect selection in our experiment (discussed above) and the assumption that 
the vast majority of somatic mutations will not affect stem cell function. We thus have a population 
of stem cells that is replicating stochastically, resulting in a process of neutral drift.  
Fourth, we assume that those stem cells that are making granulocytes are all making an 
approximately equal number of them. This assumption is likely to matter less with larger stem cell 
population sizes. 
The final important assumption that we make is that stem cells accumulate somatic 
mutations at the same rate over life, drawing the number of mutations that each stem cell acquires 
at every generation from a Poisson distribution. This is justified by the linear accumulation of 
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somatic mutations over time reported by others (Welch et al. 2012) and the relatively narrow range 
of mutation burden that we observe from our 140 clonal whole genomes (figure 1.1c). 
With this model, we simulate haematopoiesis hundreds of thousands of times with different 
values of the stem cell pool size and time between symmetrical stem cell divisions, drawing both 
from a uniform prior on the log scale (which minimal knowledge of the distribution of the data). 
We replicate the experiment on each simulation: we sample cells for whole genome sequencing, 
design a bait-set, sample granulocytes from our stem cell population, and count the number of 
mutant reads found in the granulocytes over each position in the bait-set. 
 
 
R.3.c.i.3. Choice of priors 
 
R.3.c.i.3.a. Prior on stem cell population size 
 
The adult stem cell population size was drawn from a uniform distribution on the log scale 
between 1,096 (exp(7)) and 3,269,017 (exp(15)) stem cells. A minimum number of 1,096 stem 
cells was chosen because we knew from preliminary simulations and from the reasoning above 
that a smaller number of stem cells than 1,000 could not produce the low VAF mutations that we 
observe. The maximum number of stem cells was chosen because, firstly, it was at the limits of 
what was computationally feasible with the resources available (each simulation at this upper limit 
requires approximately 150 GB of memory), and, secondly, because it was two orders of 
magnitude higher than the proposed number of stem cells (Abkowitz et al. 2002). 
 
 
R.3.c.i.3.b. Prior on generation time 
 
The Wright-Fisher generation time (which is equivalent to the mean time between 
symmetrical cell divisions for one line-of-descent) was drawn from a uniform distribution on a log 
scale between 20 days (exp(3)) and 8,103 days (exp(9) i.e. 22 years). The minimum time of 20 
days was chosen because stem cells are reportedly relatively quiescent (Arai and Suda 2007; 
Orford and Scadden 2008). Not all of a stem cell’s divisions need be symmetrical: a proportion is 
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likely to be asymmetrical, producing one daughter stem cell and one progenitor cell (Werner et al. 
2015). We are blind to asymmetrical divisions. Therefore, if a cell is dividing asymmetrically in 
addition to symmetrical divisions on average every 20 days, it will be dividing significantly faster 
than every 20 days, which seemed unlikely given prior knowledge of stem cell quiescence. 
Furthermore, shorter times between cell divisions mean that more generations need to be 
simulated, which is computationally costly. The maximum time between symmetrical cell 
divisions of 22 years was chosen because it required a very small number of HSCs to create a 
phylogeny of the right shape, and such a small number was not compatible with the observed range 
of VAFs. 
 
 
R.3.c.i.4. In silico recapitulation of our experiment 
 
3.c.4.i.a. Mutation discovery phase 
 
After simulating drift for the whole population of stem cells for the requisite number of 
generations, we choose 155 colonies for whole genome sequencing and construct a phylogeny 
from them. Of 198 colonies sequenced in our experiment, only 140 were clonal. These 140 were 
used to build the tree, and for all analyses except for the ABC. However, of the 58 polyclonal 
colonies, we could salvage 15 because they had a dominant clone and shared more than ten 
mutations with a clonal colony that was on our tree. We could therefore graft these 15 extra 
colonies onto the tree of 140 clones. This is helpful because it provides an extra time point on each 
branch onto which an extra colony is grafted. Mutations can then be classified as being shared with 
the polyclonal colony that has been grafted on, or absent from the polyclonal colony, thus 
providing additional information about the timing of the mutation. No mutations that were present 
only in polyclonal colonies (and not in clonal colonies) were used, as we could not be sure where 
to place them on the tree. 
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R.3.c.i.4.b. Mutation quantification phase 
 
We design a bait-set for the simulated tree, using the same criteria as were used to design 
the real bait-set (Methods). We then simulate the sampling of peripheral blood granulocytes. We 
generate a sample of M = 540,000 granulocyte by sampling with replacement from the stem cell 
population. This simulated sample of 540,000 cells is then split into six sub-samples each of size 
90,000 (to simulate the six sub-samples obtained from our volunteer at the nine-month time-point). 
We then simulate targeted sequencing of the mutations in the bait-set. In the observed data, there 
were 3,952 mutations in the bait-set that (after our duplicate removal and consensus calling step 
(methods)) were covered by at least 4,000 reads in the control cord blood DNA, but where no 
mutant reads were found in the cord blood. We therefore used these 3,952 mutations for analysis 
of the observed data, and also only use 3,952 mutations in the simulated bait-set. For every bait-
set locus in every sub-sample, we randomly draw a sequencing depth from the empirical 
distribution of sequencing depths for the real targeted data from the nine month time-point. We 
sample the chosen number of reads over this locus from the granulocytes without replacement and 
count the number of reads that have the mutation. 
Sequencing errors were included in the simulation as follows. The sequencing error rate 
was learnt from the control cord blood. For all 7,116 positions in the bait-set, the VAF in the cord 
blood was calculated. Where the VAF was zero (if there were no mutant reads), the VAF was set 
to 1/10,000, a value just below the rarest mutations that we could detect. For each of the 3,952 loci 
used in simulations, then, an error rate was drawn from these VAF distributions. The number of 
false positive reads was obtained by drawing from the binomial distribution, with parameter p 
equal to the randomly chosen error rate and parameter n equal to the sequencing depth. We also 
tested two other error models: one with no sequencing errors, and one with double the sequencing 
error rate observed in the cord blood controls. These made little difference to the median of the 
posterior distribution of the model but did affect its width. A separate false positive rate was 
included based on the estimated rate of homoplasy, assuming that every granulocyte has 2,000 
mutations (double the number of mutations present in a stem cell, which seemed a reasonable 
upper bound for the number of additional mutations that a granulocyte could acquire) and that 
these are spread evenly across the genome. 
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R.3.c.ii. Extraction of summary statistics 
 
We then extract summary statistics from the resulting simulated data set. There are two 
categories of summary statistics used. Only the first category of summary statistics was extracted 
for the first set of simulations, as explained below.  
The first category of summary statistics is comprised of those designed to capture the shape 
of the phylogeny, referred to as lineages through time or LTT summary statistics. We divide the 
molecular time scale, from mutation 100 to mutation 800 (beyond which some branches in our 
observed phylogeny end), into bins of molecular time each 100 substitutions wide. For each 
mutation of molecular time in a given bin, we count the number of branches extant at that slice of 
time and take the mean across all hundred mutations in that bin.  
The second category of summary statistics is made up of those designed to exploit the 
‘capture-recapture’ aspect of our approach with targeted sequencing of multiple peripheral blood 
samples. We wanted statistics that would capture whether different granulocyte samples descended 
from the same stem cell population or not. As explained above, the less overlap in the granulocyte 
sub-samples, the larger the contributing stem cell population is likely to be. For a given mutant 
read threshold (from 1 to 6 mutant reads), and a given number of samples (from 0 to 6 samples) 
we count – out of the 3,952 mutations included – how many loci have this many or more mutant 
reads in precisely this many samples. For example, one summary statistic would be the number of 
mutations in the bait-set that are supported by at least three mutant reads in two samples. These 
summary statistics are recorded for every simulation, and the same summary statistics were 
calculated for the observed data.  
 
 
R.3.c.iii. Details of ABC implementation 
 
Two sets of simulations were run, referred to hereafter as ABC1 and ABC2, both using the 
same model, but with a different prior and extracting different summary statistics.  
First, we generated 121,329 simulations drawing both the number of stem cells and the 
time between symmetrical stem cell divisions from a uniform prior on a log scale (figure 1.6a) and 
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extracted summary statistics that reflect the shape of the phylogeny (the LTT summary statistics 
explained above). This allowed us to identify a relationship between stem cell number and 
generation time, effectively defining a plausible diagonal band on the sample space of stem cell 
numbers plotted against generation time (figure 1.6b). Going backwards in time, the faster the rate 
of random drift, the more rapidly the number of lineages decreases. Thus, simulations that have 
too rapid a random drift rate (simulations with a small population size and short generation time) 
have LTT statistics that are too low for early bins of molecular time (figure 1.6o), and simulations 
that have too slow a random drift rate (with a large population size and long generation time) have 
LTT statistics that are too high for early bins of molecular time (figure 1.6p).  
For ABC2, we ran another 80,762 simulations targeting this area of the sample space 
(figure 1.6c). For this set of simulations, both the LTT and peripheral blood-derived summary 
statistics were extracted.  
 
 
3.c.iv. Comparison of simulations and observed data 
 
Summary statistics were normalised, and for each simulation the Euclidean distance 
between the simulated and observed vector of summary statistics was calculated. For ABC1, we 
simply defined the region that contained the most similar 20% of simulations, which was then used 
as the prior for ABC2. Simulations outside this range can be shown to have a branching structure 
that does not resemble that of our phylogeny (figure 1.6o-p). 
For ABC2, to maximise the accuracy of our model, we cross-validated both the number of 
simulations included in the acceptance region, and the weighting to give to the LTT statistics. For 
each of 1,000 cross validation samples, we drew one simulation to act as fake observed data and 
removed it from the pack of simulations. We then analysed the data as though our fake observed 
data were the true data. We took the n (where n is the number of accepted simulations) simulations 
that produced summary statistics that were most similar to our fake observed data, as determined 
by their Euclidean distance.  
We then calculated a number of statistics (figure 1.6e-i). First, we plotted the accepted 
simulations on a graph of stem cell numbers versus generation time (both on a log scale) and drew 
an ellipse that contained 90% of the n points inside it. We then saw whether the true value of the 
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fake observed data fell inside this ellipse. The proportion of cross validation samples for which the 
fake observed data fell inside the ellipse is shown in figure 1.6e. We also measured: the mean area 
of the ellipse (figure 1.6f); the distance between the median number of stem cells of the accepted 
simulations and the fake observed data number of stem cells (figure 1.6g); the distance between 
the median generation time of the accepted simulations and the fake observed data generation time 
(figure 1.6h); and, finally, the distance between median of the posterior of a neural network 
regression run on the accepted simulations and the fake observed stem cell number (figure 1.6i). 
We chose an LTT weighting of 1 and an acceptance region of 1,000, since this resulted in an 
accurate prediction of the stem cell number from the neural network regression and a high 
proportion of the fake observed values falling in the ellipse, while keeping the size of the ellipse 
relatively small.  
We then analysed the true observed data, using the error model that took VAFs from the 
observed control data, weighting the LTT summary statistics by 1 and choosing the 1,000 most 
similar simulations to fall in the accepted region. Of the best 1,000 simulations, 90% had more 
than 15,995 and less than 295,189 HSCs, and a generation time of more than two and less than 20 
months (figure 1.6r). 
For added precision on the number of stem cells, neural network regression was performed 
on these best 1,000 simulations using the R package abc (Csillery et al. 2012), to find the number 
of stem cells that minimised the distance between the observed and simulated summary statistics. 
The neural network regression was run using the default of one hidden layer with five units. As 
predictions from different neural networks can vary, thirty neural networks were run and the 
median provided. We found that the most likely number of stem cells ancestral to the sampled 
granulocytes was 97,000, with a 90% credibility interval of 45,000 to 215,000 (figure 1.6s). 
To test the robustness of our analysis, we repeated it with the other two error models 
described and ignored summary statistics that used a mutant read cut-off of 1, since these would 
be most sensitive to incorrect modelling of the sequencing error rate. Both of these additional 
analyses resulted in a widening of the posterior distribution for the number of contributing stem 
cells but did not significantly change its location. 
 
 
 
Figure 1.6. Approximate Bayesian Computation (ABC) to 
estimate HSC numbers. a, The joint prior distribution for HSC 
numbers and the generation time for the first ABC. b, The 
location in sample space of the 10% of simulations that produced 
ltt summary statistics most similar to the observed summary 
statistics. c, the joint prior distribution for the second ABC, in 
the area of sample space indicated to be plausible by the first set 
of simulations. d, The joint posterior distribution of the best 500 
simulations from the second ABC. Letters n, o, and p on the plot 
indicate the position in sample space from which panels n, o, and 
p were drawn, respectively. e-i, cross-validation of the model to 
choose the number of accepted simulations and the weighting 
applied to the ltt summary statistics. j, for illustrative purposes, 
five simulations were sampled for each of three population sizes 
along the plausible diagonal of sample space indicated in panel 
b. One set of summary statistics is shown for these simulations 
in k. A red line indicates a simulation coming from the area of 
sample space indicated by a red point in j; idem for blue and 
green lines. The black dotted line indicates the observed values 
for these summary statistics. This set of summary statistics 
counts, for different numbers of samples (x axis), how many of 
the 3952 mutations considered (y axis) are in this many samples 
with two or more reads, using error model 1 (which simulates 
errors according to the error rate in control DNA). l, For each of 
the 1000 simulations that produce summary statistics most 
similar to the observed, the Euclidean distance from the 
observed (y axis) is plotted against the number of stem cells in 
that simulation (x axis). This information is used by the neural 
network regression to define the most likely value for the 
number of stem cells. The most similar values are seen at around 
100,000 stem cells, which was the location of the median of the 
posterior distribution from neural network regression. m, the 
observed phylogeny, with branch points indicated by asterisks. 
n-p, phylogenies from simulations that occur at the points in 
sample space indicated in panel d. n represents a plausible 
simulation, since the pattern of branch points is not dissimilar 
from that seen in the observed phylogeny m. Simulations with 
smaller stem cell populations and faster stem cell turnover rates 
resulted in phylogenies where the stem cells are very closely 
related to each other (o), whereas those with larger populations 
and slower turnover result in phylogenies where the stem cells 
only share an embryonic common ancestor (p). q, the prior 
distribution for the number of stem cells contributing to 
granulocytes for the second ABC (i.e. the stem cell numbers for 
all 80,000 simulations). r, the distribution of stem cell numbers 
for the 1,000 simulations that produced summary statistics most 
similar to the observed summary statistics. s, the posterior 
distribution of a neural network regression run on these 1,000 
simulations. The 90% credibility interval is quoted for the stem 
cell population in each of q-s.  
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4. Clonal contributions to granulocytes and lymphocytes. 
 
 In order to examine lineage relationships at the clonal level, we performed targeted 
sequencing of B (mean coverage 2,830X) and T lymphocytes (mean coverage 3,298X), both from 
the 9-month time-point, using the same bait-set and error-correction method as for granulocytes 
(figures 1.6 and 1.8). As can be observed from the preponderance of black bars at the top of the 
phylogeny, most early embryonic branches contribute to all three cell types at the time of sampling. 
Thus, clones marked in the embryo, and perhaps early childhood, have multilineage potential, as 
has been observed in mice (Pei et al. 2017). 
 Beyond 100 mutations in molecular time, when the population size reached a plateau 
(figure 1.4d), 464 mutations distributed across 39 branches could be detected, of which 217 on 12 
branches were detected in more than one cell type. Hardly any of these were detected in all three 
lineages. We do, however, observe a number of clones that make detectable amounts of both B 
lymphocytes and granulocytes. Sequencing coverage was equally good in T lymphocytes and in 
B lymphocytes, so the failure to detect these mutations in T lymphocytes is not a result of decreased 
sensitivity. At least five of these shared granulocyte-B cell branches stretch beyond the 100 
mutations mark (figure 1.8) that we take to signify adult stem cell dynamics. Furthermore, the 
VAFs observed are similar between B cells and granulocytes, indicating a more recent common 
ancestor: the neutral drift to detectable clone sizes will have been gradual, with much of it 
occurring since the last detectable mutation. If the last detectable purple mutation in figure 1.8a 
represented the last common ancestor of granulocytes and B lymphocytes, both the B-restricted 
and granulocyte-restricted clones would have had to drift to similar sizes in the intervening time 
independently. It is more likely that they share a common ancestor well beyond the last detectable 
mutation found in both B cells and granulocytes. Thus, we demonstrate the presence of adult stem 
cell clones with both myeloid and lymphoid output in a human at homeostasis. Admittedly, the 
number of clones in which we have detected this multilineage output is small. However, there are 
no clones in which we would have been able to detect multilineage output in which we have not 
detected it (no branches beyond 100 mutations of molecular time that are exclusively dark red, 
blue, or green). This suggests that multilineage clonal output is not rare. 
We cannot exclude smaller contributions of these granulocyte- and B cell-producing clones 
to the T lymphocyte pool on the order of less than one in three thousand T lymphocytes, which 
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would fall below our detection limit for lymphocytes. Nonetheless, since this is less than half the 
proportion that these clones are contributing to granulocytes and B lymphocytes, we can 
unequivocally show an imbalance. In contrast, we observe some branches where we can detect 
very rare mutations (allele fractions of less than 1/2,000) in granulocytes (pink branches in figure 
1.8), which we did not have the sequencing depth to detect reliably in lymphocyte populations. It 
is quite plausible that these branches contribute to lymphocytes, too; we cannot, therefore, infer 
the presence of exclusively myeloid clones. 
Only a handful of mutations were found to be shared by B and T lymphocytes and absent 
from granulocytes. Even if lymphoid-biased clones were frequent, however, we would not expect 
to find many of them, as the ‘capture’ phase of our experiment was biased towards myeloid 
lineages, since isolation strategies for human stem cells inevitably also capture more differentiated 
cells, predominantly myeloid progenitors (despite possessing the same combination of surface 
markers as true HSCs).  
The observation of granulocyte-B cell restricted clones in adults would be reinforced by 
studying more cells from more people and with the ability to resolve rarer mutations. Even without 
these, our data already indicate that adult stem cell clones with both myeloid and lymphoid output 
are not infrequent in humans. In mice, tags have been found to be shared between granulocytes 
and B lymphocytes (Rodriquez-Fraticelli et al. 2018), but, unfortunately, T lymphocytes were not 
assessed. The observation of clones that produce detectable granulocyte and B lymphoid but not 
T lymphoid output could be explained in three ways. First, some individual stem cells may have a 
propensity to produce more of one mature cell type than another. This would have to be a 
somatically heritable trait, since we observe this behaviour at the level of clones that are ancestral 
to hundreds of stem cells. Such a finding of heritable stem cell heterogeneity is anticipated by the 
animal and in vitro studies discussed at the beginning of this chapter. Second, unequal clonal 
contributions to present-day blood samples might reflect the long life-span of T lymphocytes 
relative to granulocytes and some B cells: T lymphocytes could reveal the stem cell clones that 
dominated decades ago, while granulocytes and B lymphocytes show us more recent clone 
distributions. A third and related possibility is of a strong bottleneck in the T lymphocyte 
population imposed by thymic selection or infections, which would reduce the overlap between 
these populations. This could be resolved by including lymphocyte progenitors in the whole 
genome sequencing phase of the study, and by performing this experiment in children (since we 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Quantification of mutations in different fractions 
of peripheral blood. a, b, targeted sequencing data represented 
as in figure 1.5 for all fractions of peripheral blood that were 
sequenced, showing only the first 350 mutations of molecular 
time, beyond which no mutations were detectable. To allow a 
better comparison between samples sequenced at different 
depths, a different detection threshold is used relative to figure 
1.5. Data are shown prior to sequencing error correction using 
cord blood controls in the Bayesian generalised poisson mixed 
effects model (a) and after applying the error correction (b). c, 
correlations between the VAFs of all sequenced samples, shown 
on a log scale. Note that samples that were sequenced to lower 
depth cannot have VAFs as small as samples sequenced to 
higher depths. 
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Figure 1.8. Comparison of allele fractions in granulocytes 
and lymphocytes. a, the phylogeny is depicted as in figure 1.5, 
with the underlying structure of the tree shown in grey, and 
horizontal bars drawn to represent every mutation in the bait-set. 
Here the colouring of mutations reflects which peripheral blood 
cell fractions they could be detected in, as indicated by the colour 
key. Granulocytes were sequenced at greater depth than 
lymphocytes and so mutations could be detected at lower allele 
fractions in granulocytes than in lymphocytes. Therefore, two 
colours are used for granulocytes: red for mutations only 
detected in granulocytes that were are at a sufficiently high allele 
fraction to have been found in lymphocytes should they have 
been present at a similar allele fraction in lymphocytes, and pink 
for mutations that were only detected in granulocytes, but were 
at such a low allele fraction (<1/2000 reads) that if they had been 
present in lymphocytes at this allele fraction they would not have 
been detected. Arrows indicate adult clones with multilineage 
output. G, granulocytes; G low VAF, granulocytes, allele 
fraction too low to be detected in lymphocytes; B, B 
lymphocytes; T, T lymphocytes. b-f, VAFs of all mutations on 
branches (indicated by arrows in a) with mutations beyond 
molecular time 100 that are detectable in granulocytes and B 
lymphocytes but not T lymphocytes. 
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were able to culture a reasonable number of stem cells from peripheral blood, a bone marrow 
aspirate would not be necessary). 
 
 
Summary of results in this chapter 
 
The number of haematopoietic stem cells, their clonal dynamics, and the clonal 
relationships between different cell types are all poorly understood in humans because of the 
difficulty of tracking clones in unperturbed people. We used spontaneously acquired somatic 
mutations to reconstruct lineage relationships among stem cells in normal human haematopoiesis. 
We sequenced the whole genomes of 140 colonies derived from single HSPCs from one healthy 
59 year-old man. We identified the somatic mutations, reconstructed the phylogenetic relationships 
of the cells to one another, and sequenced at high depth bulk populations of granulocytes and 
lymphocytes for mutations that had been discovered by whole genome sequencing. 
We were able to reconstruct cell divisions in the early embryo. Comparisons with buccal 
epithelium indicated that the most recent common ancestor of blood existed prior to gastrulation. 
The mutation rate in the early embryo is likely to be less than two mutations per mitosis. Averaging 
over the whole of life, the mutation burden and mutational signatures were consistent across 
different HSPCs. No positive or negative selection of mutations could be identified. 
The trajectory of the number of haematopoietic stem cells over life could be inferred from 
the branching patterns in the phylogeny. The stem pool size increased rapidly during development 
and childhood and reached a stable plateau in adulthood. Using deep sequencing data, we inferred 
that the number of stem cells contributing actively to granulocytes at any given time is in the range 
45,000 – 215,000.  
Finally, we found that T and B lymphocytes have different clonal dynamics. We observed 
adult clones that produced detectable fractions of both granulocytes and B lymphocytes, but not T 
lymphocytes. Our data indicate a contribution of multipotent HSCs to B lymphopoiesis throughout 
life. 
These findings are discussed in the Discussion chapter. 
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RESULTS CHAPTER 2 
MUTATIONAL LANDSCAPE OF NORMAL COLON 
 
Introduction to this chapter 
 
I.1. Colonic stem cell numbers and clonal dynamics in health 
 
I.1.a. Monoclonal origin of crypts 
 
The human colon undergoes extraordinary amounts of cellular turnover. Its luminal surface 
area is approximately 3,300cm2 and it is renewed every 3-4 days (Potten et al. 1992). 15 million 
invaginations of the epithelium (or crypts) (Boman and Huang 2008), each containing about 2,000 
cells (Potten et al. 1992), form the regenerative unit of the colon and house four key functional cell 
types: enterocytes, goblet cells, crypt base secretory cells, and enteroendocrine cells. Rarer cell 
types include tuft, microfold, and cup cells.  
All of these differentiated cell types derive ultimately from stem cells that sit at the base of 
the crypt. The propensity of cells at the base of mouse crypts1 to phagocytose cellular debris 
allowed an early form of functional lineage tracing: when they were fed tritiated thymidine, 
phagosomes in crypt basal cells were rapidly labelled. The tritiated thymidine label could only 
later be detected in different mature cell types higher up the crypt, suggesting that basal cells were 
multipotent progenitors (Cheng and Leblond 1974).  
Not only do all cells in the crypt have a stem cell as a recent ancestor, but they can all 
retrace their line of descent to the same ancestral stem cell. Crypts from mice, chimaeric for either 
the H2 antigen, detectable with a monoclonal antibody, or a carbohydrate polymorphism stained 
with a lectin, were clonal for a given marker (Ponder et al. 1985). Similarly, detection of a Y-
chromosome-linked marker in XX-XY chimaeric mice showed the shared common origin of all 
                                                 
1 Here, as in much of the discussion on stem cell biology that follows, the experiment was performed on 
small intestine rather than colon. The stem cell biology of the colon is thought to be similar, and when there 
are notable differences between the two organs I will  draw attention to them. 
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cell types in a gastric gland (including neuroendocrine cells, which had not been demonstrated 
previously) (Thompson et al. 1990). In these chimaeras, however, large patches of epithelium 
shared a marker, and so the finding could have been a consequence of embryonic mosaicism rather 
than adult stem cell dynamics. That crypts derive from a single adult cell was confirmed using 
mice heterozygous for an inactivating mutation of a lectin-binding protein. ENU random 
mutagenesis resulted in loss of the wild type copy – and consequently the lectin stain – in a small 
proportion of cells, such that the progeny of a single cell could be traced (Winton et al. 1988). 
Treatment with ENU in adulthood resulted initially in ribbons of cells lacking staining emanating 
from one mutated cell, but after a chase period it only left wholly stained or unstained crypts 
(Winton and Ponder 1990). Similarly, treatment of mice with a mutagen resulted in sporadic loss 
of the X-linked G6PD biochemical marker in a small proportion of colonic crypts, but, importantly, 
in all the cells of affected crypts (Griffiths et al. 1988).  
 
 
I.1.b. Neutral drift dynamics 
 
The ancestral stem cell need not still be alive, and could have multiple self-renewing 
descendants (Potten and Loeffler 1990). More recent experiments have shown that a number of 
extant stem cells replace one another through a process of neutral drift, resulting, over time, in 
monoclonal conversion. By inducibly labelling less than 2% of cells with a marker at a defined 
point it was possible to determine that half of small intestinal crypt cells in a mouse were clonal 
within eight weeks, and, furthermore, that the trajectory to monoclonality was consistent with 
neutral dynamics (López-García et al. 2010). The same result was derived using a confetti system 
in mice, under the control of Lgr5, a stem cell marker (Barker et al. 2007). Initially multicoloured 
crypts became monochrome over a period of 1-6 months in a manner consistent with neutral drift 
(Snippert et al. 2010). In humans, the monoclonality of colonic crypts has been demonstrated by 
staining for loss of the cytochrome oxidase (CCO) protein, which is encoded by the mitochondrial 
genome and so – due to the higher mutation rate of the mitochondrial genome and the process of 
drift to homoplasmy such that only one mutation is necessary – is reasonably frequently inactivated 
(Baker et al. 2014). This process of neutral drift is made possible, in part, by the relative non-
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quiescence of intestinal stem cells: bromodeoxyuridine measurements indicate that the cell cycle 
time at the base of human colonic crypts is of the order of 30 hours (Potten et al. 1992). 
 
 
I.1.c. Quantification of stem cell numbers and the rate of drift 
 
 The number of stem cells and the rate of neutral drift are important parameters to 
understand cancer risk, both because stem cells are believed to be the cell of origin of cancers and 
because the number of stem cells per crypt affects the probability that a driver mutation will be 
able to colonise a crypt (see General Introduction). Furthermore, the time to monoclonality of a 
crypt is of technical interest in this dissertation. As described below, in our study we sequenced 
individual colonic crypts, which allowed us to detect mutations that were present in every cell in 
the crypt. Thus, in effect we recover the genome of the most recent common ancestor (MRCA) of 
the crypt. If this common ancestor existed a very long time ago, we might be significantly 
underestimating the mutation burden of stem cells at the time of resection.  
In mice, inducible labelling strategies have begun to unpick these parameters. Kozar et al. 
used a continuous labelling approach to mark a small proportion of cells, effectively allowing the 
output of single cells to be monitored. An out of frame reporter, under a house-keeping promoter, 
was placed next to a CA[30] microsatellite tract such that slippage of this highly mutable stretch 
would infrequently place the reporter back in frame (Kozar et al. 2013). Both wholly- and partially-
labelled crypts were observed. The former increased linearly with mouse age, while the latter 
remained constant. The proportion of each of these informs on the stem cell number and 
replacement rate (if the rate is known at which the reporter is activated), allowing the inference of 
approximately seven stem cells per crypt in mouse colon, with most crypts drifting to 
monoclonality within a few months (Lopez-Garcia 2010). Interestingly, fewer stem cells per crypt 
were observed in the small intestine, which may contribute to the decreased cancer incidence. 
 Estimates in humans are more controversial. Coalescent modelling of variation in 
methylation patterns in human crypts, proposed to act as a somatically heritable but mutable mark, 
suggested the presence of at least eight stem cells and that the time to the MRCA of the crypt in 
humans is between 15 and 40 years (Nicolas et al. 2007). Substantial uncertainty exists in these 
estimates: a small number of CpG sites were assayed in a small number of cells per crypt, and the 
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model relies on assumptions on the kinetics of methylation and demethylation as well as the shape 
of the phylogeny of how differentiated cells are related to the common ancestor of the crypt. 
Cytochrome oxidase (CCO) staining has also been used to estimate these parameters (Baker et al. 
2014). The observation that a ribbon of CCO- staining varied in width as it rose from the base of 
the crypt to the lumen led the authors to conjecture that these ‘wiggles’ might be a read-out of 
symmetrical stem cell divisions at the base. This led to the estimation of approximately six 
functional stem cells and a rapid stem cell replacement rate, with monoclonal conversion times 
approaching three weeks (calculated in Nicholson et al. 2018). Ingenious though this idea was, it 
does not fit particularly well with our understanding of transit times within the crypt. Given that it 
takes about one week for a cell to migrate from the crypt base to the gut lumen in humans, and 
cells at the crypt base divide every few days (and not all of these need be symmetric cell divisions 
(Kozar et al. 2013)), it is arguable whether a ribbon of CCO- staining captures a long enough time 
period to assay neutral drift. Only the bottom half of crypts were examined, and sometimes over 
eight wiggles per crypt are reported, which might indicate that the wiggles are rather a result of 
the behaviour of cells in the transit-amplifying compartment or that the software used to detect 
them is overly sensitive. In addition, due to mitochondrial heteroplasmy and neutral drift of 
mitochondria within the cell, the amount of cellular CCO can, in theory, fall below detectable 
levels and then recover. Finally, the continuous clonal labelling approach used in mice by Kozar 
et al. was applied to humans by staining for loss of the mPAS protein due to spontaneous somatic 
mutations (Nicholson et al. 2018). The median time to monoclonal conversion was estimated to 
be 6.3 years, and the number of stem cells to be between five and 10. A final caveat should be 
added to all the models of neutral drift discussed so far, whether in mouse or human, in that they 
treat all stem cells as having an equal chance of survival. However, 3D intravital imaging of a 
confetti mouse has indicated that stem cells further from the centre of the crypt base are more 
likely to be lost by differentiation (Ritsma et al. 2014). 
 
 
I.1.d. Crypt fission 
 
Crypts themselves occasionally divide to produce two daughter crypts (a process termed 
crypt fission) throughout life. The relevance of crypt fission to our understanding of colorectal 
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cancer is that neoplasia occurs, initially, through a process of crypt fission that allows a driver 
mutation to extend beyond the borders of the crypt in which it arose. A low crypt fission rate in 
normal colon probably reduces the rate of clonal expansion of mutations that could contribute to 
malignant transformation, and so reduces the probability of a ‘second hit’. An understanding of 
the dynamics and regulation of crypt fission is, therefore, of central importance in our model of 
the evolution to cancer. 
 In humans, patches of multiple crypts that are CCO- are observed, and both their frequency 
and size increase with age (Greaves et al. 2006). Sequencing the CCO gene in the two arms of a 
CCO- bifurcating crypt showed that they shared the same inactivating mutation, indicating that 
fission rather than fusion was occurring (Greaves et al. 2006). Modelling of the CCO- patch size 
as a simple birth process allowed an estimate of a fission event every 36 years, while modelling of 
crypt fission rates based on protein stains results in an estimate of crypts dividing on average every 
140 years (Nicholson et al. 2018). It is unclear that a simple birth process is appropriate, as that 
would result in an increase in crypt number over the course of life, which – in mice at least – does 
not seem to be the case (Bruens et al. 2017). Recently, in vivo imaging has provided evidence for 
crypt fusion events in the mouse small intestine (Bruens et al. 2017), which could serve to control 
crypt numbers. Crypt exhaustion may additionally occur. Nonetheless, simulations indicated that 
the inclusion of crypt fusion has a negligible effect on the estimation of fission rates (Nicholson et 
al. 2018). Presumably, the ability of a crypt to fission has evolved as a regenerative response to 
damage. Indeed, inflammatory conditions often increase the number of crypts seen in fission.  
 
 
I.2. The genomics of colorectal cancer 
 
 Cancer is a late product of somatic evolution, representing the end-point of the adenoma-
carcinoma sequence (General Introduction). There now follows a brief overview of the genomic 
landscape of colorectal cancers. Cancers are the winners of somatic evolution, and their features 
provide clues as to the forces that govern natural selection in the colon. Two features warrant 
discussion: the mutation burden of colorectal cancers, and the features and numbers of driver 
mutations per cancer. 
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I.2.a. Mutational processes in colorectal cancer 
 
 Colorectal adenocarcinomas are one of the most highly mutated cancer types. They are 
surpassed only by melanomas, lung cancers – which are associated with exposure to the potent 
mutagens of ultraviolet radiation and tobacco exposure, respectively – and oesophageal cancers 
(Alexandrov et al. 2018). Colorectal cancers can be separated into two groups based on their 
mutation burden: so-called ‘hypermutators’ account for ~15% of cancers with a median of ~30 
mutations per million coding bases, while the other ~85% typically have ~3 mutations per million 
coding bases (Cancer Genome Atlas Network et al. 2012). These two groups are generally 
associated with different histopathology, age-, site-, and gender-specific incidence, clinical 
features, and patterns of driver mutations. As alluded to in the General Introduction, 
hypermutators, with their high burdens of point mutations and short insertions and deletions 
(indels), tend to have far fewer copy number alterations (Cancer Genome Atlas Network et al. 
2012), which is suggestive of two evolutionary paths to colorectal cancer, both of which are 
facilitated by an increase in mutation rate.  
 The analysis of mutational signatures in colorectal cancer provides a window into the origin 
of these mutations. Deconvolution of 60 whole colorectal cancer genomes, analysed in conjunction 
with thousands of other tumours as part of the Pan Cancer Analysis of Whole Genomes, revealed 
the activity of myriad mutational processes across the cohort: 13 single base substitution (SBS), 
10 doublet base substitution (DBS), and four insertion and deletion (ID) signatures (Alexandrov 
et al. 2018) (figure 2.1). Most colorectal cancers had three to five SBS signatures, two to three ID 
signatures, and four to five DBS signatures. Signatures can be divided into those that affected 
almost all cancers and sporadic signatures that affected only a subset of cancers.  
Common signatures might represent processes that are active in normal colorectal stem 
cells or that are necessarily associated with the process of transformation; without sequencing 
normal tissues, they cannot be told apart. Signatures that are common in colorectal cancers include 
SBS1, SBS5, SBS18, DBS2, DBS4, DBS6, DBS9, ID1, and ID2. Both SBS1 and SBS5 are found 
in almost all cancers sequenced to date. SBS1 accounts for a median of ~3,000 mutations per 
colorectal cancer genome (Alexandrov et al. 2018). It is characterised by C to T mutations in an 
NCG context (the mutated base is underlined), and is thought be due to the hydrolytic deamination 
of 5-methylcytosine to uracil (Rideout et al. 1990). In replication, an A is paired with the uracil, 
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and in the following round of replication, a T is paired with that A, such that the mutation is fixed 
as a T. As such, this is a process that is likely to occur spontaneously in all cells, but whose rate 
could be increased in cancers if mutations are more likely to be fixed by DNA replication rather 
than repaired. Cancers that arise from less mitotically-active tissues tend to have lower rates of 
SBS1 and on this basis it has been proposed that SBS1 acts as a mitotic clock (Alexandrov et al. 
2018, Alexandrov et al. 2015). SBS5 is also found in almost all tissues sequenced, but is of 
unknown cause; its relatively featureless trinucleotide profile provides few clues as to its aetiology. 
SBS18 is present in a large fraction of colorectal cancers, but not all. It should be noted, though, 
that the complex nature of cancer genomes, with multiple mutational processes with overlapping 
trinucleotide profiles active in a given cancer, makes the extraction of mutational processes 
relatively complicated. SBS18 may well truly be present in all cancers but not always be detected 
because some of its mutations could be misattributed to a different signature. SBS18 is 
characterised by C to A mutations and has been linked to the activity of reactive oxygen species 
attacking guanines to form 8-Oxoguanine, which, if not excised, can pair with an A (Viel et al. 
2017). ID1 and ID2 are, respectively, single base insertions and deletions of a single T in a polyT 
tract, postulated to be due to replication slippage, and DBS2, DBS4, DBS6, and DBS9 are of 
unknown origin, although some have been observed in normal mouse cells and DBS2 and DBS4 
have been noted to correlate with the age of cancer diagnosis (Alexandrov et al. 2018). 
Sporadic mutational processes detected in the PCAWG cohort of 60 colorectal cancers 
include: SBS10a, SBS10b, SBS15, SBS17a, SBS17b, SBS28, SBS37, SBS44, SBS45, DBS5, 
DBS8, DBS10, DBS11, and ID14. Some have a known cause. For example, SBS15, SBS44, 
DBS7, DBS10, as well as a marked increase of ID1 and ID2, are associated with loss of DNA 
mismatch repair. Cases with these signatures are the ‘hypermutators’ described above; it is notable 
that hypermutation is the result of a strong increase in a small number of processes rather than a 
generalised increase in all processes. Mutations in the proof-reading domain of polymerase epsilon 
are associated with vast numbers of mutations due to SBS10a and SBS10b. A large number of 
sporadic mutation processes active in colorectal cancer, however, are still of unknown cause 
(Alexandrov et al. 2018). 
Larger structural changes have also begun to be classified thoroughly. Most colorectal 
cancers have of the order of a hundred structural variants, most of which are complex events, large  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Categories for signature decomposition, 
reproduced with permission from Alexandrov et al. (2018). An 
example signature is shown for each of single bases substitutions 
(a), doublet base substitutions (b), and small insertions and 
deletions (c), in order to show the categories into which every 
signature is separated. In figures to follow in this chapter the 
category labels are often removed due to space constraints, but 
all are plotted with the same order and colouring as here. 
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deletions, or tandem duplications (Li et al. 2017), although, as noted above, hypermutated cancers 
have very few or none. 
 Thus, the mutational processes associated with colorectal cancer are diverse and variable 
across tumours. From sequencing cancers alone, it is unclear whether this is a reflection of the 
process of transformation or of the diversity in mutational processes operative across normal 
colorectal epithelium.  
 
 
I.2.b. Driver mutations in colorectal cancer 
 
I.2.b.i. Features of driver mutations 
 
A comprehensive discussion of all driver mutations in colorectal cancer is beyond the scope 
of this chapter. Here, rather, I attempt to sketch out succinctly two of the molecular pathways that 
are frequently deregulated, and whose nature informs our understanding of somatic evolution in 
the colon. I will not discuss driver mutations that are thought to act by increasing mutation rate, 
since the debate about whether an increased mutation rate is of importance has been covered in the 
General Introduction. Studies modelling the effect of driver mutations in normal tissues are 
discussed in section I.5. of this chapter. 
 The vast majority of colorectal cancers harbour mutations that de-regulate the Wnt 
signalling pathway. Wnt ligands are absent from the microenvironment of differentiated 
colonocytes. A complex formed of APC, AXIN, and GSK3B phosphorylates β-catenin, targeting 
it for degradation. At the crypt base, however, Wnt ligands are present, and these bind to the Wnt 
receptor on crypt stem cells, signalling to inhibit the degradation of β-catenin. β-catenin may then 
shuttle to the nucleus, where, it binds the TCF4 protein and turns it from transcriptional repression 
to transcriptional activation of a wide array of genes, including CMYC and CCND1 (reviewed in 
Fearon 2011 and in Bienz and Clevers 2000). Inactivating mutations have been documented in 
colorectal cancers in APC (homozygous truncating mutations in 70-80% of sporadic tumours and 
heterozygous loss of function mutations inherited in the fully penetrant colorectal cancer syndrome 
Familial Adenomatous Polyposis) and AXIN2 (truncating mutations that are frequently 
heterozygous (Segditsas and Tomlinson 2006)). Both result in a failure to degrade β-catenin. 
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Mutations are also observed in TCF7L2 (which encodes TCF4). While it is counterintuitive that 
loss of TCF4 should promote colorectal cancer, it has been proposed that loss of the repressive 
effect of TCF4 on some genes is a large part of the effect of complexing with β-catenin (Fearon 
2011). It seems that these mutations of the Wnt signalling pathway essentially revert cells to a stem 
cell-like phenotype: disruption of the β-catenin-TCF4 complex in colorectal cancer cell lines 
halted proliferation and increased the expression of genes associated with differentiation (van der 
Wettering et al. 2002). Kinzler and Vogelstein proposed that APC is a gatekeeper gene, which they 
defined as follows: ‘gatekeeper genes are responsible for maintaining a constant cell number in 
renewing cell populations [...] Mutation of the gatekeeper leads to a permanent imbalance of cell 
division over cell death’ (Kinzler and Vogelstein 1996). 
 The second pathway that warrants brief discussion is that of Ras signalling. This pathway 
mediates pro-proliferative signalling downstream of receptor tyrosine kinases such as EGFR. 
KRAS, BRAF, PIK3CA, and PTEN all form a part of this pathway and their genes are mutated in 
colorectal cancers at frequencies of 40%, 10% (mostly in hypermutators), 20%, and 10% 
respectively (Fearon 2011). Interestingly, KRAS mutations are frequently found in hyperplastic 
polyps with little chance of progressing to cancer, indicating that they might drive proliferation 
sufficiently powerfully to create a macroscopic lesion without necessarily setting a cell firmly on 
the road to cancer. 
 To simplify the features of the most frequent driver mutations in colorectal cancer, then, it 
seems that these act through a combination inhibiting differentiation and driving proliferation. A 
plethora of other driver mutations in colorectal cancer, however, have a broad range of effects.  
 
 
I.2.b.ii. Numbers of driver mutations 
 
The number of driver mutations needed for colorectal cancer is a primary determinant of 
cancer risk (Armitage and Doll 1954, Nordling 1953, General Introduction) and contextualises the 
observation of driver mutations in normal colon: if only two driver mutations were necessary to 
cause cancer we would be far more alarmed by the observation of a single driver mutation in 
normal colorectal epithelium than if 20 were required. A distinction should be drawn between the 
number of driver mutations observed in colorectal cancers, and the number of driver mutations 
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necessary to cause a cancer. Ongoing evolution within a cancer will increase the number of 
mutations found in a cancer over the bare minimum necessary. Both will be discussed here, but 
the latter quantity is the one of greatest interest to us. 
 Tabulating the driver mutations that were known in 1990, Fearon and Vogelstein estimated 
that most cancers have four to five driver mutations (Fearon and Vogelstein 1990). This was 
probably an underestimate, as only small parts of the genome were assayed and driver mutations 
have been discovered since. A more recent analysis of 52 colorectal cancer whole genomes that 
identified coding and non-coding driver mutations with a method that was largely based on prior 
knowledge found a mean of 7.4 driver point mutations and 2.5 driver genomic rearrangements per 
colorectal cancer (Sabarinathan et al. 2017). There was substantial variation, however, as almost 
20% of the cancers had three or fewer drivers, and another ~20% had 10 or more. Approaches that 
do not rely on prior knowledge are perhaps more robust and comprehensive. Martincorena et al. 
developed a dNdS method to detect driver point mutations in the coding regions of cancer 
genomes. This method compares the ratio of nonsynonymous to synonymous mutations in genes, 
under the assumption that nonsynonymous mutations code for proteins and are therefore subject 
to selection, while synonymous mutations have no functional impact. Thus, an excess of 
nonsynonymous mutations indicates positive selection of the gene, while a depletion indicates 
negative selection. The trinucleotide composition of the gene, the mutational processes active in 
the tumour, and local mutation rate were taken into account. Using this method, a mean of 10 
positively-selected coding point mutations per tumour was estimated from hundreds of colorectal 
cancer exomes (Martincorena et al. 2017). Perhaps a similar analysis, restricted to the tumours that 
are estimated to have transformed recently, might be informative for the minimum number of 
mutations necessary to cause cancer, although some driver events, including rearrangements, 
noncoding mutations, and epigenetic alterations would be missed. 
 Estimates of the minimum number of driver mutations necessary were first derived using 
cancer incidence data. It was observed that the incidence of cancer rose proportionately to four to 
six times the power of age, which was interpreted as indicating that five to seven rate-limiting 
events (often assumed to be driver mutations) were necessary to cause a cancer (Nordling 1953, 
Armitage and Doll 1954, General Introduction). This method assumes that driver mutations are 
independent events; if each driver mutation induces a clonal expansion or increases the mutation 
rate, and thus increases the probability of another mutation affecting one cell of the mutated clone, 
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the number of driver mutations could be lower. Realisation of this, along with the discovery of 
recessive oncogenesis (Knudson 1971) led to the elaboration of a multi-stage clonal expansion 
model. In this model, a number of mutations, each considered to be an independent rare event, 
must accumulate in a cell before it undergoes a clonal expansion, and then another high frequency 
event must occur (another mutation in any one of the many mutated cells). Fitting this model to 
colorectal cancer incidence data, trying different numbers of pre-clonal expansion mutations, 
showed that the most likely number of pre-clonal expansion mutations was just two (Luebeck and 
Moolgavkar 2002). These two mutations were posited to correspond each to the inactivation of 
one allele of the APC gene. Revealing though this is, assumptions are made that could be incorrect: 
the first mutation may already cause a small clonal expansion and neutral drift within the crypt is 
not taken into account. 
 Tomasetti et al. observed that patients with Lynch syndrome have a 114-fold risk of cancer 
over the general population, but that the microsatellite unstable tumours that these patients get only 
have eight times as many mutations as microsatellite stable sporadic tumours. From this they 
inferred that three driver mutations are sufficient to cause cancer (Tomasetti et al. 2014). This 
analysis ignores the fact that the mutation rate is only accelerated in some of the cells in the colon 
of Lynch syndrome patients, those that have lost the second copy of a mismatch repair gene. It 
would hold better for patients born with biallelic mismatch repair, who get colorectal cancer much 
younger than Lynch syndrome patients (Wimmer and Kratz 2010). Secondly, the analysis does not 
consider the different pathways to cancer taken by mismatch repair deficient versus proficient 
cancers; for instance, the former often have driver mutations in TGFBRII and BAX, which contain 
microsatellite tracts and so must be mutated disproportionately more rapidly than other driver 
mutations. 
 An orthogonal approach to estimate the number of driver mutations per patient is to induce 
different combinations of driver mutations in cancer models. For example, intestinal organoids (in 
vitro clonal expansions that recapitulate crypt organisation) engineered to have driver mutations 
in APC, TP53, KRAS, and SMAD4 grew independently of niche factors and developed a 
morphology similar to organoids derived from invasive carcinomas (Drost et al. 2015). 
 In summary, then, we still do not know conclusively the minimum number of driver 
mutations needed for a colorectal cancer. The weight of the evidence, however, seems to point to 
a handful of mutations, probably between two and seven, and thus fewer than the observed counts. 
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I.3. Colorectal cancer incidence  
 
Some features of colon cancer incidence deserve a brief mention. The age incidence of colorectal 
cancer has been discussed in the context of driver mutations. Three other features of cancer 
incidence, however, raise questions of colon biology. 
 Firstly, while in the West colonic cancer is a common disease, with a lifetime risk of about 
5% (Cancer Research UK Bowel Cancer Incidence Statistics), other parts of the world have much 
lower rates. Comparing extremes, there is a 10-fold age-standardised incidence difference between 
central Africa and Oceania. While this may be partly genetic, countries in Eastern Europe or in 
Asia that have recently adopted a more Western diet have seen rapid increases in incidence. A 
number of risk factors have been identified, including smoking, alcohol, and eating processed 
meats, as well as composition of the microbiome, infections with Fusobacterium spp., and 
inflammatory diseases like ulcerative colitis. Conversely, low-dose aspirin has been shown to have 
a protective effect (Brenner et al. 2014). All of these could presumably alter one or both of the 
mutation rate and selection pressures in the colon, but their precise mechanism of action is as yet 
incompletely understood. 
 Secondly, differences in cancer incidence between parts of the gut are intriguing. Most 
strikingly, in the UK, the incidence of adenocarcinoma in the large bowel is approximately 60-
fold higher than in the small bowel (Cancer Research UK Bowel Cancer Incidence Statistics, 
Aparicio et al. 2014), despite their similar stem cell biology. I am not aware of a simple explanation 
for this from the perspective of comparative evolution. Relative to other primates the colon has 
reduced in size even more than the small intestine: the colon takes up about 20% of the gut, 
whereas in other large primates it is closer to 50% (Milton 1987). While the function of the human 
colon is largely limited to water reabsorption, in primates such as gorillas the colon plays a major 
role as a fermenting chamber. Short chain fatty acids produced as a result of bacterial fermentation 
of fibre provides over half of a gorilla’s calories, compared to less than 10% in a human (Popovich 
et al. 1997). Combined with the geographic variability in colon cancer risk, we can speculate that 
dietary changes associated with ever more energy-rich foods might be responsible for the high 
incidence of colorectal cancer observed nowadays in the Western world. 
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 Thirdly, even within the colon there are substantial differences in cancer incidence. In men, 
cancer incidence is approximately twice as high in the sigmoid colon as in the caecum (23% v. 
12%), while in women it is only slightly higher (20% v. 17%) (Cancer Research UK Bowel Cancer 
Incidence Statistics). Clinical factors may play a role in these incidence rates, since left-sided 
cancers typically cause symptoms earlier, but the difference is nonetheless striking and, to my 
knowledge, unexplained. These differences could be caused by small differences in the rate of 
known mutational processes, different frequencies of activity of sporadic mutational processes, 
differences in stem cell dynamics (such as stem cell numbers per crypt), or other factors. 
 The sequencing of normal colonic and small intestinal stem cells can begin to resolve the 
role of somatic mutations in these curious discrepancies in cancer incidence. 
 
 
I.4. Current understanding of somatic mutations in normal colon 
 
I.4.a. Mutation rates 
 
In recent years there has been a flurry of interest in the mutational processes in normal 
tissues, including in normal colon. The mutations in normal colon can be inferred from cancer 
genomes, which represent the sum of the mutations that occurred before and after transformation. 
Assuming a similar lag time across colorectal adenocarcinomas between the departure from 
normal mutational processes and resection, the number of mutations due to normal mutational 
processes should correlate with patient age. Examination of this relationship in colon revealed that 
only signature 1 correlated with age, with a rate of 23 (95% CI 19-28) mutations per year 
(Alexandrov et al. 2015).2  Interestingly, the curve passes through the origin. An increase in the 
mutation rate of signature 1 during carcinogenesis would shift the curve up, whereas a lag between 
diagnosis and the time to the most recent common ancestor of the tumour in whom mutations can 
be called would shift the curve down. While a novel insight, the authors note that ‘Peering through 
the “cracked lens” of cancer genomes may obscure or distort the estimates of clock-like mutation 
                                                 
2 Please note that this is the COSMIC version of signature 1, which is not composed exclusively of C to T 
at CpG mutations but has some background in other contexts that resemble those of signature 5. Using the 
PCAWG SBS1, the number of mutations attributed to this signature would be lower, and signature 5 may 
be found to accumulate linearly. 
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rates of normal cells that are progenitors of the cancers’ (Alexandrov et al. 2015). Sequencing the 
genomes of normal cells provides far greater resolution and allows the investigation of non-clock-
like processes. 
 Normal organoids derived from 21 single colonic stem cells from six patients ranging in 
age from nine to 67 years old (although none was between the ages of 15 and 53) provided the first 
clear insight into the mutations in normal colonic stem cells (Blokzijl et al. 2016). Small intestinal 
organoids were derived as well and, remarkably, both had the same mutation rate of 36 mutations 
per year (95% CI 26.9-50.6 for colon and 25.8-43.6 for small bowel), which indicates that the 
model of cancer risk being mostly due to stem cell divisions (Tomasetti and Vogelstein 2015, 
General Introduction) does not explain the difference between cancer incidence in the large and 
small bowel. Interestingly, four out of 15 colonic organoids that could be assessed were found to 
have structural variants, including a complex translocation and a trisomy of chromosome 13, while 
small deletions were found in three out of 14 small intestinal organoids. Similarly, high density 
SNP arrays on individual human colonic crypts showed the presence of deletions and 
amplifications, which increased in prevalence with age, with detectable copy number changes in 
one in seven crypts from a 78 year-old. (Hsieh et al. 2013). 
 Blokzijl and colleagues found three single base substitution signatures to be operative in 
colonic organoids: signatures 1, 5, and 18. Numbers are not provided in the text, but judging from 
the figures, signature 1 accumulated at a rate of about 25 (95% confidence interval ~18-38),3 
signature 5 at about 10, and signature 18 at about five mutations per year. Similar numbers were 
found in the small bowel, with a little less signature 1 and more signature 5. The rate of 
accumulation for signature 18 is not significantly different from 0, and signature 18 was found to 
be enriched in sequential in vitro cultures, which led the authors to ascribe it to an oxidative process 
during organoid culture. For all signatures in colon the slope of the curve of mutation burden versus 
age cuts the y intercept near to, but slightly above, the origin, which hints at a period of transiently 
increased mutation rate. The authors remark on the lack of interindividual variability in mutational 
processes, but with only six individuals they were unlikely to capture mutational processes that 
are not ubiquitous. No driver mutations were found, but one disadvantage of the organoid culture 
system is that it can select against driver mutations in certain tissues; indeed, in the colon, wild-
                                                 
3 Again, this is the COSMIC version of signature 1. Using the PCAWG definition, probably fewer 
mutations would be attributed to SBS1 and more to SBS5. 
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type organoids will outcompete mutant ones unless niche factors are removed (van de Wetering et 
al. 2015). Despite its relatively limited power, this study is seminal in that clean whole genomes 
of single normal cells were seen for the first time. The discrepancy between the mutation burden 
of ~3,000 mutations in a colonic stem cell from a 60 year-old and the average mutation burden of 
10,000-20,000 mutations in a non-hypermutated colorectal cancer demonstrates that cancers have 
an elevated mutation burden over their normal counterparts. 
Nonetheless, until normal and tumour from the same people are studied, it remains 
theoretically possible that those people who get cancer have an elevated mutation rate all around 
their bowel. In an attempt to resolve this, organoids were derived from APCmin/+ mouse 
adenomatous crypts and normal crypts and exome sequenced (Lugli et al. 2017). The rate of 
acquisition of point mutations was found to be ~11 fold higher in adenomas, although small 
numbers of mutations were captured: only 71 mutations were seen in total across seven normal 
organoids and 15 tumour-derived organoids. The caveats of organoids (as discussed above) 
remain, and mouse intestinal organoids have been shown to have different mutational spectra to 
human ones, with an enrichment of C to A and fewer C to T mutations (Blokzijl et al. 2016, Behjati 
et al. 2014). Furthermore, while this indicates that the people who get cancer need not have a 
generally increased mutation rate, it is possible that the cells that become cancerous could, even 
prior to transformation, have had an increased mutation rate. A phylogenetic analysis of tumours 
and comparison to normal tissues from the same patients could resolve this. 
 An orthogonal approach to quantify mutation rates in normal tissues despite their 
polyclonality is to perform very deep and highly error-corrected sequencing, such that mutations 
in individual molecules of DNA can be called reliably (General Introduction). Analysis of normal 
colonic epithelium from 11 individuals showed an increase in mutation rate with age, reaching 
~3,500 mutations per genome in people over the age of 40 (Hoang et al. 2016), which is similar to 
the number found by sequencing organoids. It should be noted that this assays mutations across 
all cells in the epithelium, some of which will have arisen during the process of differentiation, 
while organoids only report the mutations in stem cells. The similarity between these two estimates 
then indicates that there is no dramatic increase in mutation rates over the course of differentiation. 
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I.4.b. Driver mutations in normal colon 
 
Relatively little is known about the frequency of driver mutations in normal human colon, 
largely due to difficulty in their detection. To my knowledge, two approaches have been used so 
far: PCR-based methods to detect specific mutations, which are only practical for assaying 
hotspots, and staining for tumour suppressor proteins. This detects homozygous mutations that 
result in a loss of expression rather than merely a loss of function. 
 KRAS hotspot mutations have been detected through PCR-based methods since 1998 in a 
number of studies, but most were non-quantitative or only semi-quantitative and frequently failed 
to detect KRAS mutations in normal mucosa (discussed in Parsons et al. 2010). Parsons and 
colleagues used allele-specific competitive blocker polymerase chain reaction (ACB-PCR) to 
quantify KRAS codon 12 GTT and GAT mutations in 89 samples of colonic mucosa (Parsons et 
al. 2010). Mutant KRAS was detected in all samples of normal mucosa, and it was estimated that 
1 in 3,500 normal cells contained a KRAS codon 12 mutation. This is 60 times more frequent than 
the mutation is expected to occur by chance (Tomasetti et al. 2013), indicating positive selection. 
KRAS mutations were more frequent in the sigmoid colon, concordant with the observation that 
sigmoid tumours more frequently have KRAS mutations. Interestingly, the frequency of KRAS 
codon 12 GTT mutations was found to be higher in adenomas than in carcinomas, indicating that 
some KRAS mutations may promote the transition to malignancy more effectively than others. No 
correlation of variant allele fraction was observed with the patients’ age, which may be a result of 
the relatively small age span covered (50 to 80 years old). A more recent study using targeted 
sequencing on a larger cohort of patients validated the presence of KRAS mutations in normal 
colon (Nicholson et al. 2018). Similarly, ACB-PCR investigation of PIK3CA found that the 
H1047R mutation was above the detection threshold of 1x10−5 in 20 out of 20 normal samples, 
whereas the E545K mutation was not detected in any of the 20 samples (Parsons et al. 2017). 
 Recently, staining for four putative tumour suppressor proteins located on the X 
chromosome (such that loss of one allele was sufficient to inactivate all copies of the protein) was 
performed for 186 patients across an age range (Nicholson et al. 2018). One of these, STAG2, was 
found to be lost in most patients at a mean frequency of about one in 7,000 crypts in a 60 year-old. 
The mechanisms by which these driver mutations might colonise colorectal epithelium are 
discussed below. 
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I.5. Quantitative insights into the earliest stages of colorectal cancer evolution 
 
In order to form a tumour, driver mutations that occur in colonic stem cells must be able 
first to sweep through the crypt and second to spread beyond it. Quantitative analyses of the effects 
of driver mutations in mouse models, and more recently in humans, have begun to elucidate how 
this occurs. 
 
 
I.5.a. Driver mutations skew the odds of stem cell competition 
 
Under a model of neutral drift, neutral mutations that arise in a single stem cell have a 
probability of becoming fixed that is inversely proportional to the number of stem cells per crypt. 
A mutation that decreases the probability that the cell in which it occurs will be lost from the crypt 
is more likely to be able to go on to form a tumour. Mouse models indicate that this is a property 
of common colorectal cancer driver mutations in Apc and Kras (Vermeulen et al. 2013, Snippert 
et al. 2014). Vermeulen et al. (2013) induced driver mutations and a coloured tag in mice at 
infrequent levels, such that only one cell in a crypt would be mutated. Quantifying the growth of 
the labelled cells allowed a model of the benefit that the driver mutation conferred. Kras G12D 
mutant stem cells outcompeted their wild-type neighbours 80% of the time. Snippert et al. (2014) 
induced both Kras G12D and the confetti reporter at a low frequency in Lgr5 positive cells, and 
similarly found that the mutant cells had a higher chance of sweeping through a crypt. An EdU 
pulse showed that Kras mutant cells were cycling faster, consistent with our understanding of the 
Ras pathway in driving proliferation.  
Vermeulen et al. also studied Apc and P53. Interestingly, Apc +/- cells outcompeted Apc 
+/+ cells, but Apc -/- cells outcompeted Apc +/- cells. This shows that mutations of tumour 
suppressor gene alleles are not necessarily independent events, as they are frequently modelled to 
be. The selective advantage of Apc mutations within the crypt is consistent with its suggested role 
in controlling the balance stem cell self-renewal and differentiation (section I.4.b.).  As discussed 
in the General Introduction, P53 mutations were only found to be advantageous when colitis was 
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induced. The concept of a context-specific driver mutation is both fascinating and daunting in that 
it adds another layer of complexity to the construction of quantitative models of cancer. 
 In humans, comparing STAG2 to a neutral mark showed that the proportion of crypts that 
had lost the expression of STAG2 in all cells was increased relative to the proportion of crypts 
where STAG2 was lost in only a fraction of cells, indicating more rapid clonal sweeps (Nicholson 
et al. 2018). STAG2 loss was estimated to increase the probability of replacing a wild type 
neighbour from 0.5 to 0.99. 
 
 
I.5.b. Driver mutations increase the rate of crypt fission 
 
 Crypt fission is rare physiologically (Baker et al. 2014, Nicholson et al. 2018), so unless a 
driver mutation can increase this rate, it is likely to remain entombed in its own crypt. It seems that 
as well as giving a selective advantage within the crypt, canonical driver mutations also promote 
clonal expansion beyond the crypt. 
 Snippert et al.’s (2014) multi-coloured labelling method allowed them to analyse the 
dynamics of crypts that had been fully colonised by Kras. In the presence of Kras mutations, 
adjacent crypts were more likely to be the same colour, which indicated an excess of crypt fission 
events. It was estimated that Kras G12D increased the rate of crypt fission 30-fold. In humans, the 
discrepancy between the rate at which KRAS mutations should occur by chance and their allele 
fraction in bulk epithelium indicates that they must increase the rate of crypt fission approximately 
10-fold (Nicholson et al. 2018). Similarly, STAG2-negative patches of epithelium tended to be 
larger than patches of epithelium negative for neutral marks. Modelling the growth of these patches 
with age showed that 0.7% of crypts with neutral marks fissioned per year, whereas 2.15% of 
crypts with STAG2 loss fissioned per year. 
  Theoretically, early driver mutations need not cause crypt fission. In ulcerative colitis (a 
risk factor for colorectal cancer), crypt fission rates are increased, presumably as part of a 
wounding response, and so driver mutations could hitch-hike out of the crypt; once the clone was 
big enough, a second driver mutation that did allow a disruption of the tissue architecture would 
be more likely to strike the clone. Nonetheless, it seems probable that most colorectal cancer 
drivers that tend to occur early in the adenoma-carcinoma sequence will promote crypt fission as 
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it would provide a strong fitness advantage.  Many known tumour suppressor genes seem to have 
evolved at the time when our ancestors became multicellular (Domazet-Loso and Tautz 2010), and 
it has been suggested that they served the purpose of limiting the selfish behaviour of cells in 
metazoa. With this in mind it is perhaps not so surprising that their deregulation results in an 
atavism that involves concomitant proliferation and disruption of tissue architecture. 
 Thus, we begin to be able to describe in a quantitative manner how driver mutations can 
colonise the colorectal epithelium. Much remains unanswered, however. To list but a few 
questions: what are the actual mechanisms behind a competitive advantage within the crypt, and 
what governs crypt fission? Are mutations that allow cells to outcompete their wild type 
neighbours necessarily advantageous to cancer? What are the effects of combinations of driver 
mutations? And what other driver mutations lurk in normal colonic epithelium? 
 
 
 
Results 
 
R.1. Study design 
 
 We aimed to investigate the landscape of somatic mutations in normal colon. A small 
number of normal colonic organoids had previously been sequenced (Blokzijl et al. 2016, section 
I.4.a), which indicated the activity of only three mutational signatures in normal colon and little 
variation in between different samples. We designed an experiment to explore the variety in 
mutation burden, mutational processes, and frequency of driver mutations in the normal colonic 
mucosa between different people and between different crypts within one person. We set out to 
exploit the stem cell architecture of the colon as a clonal unit by laser capture microdissection of 
single crypts, followed by sequencing. The advantages of laser capture microdissection over 
organoids (which were used by Blokzijl and colleagues (2016)) are the following: the method is 
more easily scaled to analysing hundreds of samples; spatial information on the location of the 
crypts is retained, allowing the investigation of processes such as crypt fission; there is no selection 
of crypts in culture, allowing an unbiased discovery of driver mutations; and no mutations are 
acquired in vitro. On the other hand, one downside of bulk sequencing whole crypts is that only 
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mutations in the most recent common ancestor of the crypt are called. The time to the most recent 
common ancestor of the crypt is likely to be within the decade before resection (section I.1.c.). 
This should be borne in mind in analyses of mutation burden, but is not problematic for the 
discovery of mutational signatures. 
 
 
R.2. Development of a protocol to sequence individual crypts 
 
 At the time when this experiment was begun (Autumn 2015), 500ng of DNA were required 
for Illumina to guarantee sequencing success, and sequencing was rarely performed with less than 
200ng. Colonic crypts, each with ~2,000 cells (~12ng of DNA) of which only a fraction are 
obtained in a given section, were far below this threshold. We developed a pipeline to allow the 
sequencing of single colonic crypts. Peter Ellis developed a more sensitive library preparation 
method (Methods), while I, with advice from Robert Osborne, optimised the thickness of sections, 
the choice of fixative, the staining protocol, and the lysis method. All experiments were performed 
on fresh frozen colonic tissue, initially from a mouse, and later from a human. 
 The thickness of sections was chosen to be the largest possible that still allowed the 
dissection of single crypts. In very thick sections, if crypts are visualised longitudinally it may be 
that a fragment of another crypt is hidden behind the back wall of the crypt that is being dissected, 
which would result in a polyclonal sample. The spacing between crypts may vary depending on 
factors such as mucosal oedema. Images of en face crypt sections from a number of mucosal 
samples, however, showed that 30 micron sections rarely resulted in capturing one crypt behind 
another. The staining regimen was chosen to be the simplest that still allowed crypts to be 
visualised, the rationale being that any unnecessary chemicals might damage DNA. Furthermore, 
as these experiments require very long days, any time that can be saved is valuable. Crypts were 
therefore stained only with Gill’s haematoxylin and no eosin. With 30 micron sections and staining 
with haematoxylin, crypts could clearly be seen as clonal units (figure 2.2a). The images are much 
less attractive than those in textbooks due to a combination of the thickness of the section 
(pathology sections are often only 4 microns thick), the use of fresh frozen tissue (whereas 
pathology sections are formalin-fixed and paraffin-embedded), the absence of a coverslip (since 
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this cannot be used in laser capture microdissection), and the fact that sections were only stained 
with haematoxylin (rather than haematoxylin and eosin as in standard pathology). 
 The best fixative and lysis methods were evaluated jointly by the quantification of libraries 
made by Peter Ellis. Four fixatives were tested: acetone, paraformaldehyde, methanol, and ethanol. 
Three different lysis methods were assayed: alkaline lysis, protease lysis, and chaotropic lysis 
(RLT). Below are the results for half a plate testing these combinations. From these results and 
repeat experiments that confirmed them, fixation with methanol and protease lysis were chosen.  
 
 7 8 9 10 11 12 
A blank blank blank blank blank blank 
B Alk EtOH 1 crypt Alk PFA 1 crypt Prot EtOH 1 crypt Prot PFA 1 crypt RLT EtOH 1 crypt RLT PFA 1 crypt 
C Alk EtOH 1 crypt Alk PFA 1 crypt Prot EtOH 1 crypt Prot PFA 1 crypt RLT EtOH 1 crypt RLT PFA 1 crypt 
D Alk EtOH 1 crypt Alk PFA 1 crypt Prot EtOH 1 crypt Prot PFA 1 crypt RLT EtOH 1 crypt RLT PFA 1 crypt 
E Alk ace 1 crypt Alk MeOH 1 crypt Prot ace 1 crypt Prot MeOH 1 crypt RLT ace 1 crypt RLT MeOH 1 crypt 
F Alk ace 1 crypt Alk MeOH 1 crypt Prot ace 1 crypt Prot MeOH 1 crypt RLT ace 1 crypt RLT MeOH 1 crypt 
G Alk ace 1 crypt Alk MeOH 1 crypt Prot ace 1 crypt Prot MeOH 1 crypt RLT ace 1 crypt RLT MeOH 1 crypt 
H blank blank blank blank blank blank 
       
A 0.076 0.12 0.113 0.12 0.14 0.167 
B 0.233 0.114 0.12 1.71 0.125 0.168 
C 0.086 0.092 0.098 2.55 0.139 0.133 
D 0.079 0.08 1.504 0.198 0.121 0.152 
E 0.144 0.204 0.693 28.895 0.118 0.152 
F 0.073 0.248 11.444 18.849 0.121 0.135 
G 0.156 0.096 19.788 6.247 0.12 0.173 
H 0.107 0.1 0.11 0.111 0.125 0.127 
       
Table 2.1. Quantification of libraries to test fixation and lysis condition. The top panel shows the layout of this half of the plate. The bottom 
panel shows library preparation results, in ng/ml. Alk, alkaline lysis; Prot, protease lysis; RLT, chaotropic lysis; EtOH, ethanol fixation; ace, 
acetone fixation; PFA, paraformaldehyde fixation; MeOH, methanol fixation. 
 
With these sample preparation methods and the library construction protocol developed by Peter 
Ellis, 11 single colonic crypts from one sample were sequenced at 1-2x coverage each. Even 
coverage across the genome was observed, and sequencing metrics were acceptable. Pooling the 
crypts allowed known germline mutations in this patient to be recovered. Sequencing at higher 
coverage (~15X per crypt) allowed somatic mutations to be called using our standard algorithms  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Laser capture microdissection of crypts. a, a 
representative image of a section of colonic tissue, with a 
magnified inset showing the section before and after dissection 
of a crypt. b-c, the coverage of crypts that underwent whole 
genome (b) and targeted (c) sequencing. Crypts are ordered by 
their mean depth (shown below), and for each crypt the 
proportion that is covered by a certain read depth is shown as  a 
stacked barplot. d-e, their respective VAF (which is half of the 
clonal fraction).  f-h, the distribution of coverage over exonic 
regions of putative colorectal cancer driver genes, from 
combining both whole genome and targeted data. f, the mean 
coverage across all samples of each gene. g, the number of crypts 
in which each gene was covered by an average of >7 reads, and 
h, the number of crypts in which each gene was covered by an 
average of >9 reads. Please note that the ordering of genes in 
each figure is different. 
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that have been developed for cancer genomes. Subsequently, bioinformatic filters were developed 
by Mathijs Sanders to remove artefacts that are due to this library preparation method (Methods). 
It should be noted that some wells are empty because the crypt does not fall into the well. 
Electrostatic attractions often cause a dissected segment to stick to the underside of the slide. 
Visual inspection of adjacent wells never showed a crypt that had gone into the wrong well. In 
general, 30-40% of dissected crypts resulted in libraries with over 5ng/ul, which was chosen as the 
threshold to proceed to sequencing for most experiments. 
 
 
R.3. Samples 
 
 Samples were obtained from four cohorts in order to cover as broad an age span as possible 
(Methods). 42 patients aged 11 to 78, 27 of whom had no diagnosis of colorectal disease and 15 
of whom had been found to have a colorectal adenocarcinoma, were investigated. Wherever 
possible, biopsies from the caecum, transverse, and sigmoid colon were taken, as well as terminal 
ileum in a subset of cases. From these samples I dissected >5,000 crypts, of which 2,035 were 
sequenced: 571 were whole genome sequenced at ~15X coverage (figure 2.2b), and 1,464 
underwent targeted sequencing using a bait-set of known cancer genes. Inspection of the allele 
fractions from the whole genomes showed that most crypts were 80-90% clonal (figure 2.2d), with 
some contamination which is likely to be stromal. The clonality of crypts that underwent targeted 
sequencing should be the same, but its assessment is less accurate as few mutations are called per 
genome (figure 2.2e). Targeted sequencing is more sensitive to low amounts of input DNA because 
of the additional step of bait hybridisation. Targeted sequencing on such small quantities of DNA 
was at the limit of current technical capabilities and variable coverage was achieved (figure 2.2c). 
CaVEMan (the algorithm used to call substitutions) requires – in most cases – three reads to call a 
mutation in a diploid genome. With a depth of eight reads, a clonal sample will achieve this many 
mutant reads 85% of the time (based on the binomial distribution). We therefore considered that 
only sites covered by at least eight reads could be genotyped with acceptable accuracy. Pindel (the 
algorithm used to call small insertions and deletions), however, requires four mutant reads to call 
a mutation. With a depth of 10 reads, a clonal sample will achieve this many mutant reads 83% of 
the time, and so we only considered that we could accurately genotype indels where sites were 
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covered by at least 10 reads. Because of the different coverage requirements for calling 
substitutions vs small indels, we estimate that we were adequately powered to call substitutions in 
1,403 and indels in 1,046 of all crypts (genomes and targeted combined). 
 
 
R.4. Driver mutations 
 
 Two approaches were taken to discover driver mutations in normal crypts: first a modelling 
method to detect positive or negative selection of genes, and second, manual annotation based on 
prior knowledge. 
A dNdS approach (section I.2.b.ii., Methods, Universal patterns) was used to detect 
positive or negative selection. Two separate analyses were performed: a genome-wide analysis 
using only the whole genomes, and an analysis restricted to 90 putative colorectal cancer driver 
genes (Appendix B) that were included in our bait-set, using combined genomes and targeted 
sequences. In both analyses, the 95% CI for the global dNdS spanned 1, which indicates that the 
vast majority of the mutations in our dataset are selectively neutral. In the genome-wide analysis, 
no genes were significantly mutated. In the analysis of 90 genes, however, there was evidence of 
positive selection of two genes: AXIN2 (three truncating mutations, adjusted p value 0.004), and 
STAG2 (two truncating mutations, adjusted p value 0.038). 
AXIN2 is a negative regulator of the WNT signalling pathway (section I.2.b.i.). AXIN2 is 
inactivated in 2.3% of colorectal adenocarcinomas and smaller proportions of other cancer types 
(Forbes et al. 2017). One of the three AXIN2 nonsense mutations was present in two adjacent crypts 
that were closely related genetically, sharing 1,606 SBS1 mutations; the AXIN2 mutation must 
have occurred in their common ancestor which then underwent crypt fission. In one sister crypt, 
but not the other, the AXIN2 mutation was rendered homozygous by copy number neutral loss of 
heterozygosity of chromosome 17q (figure 2.3a-d). This suggests that while loss of one copy of 
AXIN2 already confers a growth advantage and may have contributed to the crypt fission, loss of 
a second copy could provide a further advantage and aid the expansion of the mutant clone, as has 
been shown for other tumour suppressors in mouse models (section I.5.a.). This provides evidence 
for ongoing clonal evolution in normal colon. 
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STAG2 is a component of the cohesin complex, which has roles in sister chromatid 
cohesion, DNA repair, and regulation of gene expression and chromatin structure (Hill et al. 2016). 
Although STAG2 loss has been associated with aneuploidy in solid tumours (Solomon et al. 2011), 
this is not always the case (Hill et al. 2016, Balbas-Martinez et al. 2013, Taylor et al. 2014), and 
we do not observe this here. It is inactivated in 0.9% of colonic adenocarcinomas, and more 
frequently in other tumour types (Forbes et al. 2017). In our dataset, both STAG2 nonsense 
mutations occurred in men, so no wild type copies of this X chromosome recessive cancer gene 
would remain in these cells. STAG2 loss has previously been shown to confer a proliferative 
advantage in human colon (section I.5.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Driver mutations in normal colon. a-d, driver 
mutation in AXIN2. a, a section (after dissection) in which an 
inactivating AXIN2 mutation was found. Red dots represent 
crypts with the AXIN2 mutation. Blue dots represent crypts that 
could be assessed and were found not to have the mutation. 
Crypts without dots failed sequencing and could not be assessed. 
b, the two crypts with the AXIN2 mutations prior to dissection 
did not appear different to any other crypts. c, copy neutral loss 
of heterozygosity (CNN-LOH) of one of the crypts over the 
AXIN2 locus. The copy number state (y axis) for every 
chromosome is shown, with one allele coloured red and the other 
green. d, Jbrowse image of reads supporting the AXIN2 
mutations in each of the crypts. The mutation is coloured red. 25 
out of 29 reads support the mutation in the crypt that has CNN-
LOH; the four reads that do not are presumably the result of 
stromal contamination. e, putative driver missense mutations in 
oncogene hotspots. The number of substitutions catalogued in 
COSMIC (Forbes et al. 2017) are shown on the y axis at each 
position along the gene, with the mutations observed in our 
cohort highlighted. 
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Additional potential driver mutations were identified by manual curation based on the 
known cancer genes in colorectal cancer and their distinctive patterns of mutation. Nine canonical 
missense hotspot mutations in the dominantly acting cancer genes PIK3CA (E542K, R38H (a 
minor hotspot)), ERBB2 (R678Q, V842I, T862A), ERBB3 (R475W, R667L), and FBXW7 (R505C, 
a major hotspot, and R658Q, a minor hotspot) were observed (figure 2.3e). Given the specificity 
of these mutation hotspots, the majority of these are likely to be driver mutations and confer some 
growth advantage. As with AXIN2, the PIK3CA E542K mutation was also in two adjacent crypts 
which shared 2,516 SBS1 mutations and had 93 and 208 private SBS1 mutations, implying a recent 
crypt fission event. Indeed, these two crypts shared more mutations than any other pair of crypts 
in our dataset.  
Finally, a series of heterozygous truncating mutations in the recessive colorectal cancer 
genes ARID2, ATM (two mutations), ATR, BRCA2, CDK12 (two mutations), CDKN1B, RNF43 
(two mutations), TBL1XR1, and TP53 were found. They were not associated with loss of 
heterozygosity, and no crypt had more than one driver mutation. It is likely that some of these did 
not confer any selective advantage. Nonetheless, in mouse colon heterozygous nonsense mutations 
of the Apc tumour suppressor gene can confer a selective advantage (Vermeulen et al. 2013), and 
indeed the AXIN2 mutations for which we have compelling evidence of driver function were 
mostly heterozygous. Even if not currently advantageous, these mutations could set the scene for 
future clonal expansions, through loss of the remaining wild type copy or a change in 
microenvironment as has been observed for P53 (General Introduction, section I.5.a. of this 
chapter). 
On the basis of these findings, treating the AXIN2, STAG2, and dominant cancer gene 
hotspot mutations as drivers (i.e. all but the heterozygous mutations in recessive cancer genes) we 
estimate that at least 1% of normal colorectal crypts in a 50-60 year old carries a driver mutation. 
We are underpowered to detect a change in driver frequency with age. Since there are ~15 million 
crypts in the colon, ~150,000 crypts carry a driver. In the over 70s, ~40% of people have an 
adenoma on colonoscopy (Corley et al. 2013) and ~5% of people develop colorectal cancer over 
their lifetime (Cancer Research UK bowel cancer incidence statistics), and some of these may arise 
from more recently-acquired driver mutations. Therefore, only an extremely small proportion of 
these crypts with driver mutations becomes a macroscopically detectable adenoma (< 1/375,000) 
or carcinoma (< 1/3,000,000) within the following few decades.  
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Given that they are so common in colorectal cancer and absent from our dataset, we might 
conjecture that crypts with driver mutations in APC or KRAS as a first hit might have a higher 
chance of progressing. Using the mutation rate observed in our data, we can estimate that even if 
they were selectively neutral, 12,000 crypts from a 50-60 year old would have inactivated one 
copy of APC, and five crypts would have both copies inactivated. As even heterozygous Apc 
mutations confer a selective advantage in mouse models (Vermeulen et al. 2013), the true 
frequency is likely to be higher. PCR-based analysis of bulk epithelium has shown that 1 in 3,500 
epithelial cells bears KRAS G12D (Parsons et al. 2010), which would indicate a few thousand 
crypts with this mutation per colon. Thus, even for these mutations, the probability of progression 
to cancer must remain low. 
Comparison of the frequency of particular cancer gene mutations between normal 
epithelium and colorectal cancers extends the adenoma-carcinoma sequence and informs on the 
properties of driver mutations. Mutations reported in 260 cancers (Cancer Genome Atlas Research 
Network et al. 2012) were annotated for driver mutations using the same criteria as for the manual 
annotation of driver mutations in normal tissues. The pattern of driver mutations is different 
between cancer and normal tissues (p=0.003 by randomization test, figure 2.4). In colorectal 
cancer, mutations in APC, KRAS and TP53 are common, accounting for 56% of base substitution 
and indel drivers but are comparatively rare among normal crypts with driver mutations (1 out 14 
drivers). By contrast, mutations in, for example, ERBB2 and ERBB3 are relatively common in 
normal crypts with drivers (5/14) but rare in colorectal cancer (7/631). It is, therefore, not simply 
that the genes found in cancers are found at lower frequencies in normal tissues, but rather some 
account for a greater proportion of driver mutations in cancer than they do in normal tissues.  
A mutation may be enriched in a cancer for four reasons: (1) the mutation itself has itself 
promoted progression of the lesion; (2) the mutation provides a selective advantage only in a 
neoplastic microenvironment; (3) the mutation occurs more frequently in the cancer due to an 
increased mutation rate; or (4), the mutation itself increases the mutation rate and so the probability 
of one of its descendants acquiring a mutation with properties (1) or (2). Mutations that provide a 
selective advantage in normal tissues but do not confer any of the above properties will be found 
at equal frequencies in cancer and in normal tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Comparison of driver frequency in normal colon 
and colorectal cancer. The frequency of driver mutations in 
colorectal cancer is derived using data from Cancer Genome 
Atlas Network (2012). a, the proportion of crypts or cancers with 
driver mutations in each gene found in either of the two groups. 
b, the proportion of driver mutations in each gene in normal and 
cancer. 
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Thus, APC, KRAS, and TP53 mutations, which are present orders of magnitude more frequently 
in cancer than in normal tissues (figure 2.4a) will confer properties (1)-(4), while mutations in 
ERBB2 or STAG2, which are not significantly enriched in cancers, may merely provide a selective 
advantage in normal tissues without promoting cancer development. The distinction must therefore 
be drawn between mutations that are under positive selection and those that actually promote 
cancer development, although there will be significant overlap between the two categories.  
Uneven coverage over the genome presents some difficulties when estimating the 
frequency of driver mutations. Ideally, every locus in every gene would be covered by many reads 
in every crypt, and the true frequency of driver mutations would need no correction. Second best, 
all genes would be covered equally well, but all genes would not be callable in a certain proportion 
of crypts. The frequency of driver mutations could then be estimated by dividing the number of 
drivers by the number of crypts in which they were callable. Third best, coverage would be even 
within each gene, but some genes would be better covered than others. If there were a sufficient 
frequency of drivers in each gene, we could estimate the true frequency of drivers per gene. Let us 
imagine that gene A achieves sufficient coverage to call mutations in 1,000 crypts and 10 drivers 
are found in it, and gene B achieves sufficient coverage to call mutations in 2,000 crypts and 100 
drivers are found in it, we would say that the 1% of crypts have gene A drivers and 5% of crypts 
have gene B drivers. Assuming that these were occurring in different crypts, we would conclude 
that 6% of crypts have driver mutations.   
The first challenge of our data is that the driver frequency is so low that we cannot estimate 
a per-gene driver frequency. All we can do to derive a meaningful estimate is to pool our driver 
mutations. Thus, if we can detect one gene A and one gene B driver mutation in our cohort, and 
the mean number of crypts in which we can call mutations accurately over all base pairs is 1,500, 
our best estimate is that two in 1,500 crypts has a driver mutation. 
The second challenge is that coverage may fluctuate even within a gene. Some portions of 
a gene may be well covered in 1,000 crypts, and others in 2,000 crypts. All we can do here is treat 
different parts of a gene with different coverage like the different genes in the section above; that 
is to say, to take an average of the number of crypts in which they are covered. The approach that 
we took, therefore, was to calculate, for the average exonic base pair in our 90 cancer genes, the 
number of crypts in which that base pair was covered by >=8 reads (for substitutions) and by >=10 
reads (for indels).  64% of all bases in the targeted panel across all crypts are covered by >=8 reads, 
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which equates to a number of callable bases equivalent to having sequenced ~1,400 crypts with 
perfect coverage over every base in every crypt. This average number of crypts in which all base 
pairs achieve good coverage becomes the denominator for calculating the driver mutation 
frequency (with the number of drivers observed in the dataset as the numerator). A similar 
approach can be taken with indels. 
Note that for this reason of uneven coverage, this approach is less suitable to estimating 
the frequency of mutations in a given gene. Particular driver mutations, may be under-represented 
in our cohort. If one part of gene A is covered by a very low number of crypts, and that it is this 
part where most driver mutations occur, we will underestimate the frequency of driver mutations 
in gene A. Similarly, other driver mutations may be over-represented. This should be borne in 
mind when considering figure 2.4. The true frequencies of driver mutations in these genes may, in 
time, reveal themselves to be different to those that we have estimated from imperfect data here. 
We nonetheless present this figure as a preliminary indication of the landscape of driver mutations 
in normal colon. 
Our estimate of 1% uses a global correction, on the assumption that under-representation 
and over-representation will even itself out when estimating the total frequency of driver mutations 
in the whole dataset. Without prior knowledge of which are under-represented and which are over-
represented, using a mean is a valid approach. We stress the highly simplified nature of this 
approach. It is our resort because the frequency of driver mutations in our dataset is so low. The 
value that we derive of 1% of colonic crypts bearing a driver should be taken as a first ballpark 
estimate to guide further investigation. Further studies of larger numbers of crypts will be required 
to achieve greater accuracy. 
 
 
R.5. Mutational processes and rates in the colons of different people 
 
There was substantial variation in mutation burdens between individual crypts, ranging 
from 1,508 to 15,329 for individuals in their sixties, which was not obviously attributable to 
technical factors. To explore the biological basis of this variation we extracted mutational 
signatures from the whole genomes and estimated their contribution to the mutation burden of each 
crypt. 
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 We first derived phylogenies of how crypts from each patient were related to one another 
and assigned every mutation to a branch of a phylogeny. This allowed us to treat every branch as 
a sample in signature extraction. This has the dual advantage of avoiding double counting of 
mutations in signature extraction (as mutations shared between two crypts are only counted once 
with this method, while they would be counted twice if every crypt were treated as a sample), and 
of allowing us to time mutational signatures over the course of life, since mutations shared by two 
samples must have occurred before mutations that are private to one of them.  
 The mutational signatures that are extracted from an analysis are dependent on the samples 
that went into it. If all samples have perfectly correlated contributions of different processes, these 
will only be extracted as one signature. A cohort of normal genomes from a single tissue runs this 
risk. We wanted to be able to frame our signature extraction results in the context of previous work 
in cancers, in order to allow comparisons with different studies. We therefore performed a 
signature extraction using a hierarchical Dirichlet process (HDP) (Roberts et al. 2015, Roberts et 
al. 2018), providing the algorithm with the catalogue of mutational signatures extracted from the 
Pan Cancer Analysis of Whole Genomes (PCAWG) (Alexandrov et al. 2018). This allows 
simultaneous discovery of new signatures and matching to known ones. Nine single base 
substitution (SBS), two doublet base substitution (DBS), and five indel (ID) signatures were 
discovered (figure 2.5). Despite pre-conditioning, signatures that were perfectly correlated in all 
samples were still amalgamated. This occurred, for example, with signatures 1, 5, and 18. 
Therefore, expectation maximisation was used to deconvolute all HDP signatures into known 
PCAWG signatures. If a signature reconstituted from the components that expectation 
maximisation extracted (only including PCAWG signatures that accounted for at least 10% of 
mutations in each sample to avoid over-fitting) had a cosine similarity to the HDP signature of 
more than 0.95, the signature is hereafter presented as its expectation maximisation deconvolution 
(Methods). Three HDP signatures met these criteria: the HDP SBS1 signature was deconvoluted 
into a mixture of PCAWG SBS1, PCAWG SBS5, and PCAWG SBS18; the HDP DBSN1 was 
deconvoluted in PCAWG DBS2, PCAWG DBS4, PCAWG DBS6, PCAWG DBS9, and PCAWG 
DBS11; and the HDP IDN1 was deconvoluted into PCAWG ID1, PCAWG ID2, and PCAWG ID5 
(figure 2.6). To test the robustness of this signature analysis, other signature extraction methods 
were used: HDP with no pre-conditioning, the non-negative matrix factorisation (NNMF) method 
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used by Blokzijl and colleagues (2016), and a version of the NNMF algorithm used by Alexandrov 
and colleagues (Alexandrov et al. 2018). These all produced comparable results (figure 2.8). 
 Following expectation maximisation deconvolution, we found nine SBS, six DBS, and five 
ID signatures in our dataset (figure 2.7). Of these, 14 were known and six were novel (denoted by 
an “N” in their nomenclature, e.g. “SBSN1”). The signatures can be divided into those that are 
common and those that are rare depending on whether they are present in more or less than 85% 
of crypts. The common signatures are:  SBS1, SBS5, SBS18, DBS2, DBS4, DBS6, DBS9, DBS11, 
ID1, ID2, and ID5. The rare signatures are: SBS2, SBS13, four novel SBS signatures (SBSN1 – 
SBSN4), DBS8, and two novel ID signatures (IDN2 and IDN3). The correlation with age of every 
signature is shown in figure 2.10. 
 The mutational signatures extracted are dependent both on the process causing mutations 
and on the trinucleotide composition of the genome. As variable coverage was achieved across the 
genome of crypts (figure 2.2), it was theoretically possible that some of our lower coverage crypts 
may be altering the profile of the signatures that were extracted. Mutational signatures were 
historically extracted from exome data (Alexandrov et al. 2013), and when they were updated to 
include genomes (Alexandrov et al. 2018), mutational processes largely remained the same. Those 
that changed in profile did so as a result of including additional samples with very simple 
trinucleotide profiles that allowed the NMF algorithm to draw out the salient features of the 
signature more clearly, rather than because of including other parts of the genome with a different 
trinucleotide composition. This would suggest that the trinucleotide profile of parts of the genome 
that are less well covered in some crypts would have less of an effect on the signatures extracted 
than one might expect. So as to detect changes in mutational signature composition that might be 
due to coverage, we ordered crypts by increasing coverage, and plotted the proportional 
contribution of different signatures to them (figure 2.9a). No obvious systematic differences with 
coverage are observed, and all novel signatures are seen in crypts with both good and bad coverage. 
Second, we compared the raw trinucleotide profiles of a representative selection of six of our 
lowest-depth crypts (all with average depth <10X), with the trinucleotide profile of six normal 
colonic organoids (see section R.7.), all of which were sequenced at 30-40X. There are no obvious 
differences between the trinucleotide profiles of these high- and low-coverage samples (figure 
2.9b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Signatures of mutational processes in normal 
colon. Signatures extracted by HDP are shown, with the 
trinucleotide context of a sample that contains a large proportion 
of the relevant signature shown underneath. Signatures are 
presented as in figure 2.1.  
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Figure 2.6. Expectation maximisation (EM) decomposition 
of HDP signatures. Three signatures were decomposed by EM. 
For each signature, the original HDP version in shown on the top 
left, the PCAWG signatures that are deemed by EM to contribute 
at least 10% of mutations to it on the right, and the reconstituted 
signature built by combining the PCAWG signatures on the 
bottom left. The cosine similarity of the reconstituted signature 
to the original is shown in the title to the reconstituted signature 
plot. 
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Figure 2.7. Final set of signatures in normal colon, following 
EM decomposition. These are the set that are used in analyses. 
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Figure 2.8. Validation of single base substitution signatures. 
Other methods of signature extraction were run to test the 
robustness of signature decomposition. a, HDP without pre-
conditioning on PCAWG. b, In-house NNMF without pre-
conditioning on PCAWG. c, NNMF implemented by the 
MutationalPatterns R package (Blokzijl et al. 2016). 
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Figure 2.9. Mutational signatures with coverage. a, crypts are 
ranked by their median coverage, with coverage increasing from 
left to right. The proportional contribution of each signature is 
presented a stacked barplot. b, the trinucleotide profile of six 
crypts with high coverage are boxed in red, and the trinucleotide 
profile of six crypts with low coverage are boxed in blue. The 
high coverage samples are normal colonic organoids (see section 
R7) all sequenced at >30X, whereas the low coverage samples 
are laser capture microdissected crypts all with coverage <10X. 
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Figure 2.10. Mutation burden v. age for every signature. For 
each signature, the total number of mutations in every crypt 
attributed to each signature is plotted against the age of the 
patient from whom the crypt derives. Points are coloured by the 
anatomical location from of the crypt. Mutation burden is 
adjusted for the callable proportion of the genome (Methods 
section 12). 
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R.5.a. Common mutational signatures 
 
All three of SBS1, SBS5, and SBS18 were found in all crypts from all patients and 
correlated linearly with their age, indicating that the underlying mutational processes are 
continuously active in all individuals throughout life. There was, however, substantial variation in 
mutation burdens for each of these signatures between crypts from the same individual. These 
were partly explained by differences between sites in the colon: for all three signatures, mutations 
accumulated at the fastest rate in right colon (ascending and caecum), then transverse colon, and 
slowest in left colon (caecum and sigmoid). Terminal ileum accumulated mutations at a similar 
rate to the left colon (figure 2.11). Even taking site differences into account, however, there was 
still substantial spread of mutation burden, and in the case of SBS18 one strong outlier. For 
example, the mean ratio of SBS1 burden between the most and least mutated crypts from the same 
site of one person is 1:1.3, and the mean ratio between the SBS1 mutation burden of crypts from 
the same site in two people in their 60s is 1:1.4. The cause of this variability is unknown, but 
possible explanations include differences in cell division rate, exposure to locally acting mutagens, 
and variability in the time to the most recent common ancestor of each crypt. Interestingly, 
bromodeoxyuridine staining of colonic crypts showed substantial inter- and intrapatient variability 
in cell division rates (Potten et al. 1992). For SBS1 and SBS5, which appear to accumulate in a 
clock-like manner, the x axis intercept is of approximately five to 10 years of age. With a linear 
mutation rate the x axis intercept would represent the time to the most recent common ancestor of 
the crypt, and this is similar to previous estimates of the duration of monoclonal conversion in 
humans (section I.1.c.).  
DBS 2, 4, 6, 8, and 11 were all extracted by HDP as one mutational processes that was 
present in almost all crypts and deconvoluted into these signatures by expectation maximization. 
These processes must therefore be tightly correlated in normal colonic crypts. As numbers of 
doublet base substitutions are small, we are underpowered to detect differences between sites. 
Similarly, ID1, ID2, and ID5 were all extracted as one ubiquitous signature by HDP, and 
deconvoluted into their constituents by expectation maximization. They correlate with the age of 
diagnosis of the patient, which is consistent with their proposed aetiology in replication slippage, 
and show the same ordering of mutation burden between sites as SBS1, SBS5, and SBS18 (figure 
2.11). 
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Thus, the signatures that we found to be common have in some shape or form been 
described before. The size of the cohort and the low complexity of normal genomes relative to 
cancerous ones allow us to gain novel insights. 
 
 
R.5.b. Rare mutational signatures 
 
Many mutational processes, both known and novel, only affected subsets of crypts. SBS2 
and SBS13 are known signatures predominantly characterised by C>T and C>G mutations 
respectively at TCA and TCT trinucleotides. They are thought to be due to activity of the APOBEC 
family of cytidine deaminases and often occur together (Alexandrov et al. 2013, Roberts et al. 
2013). The C>T mutations may be a result of cytidine deamination, while the C>G and C>A (and 
possibly some C>T) mutations may be the errors of translesion polymerases following excision of 
uracils by repair machinery (Helleday et al. 2014).  SBS2 and SBS13 were clearly observed in a 
colonic crypt from one individual and in an ileal crypt from another, each with >100 mutations of 
SBS2/13; smaller contributions may be present in other crypts. Therefore, APOBEC DNA-editing 
of the human genome occurs in gastrointestinal stem cells, to our knowledge the first time that it 
has been shown in normal cells (beyond the physiological role of AID, an APOBEC family 
member, in lymphocytes). The wider sequence context of the mutations suggests that APOBEC3A 
is the major contributing enzyme (Chan et al. 2015).  
A novel signature (described as novel here, as it was unknown at the time that we found it, 
although it has since been observed in oral squamous cell carcinomas (Boot et al. 2018)), SBSN2, 
characterised predominantly by T>C mutations at ATA, ATT, and TTT, and T>G mutations at 
TTT was detected in 30% of crypts. In the most affected crypts, it accounted for 3,000 mutations, 
doubling the mutation burden. SBSN2 exhibits strong transcription strand bias, with 2.5 times as 
many T>A mutations occurring on the untranscribed as on the transcribed strand. Transcription 
strand bias is often due to transcription coupled nucleotide excision repair (TC-NER) acting on 
DNA with covalently bound bulky adducts and distortion of the helical structure. Assuming that 
this is the case, damage to adenine by a carcinogen may underlie SBSN2. SBSN2 exhibited a 
highly variable mutational burden between individuals and between crypts from the same 
individual that was not attributable to age. Examination of the branches of phylogenies in which 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11. Linear modelling of signature accumulation. For 
signatures that appeared to show a linear accumulation with age, 
the mutation rate per site was determined using mixed models, 
with age and site as fixed effects, and patient as a random effect. 
Confidence intervals were determined by bootstrapping. 
Mutation burden is adjusted for the callable proportion of the 
genome (Methods section 12). 
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 SBSN2 occurred showed that whenever SBSN2 could be timed, it always occurred early in life 
(figure 2.12 f, h, z, aa, am, ao). Assuming a constant mutation rate of SBS1 (as indicated by the 
age correlation observed), SBSN2 occurs in the first ten years of life. It cannot be the result of one 
brief mutagenic burst, since it is found in sequential branches (figure 2.12ao). In addition, SBSN2 
clustered spatially. In a thirty-six year-old patient, crypts from all around the colon were affected, 
but not crypts from the ileum. In other patients, crypts from the left colon were much more affected 
than crypts from other parts of the colon. This was not due simply to the sharing of mutations 
between crypts. SBSN2 correlates with IDN2, another novel signature characterised by deletion 
of single T in a run of Ts with a mode length of four (compare ochre bars in ID trees and pink bars 
in SBS trees in figure 2.12). The initiating events for this relatively common mutational process 
are unknown, but our data indicate an extrinsic, locally-acting mutagen that affects children. Many 
causes are possible, including diet, infections, and microbiome composition.  
SBSN3 was predominantly characterised by C>T substitutions at ACA, T>A at CTN, and 
T>G at GTG. It was present in five individuals and in these in a subset of crypts (figure 2.12 e, aa, 
af, ai, aj). Like SBSN2, SBSN3 was active early in life in the two patients in whom we could time 
it (figure 2.12 aa, ai), and even when mutations were not shared we could detect spatial clustering. 
The cause of SBSN3 is unknown, but here again we have evidence of an early, locally-acting 
process. SBSN3 correlated with DBS8 and IDN3 (compare dark grey in SBS trees, dark grey in 
DBS trees, and green in ID trees). DBS8 is composed of AC > CA and AC > CT mutations, thus 
representing some of the same set of base changes as SBSN3. DBS8 has been reported in rare 
hypermutated cancers with no obvious cause for their hypermutation (Alexandrov et al. 2018). 
IDN3 is dominated by the deletion of a single T with no other Ts surrounding it. 
All crypts from the left, right, and transverse colon of a 66 year-old man were dominated 
by a mean of 8,567 mutations due to a new signature, SBSN1. This signature is characterised by 
T>A substitutions with a transcriptional strand bias that is again consistent with damage to 
adenines. The mutation burden in his colorectal epithelium was three- to five-fold higher than 
expected for his age, and thus by extrapolation equivalent to that of a 200-300 year-old. This 
individual had a rich and unusual clinical history: initially diagnosed with a large anaplastic 
lymphoma in 1994 and treated with six cycles of CHOP (cyclophosphamide, doxorubicin, 
vincristine, prednisolone), the diagnosis was subsequently revised to Hodgkin’s lymphoma, and 
in 2002 he was treated with three cycles of Chl-VPP / PABlOE (chlorambucil, vinblastine, 
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procarbazine and prednisolone, alternating with prednisolone, doxorubicin, bleomycin, vincristine 
and etoposide). In 2011 he had a positive faecal occult blood test, for which he had a colonoscopy 
(when the biopsies that we used were taken) and a caecal adenocarcinoma was found. Two years 
later this gentleman died from a diffuse large B cell lymphoma.  
SBSN1 bears a strong resemblance to SBS25 (cosine similarity 0.9), and they share the 
same transcription strand bias.  Signature 25 has previously been detected only in two lymphoma 
cell lines derived from lymphomas from patients who had received chemotherapy. The case history 
of one of these patients is available (Wolf et al. 1996): he too had been treated with a cocktail of 
chemotherapies, with overlap of several drugs (cyclophosphamide, doxorubicin, 
vincristine/vinblastine, prednisolone, procarbazine, bleomycin). He had also been treated with an 
experimental ricin-coupled anti-CD25 immunotoxin. Signature 25 was not detected in any of 
23,829 cancers in PCAWG and so represents a very rare mutational process. The vast majority of 
PCAWG cancers were primaries that had not been exposed to chemotherapy, and so it seems likely 
that chemotherapy is responsible, either through the action of one cytotoxic agent, a combination 
of them, or their interaction with a germline polymorphism. Cyclophosphamide has been observed 
to cause T>A mutations in the chicken DT40 cell line (Szilkrist et al. 2016); further work testing 
different chemotherapies on human cells would be required to identify the causal agent. To our 
knowledge, this is the first report of the mutagenic consequence of chemotherapy in normal human 
cells in vivo.  
To determine whether this process could have played a part in the development of this 
gentleman’s adenocarcinoma, we obtained the biopsy of his tumour taken during the same 
colonoscopy as the normal samples. The tumour was necrotic and individual crypts could not be 
distinguished. We therefore bulk-sequenced it. This complicates comparisons of mutation burden 
between the tumour and normal sample, since the time to the most recent common ancestor of the 
tumour and the normal samples need not be the same.  The tumour was not closely related to any 
of the individual crypts. As with most tumours, it had an excess of mutational processes not seen 
in the normal crypts, including single base substitutions, small insertions and deletions, and copy 
number changes. The T>A mutational process was present in the clonal peak of mutations, but not 
subclonally, indicating that exposure to chemotherapy predated the last clonal sweep of the 
tumour; indeed, it is quite plausible that it could have occurred while the tumour was still a normal 
crypt. After adjusting for copy number changes, a similar number of T>A mutations were present  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Crypt phylogenies. For every patient, the 
phylogeny of crypts is shown three times: on top, with branch 
lengths proportional to the number of single base substitutions; 
in the middle, with branch lengths proportional to the number of 
doublet base substitutions; on the bottom, with branch lengths 
proportional to the number of small insertions and deletions. 
Scale bars are shown on the right-hand side. A stacked barplot 
of the mutational signatures that contribute to each branch is 
overlaid over every branch. Please note that the ordering of 
signatures along a given branch is just for visualisation purposes: 
we cannot distinguish the timing of different signatures along a 
branch. In most cases, crypts from the same individual are 
distant from one another, and so we would not expect to see late 
branching events. 
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in the trunk of the tumour to the normal crypts. The tumour was driven by a clonal KRAS G12D 
hotspot substitution and two inactivating mutations (one substitution and one indel) in APC. These 
were not due to T>A mutations, and so the mutagenic activity of this chemotherapy cannot be held 
directly responsible for the development of the tumour. It is possible, however, that the selection 
pressure of chemotherapy could have provided the conditions for a pre-malignant clone to expand 
and progress.  
 
 
R.5.c. Large scale genomic rearrangements in normal colon 
 
 Colorectal cancers frequently bear a large number of genomic rearrangements (Li et al. 
2017), and rearrangements were found in four out of 15 organoids (Blokzijl et al. 2016). In our 
larger cohort, we sought evidence of large copy number changes in 449 crypts that had >10X 
coverage and >0.3 VAF sufficient for us to call copy number changes accurately. In stark contrast 
to colorectal cancers, 82% of evaluable crypts had no large-scale genomic rearrangements. 
Remarkably, however, five crypts had seven whole chromosome copy number increases affecting 
the same three chromosomes. We observed: amplification of both copies of chromosome 3; 
trisomy 3 and trisomy 9; trisomy 7; amplification of both copies of both chromosome 7 and of the 
X chromosome; and amplifications of both copies of both chromosome 7 and chromosome 9 
(figure 2.13a). We also observed an amplification of the X chromosome. All amplifications 
increased the copy number of the chromosome by one or two copies. We did not observe any 
chromosomal deletions. While regions of chromosome 7 are often amplified in colorectal cancer 
(Cancer Genome Atlas Network et al. 2012), we are not aware of frequent amplifications of 
chromosomes 3 and 9. In addition, we found large regions of copy neutral loss of heterozygosity 
in 12 crypts, affecting 1p, 6p, 7p, 8q, 9q, 10q (twice), 17p, 17q, 18q, 21q, 22q, and the X 
chromosome (e.g. figure 2.3c). 
Five of these copy number changes could be timed reliably by using their allele fractions 
to assign mutations to a copy number state. The count of mutations at each copy state can be used 
to estimate when the copy number change occurred. This is because mutations that occur before a 
chromosomal gain will be on two copies, whereas those that occurred after it will be on one copy. 
Timing these seven changes showed that they all occurred between the ages of 20 and 51 (figure 
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2.13b). Two gains in the same crypt were timed independently and found to occur at the same 
time, suggesting that they occurred as one event. This analysis requires the assumption of a 
constant mutation rate per length of DNA over life, which seems reasonable given that the 
signatures that are responsible for the majority of mutations in normal colorectal genomes correlate 
linearly with the age of the patients from whom they are derived. Trinucleotide plots of the 
mutations assigned to each copy number state were inspected and showed no dramatic change in 
mutational profile. 
 Structural variants were detected by abnormally mapping reads. We observed 48 deletions, 
18 tandem duplications, four translocations, and two inversions. All were private to a single crypt, 
except for one which was shared between two adjacent crypts from one patient, which share a very 
distant common ancestor: this must reflect a deletion that occurred in the embryo or in early 
childhood.  
 
 
R.6. Comparison of mutational signatures in our cohort and PCAWG colorectal cancers 
 
 The total mutation burden in most crypts that we sequenced is of the order of 3,000 
mutations per genome, substantially less than the mutation burden of 10,000-20,000 mutations per 
genome in even non-hypermutated colorectal adenocarcinomas. We sought to explain the source 
of the mutational excess in cancers by comparing the number of mutations due to each mutational 
signature in PCAWG colorectal adenocarcinomas and our normal tissues (figure 2.14). A number 
of complicating factors should be borne in mind: tumours and normal crypts have a different time 
to their MRCA; patients were of different ages, although in both cohorts most samples come from 
patients in their 50s and 60s; they were sequenced on different platforms and mutations called with 
different filters; and signatures were extracted separately (although the same set of reference 
signatures was used).  
 As anticipated, the total mutation burden in colorectal cancers is always higher than in 
normal crypts, with the exception of those from the patient who had been exposed to 
chemotherapy. The mutation burden of the near-ubiquitous signatures SBS1, SBS5, SBS18, 
DBS2, DBS4, DBS6, DBS9, ID1, and ID2 was higher in tumour samples than in normal samples, 
suggesting an acceleration of normal mutational processes. Some rare mutational processes were  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Copy number changes in normal colon. a, whole 
chromosome amplifications in five crypts. The copy number 
state (y axis) for each allele, one coloured red, and one coloured 
green, is shown. Chromosomes are labelled along the top of the 
graph. b, timing of copy number changes throughout life. 
Vertical bars represent 95% confidence intervals determined by 
bootstrapping. 
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Figure 2.14. Mutation burden of each signature in normal 
crypts versus cancer. For every signature, the (mutation 
burden+1) of every sample is shown on the y axis on a log scale. 
Normal colon and cancer samples are ordered within their 
groups. Colorectal adenocarcinoma signature attributions and 
burden are from Alexandrov et al. (2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1e+021e+041e+06
To
ta
l
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
505005000
S
B
S
1
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
110010000
S
B
S
5
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1e+001e+04
S
B
S
10
a
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
110010000
S
B
S
10
b
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
11010010000
S
B
S
15
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1550500
S
B
S
17
a
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1550500
S
B
S
17
b
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
11010010000
S
B
S
18
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1e+001e+04
S
B
S
28
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
110010000
S
B
S
37
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
11010010000
S
B
S
40
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
110010000
S
B
S
44
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1550500
S
B
S
45
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1520100
S
B
S
2
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1520100
S
B
S
13
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
11010010000
sb
s.
N
1
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1550500
sb
s.
N
2
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1550500
sb
s.
N
3
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1550500
sb
s.
N
4
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
12520100
D
B
S
2
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
15505005000
D
B
S
3
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●
●●●●●●●●●●●●●●● ●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●
0
10
0
30
0
50
0
12510
D
B
S
4
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
12346
D
B
S
5
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1251020
D
B
S
6
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1520100
D
B
S
7
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1520100
D
B
S
8
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
1252050
D
B
S
9
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1520100500
D
B
S
10
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
12510
D
B
S
11
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
11010010000
ID
1
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
110010000
ID
2
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
11010010000
ID
5
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1550500
ID
14
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●● ●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●
0
10
0
30
0
50
0
1520100500
id
.N
2
Counts + 1
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●● ●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●
0
10
0
30
0
50
0
12520100
id
.N
3
Counts + 1
●●
N
or
m
al
 c
ol
on
C
ol
or
ec
ta
l a
de
no
ca
rc
in
om
a
R
an
ke
d 
sa
m
pl
e
Log(mutations+1)
 182
only found in tumours, such as SBS10a or SBS10b and SBS17. Perhaps if a larger number of 
normal crypts had been sequenced these mutational processes would eventually have been found 
in normal tissues too; nonetheless, sporadic mutational processes do seem to be enriched in cancers 
relative to normal tissue. Conversely, all the novel signatures were (by definition) found only in 
normal tissues. No mutational processes were found in all tumours and only in tumours. Thus, 
there is no process that is specific to and intrinsically linked with malignancy. 
 
 
R.7. Mutational processes and rates in the progression from normal to cancer 
 
 The additional mutational processes detected in cancers could have occurred during the 
process of transformation or have preceded it: it could be that rare colonic cells with a naturally 
higher mutation burden are more likely to become cancerous. Furthermore, as explained above, 
the comparison of bulk tumour samples with normal colonic crypts is complicated by the 
difference in the time to the most recent common ancestor of each sample. We reasoned that the 
former difficulty could be resolved by reconstructing the mutational life history of the tumour 
through multi-region sequencing, and the latter by sequencing single cells derived from tumour 
and normal epithelium. We set out to achieve this by analysing organoids derived from three 
patients undergoing a resection for colorectal cancer. For each patient, organoids were derived 
from single cells from a tumour and from individual normal crypts five centimetres away from the 
tumour. From the first patient we whole genome sequenced four normal and seven tumour 
organoids, from the second five normal and 11 tumour organoids, and from the third four normal 
and eight tumour organoids. This study was set up by Sam Behjati and Sophie Roerink and 
organoids were generated by the Clevers group at the Hubrecht Institute. 
 
 
 
R.7.a. Comparison of mutational processes in single cells from cancer and normal colon 
 
For all three patients, all tumour organoids had many more mutations than any of the 
normal organoids. Subcloning of organoids showed that the mutation burden acquired in vitro was 
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minimal, as had been shown by others (Blokzijl et al. 2016).  Patient 1 had a mismatch repair 
deficient tumour. Methylation profiling (analysed by Matthew Young) showed that this was due 
to hypermethylation of the MLH1 promoter. This patient had a mean of 3,792 substitutions in 
normal clones but 72,398 substitutions in tumour clones. Patients 2 and 3, who had mismatch 
repair proficient tumours, had means of 3,172 and 3,621 substitutions in their normal organoids, 
and of 22,291 and 14,209 substitutions, respectively, in their tumour-derived organoids (figure 
2.15a). Similarly, the mean burden of indels in normal organoids for patients 1-3 was 227, 130, 
and 167, while the mean indel burden in their tumour organoids was 27,893, 1,485, and 2,021. 
There was a mean of one structural variant in normal organoids, compared to a mean of 71, 176, 
and 67 from the tumours of patients 1-3. Thus, as one would expect from the comparison of 
mutation burden between normal colonic crypts and cancer genomes, the mutation burden is 
increased in cancer relative to normal tissue even within the same patient. Tumour organoids were 
derived from single cells, while normal organoids were derived from single crypts. More than one 
stem cell from a crypt might have contributed to the organoid, and so the most recent common 
ancestor of normal organoids may predate the resection, while that of tumour organoids will not. 
Nonetheless, the difference is likely to be less than a decade and cannot explain the discrepancy in 
mutation burden between tumour and normal organoids. 
To investigate the origin of the increased burden of mutations in cancer relative to normal, 
signatures of mutational processes were extracted for substitutions by Ludmil Alexandrov using 
NNMF. Signatures are referred to here by their numbers in COSMIC (Forbes et al. 2017).4 All the 
mutations in normal clones were attributed to signatures 1 and 5. Additional mutational signatures 
were found in the tumours (figure 2.15). These included: signatures associated with mismatch 
repair deficiency in patient 1 (signatures 6, 20, and 26); signature 17 in patients 1 and 2, which is 
of unknown cause and is found in a minority of colorectal cancers; signature 18 in patients 2 and 
3, which is thought to be associated with reactive oxygen species; and a novel signature (figure 
2.15b), found in only six out of eight cancer-derived organoids in patient 3. 100 mutations that 
were likely to be due to this novel signature were validated by capillary sequencing (data not 
shown). 
                                                 
4 Please note that signature profiles here reflect the TCGA and cosmic versions, which means the number 
of mutations attributed to each signature cannot be compared directly to analyses that used the PCAWG 
catalogue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Mutation burden of colonic organoids. a, 
barplots of the mutation burden in every organoid. For 
substitutions, mutations are broken down by signature, 
according to the COSMIC catalogue (NB not the PCAWG 
catalogue), whereas indels are classified as insertion or deletion, 
and structural variants as inversion, deletion, tandem-
duplication, or translocation. For each patient the burden in 
normal and tumour organoids are shown. b, the trinucleotide 
spectrum of the novel signature (yellow in a). 
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While the majority of the discrepancy between tumour and normal could be attributed to 
additional mutational signatures, tumour cells also had an increased burden of signatures 1 and 5 
relative to the normal cells. Given signature 1’s proposed correlation with mitoses, this suggests 
that cancer cells have undergone more cell divisions. Indeed, increased rates of Ki67 staining, a 
marker of proliferation, are observed in the resected cancer specimens (staining performed by 
collaborators; data not shown). However, the increase in signature 1 is not sufficient to explain the 
discrepancy in the number of mutations between tumour and normal. The fact that cancer cells 
have additional mutational signatures that are not seen in normal cells shows that additional 
mutational processes are operative, which must mean an increase in mutation rate per cell division.  
Thus, cancer cells, even in MMR proficient patients, show an increase in mutation rate per cell 
division. The cause of this increased mutation rate per cell division warrants further investigation. 
Some cancer-specific signatures, as in mismatch-repair deficiency, may be a result from the loss 
of a repair process that occurs in normal cells. Others may be the result of new mutagenic 
exposures. For example, as signature 18 has been associated with oxidative damage (Viel et al. 
2017), its acceleration in all three tumours relative to normal tempts one to speculate that it might 
be a result of the change in metabolism associated with tumour growth (Warburg et al. 1927).  
 
 
R.7.b. Reconstructing the mutational histories of tumours with phylogenies 
 
Phylogenies were constructed for the samples derived from each patient (Methods), and 
mutations were assigned to each branch. Signatures were extracted treating every branch as an 
independent sample (Methods), which allowed us to see the mutational processes operative at 
different stages of tumour evolution (figure 2.16). For patient 2, in the trunk of whose tumour a 
whole genome duplication was present, mutations in the trunk were further separated according to 
whether they occurred before or after the whole genome duplication (Methods). 
 In all patients, the trunk of the tumour contained a greater proportion of signatures 1 and 
5 than later branches, suggesting that the additional mutational signatures in cancer cells were not 
present through their whole life history. This was clearest in patient 2. While signature 1 accounted 
for approximately 60% of the mutations before the whole genome duplication, afterwards it only 
accounted for 30%, with signature 17 becoming much more prominent.  In patient 3, a subclonal 
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signature was observed (yellow in figure 2.16c), indicating ongoing diversification of mutational 
processes through tumour evolution. This could be a result of a heritable change (such as loss of 
another repair protein) or may reflect the particular microenvironment of different tumour regions, 
since the phylogeny covaries with the spatial structure of the tumour. Likewise, rearrangements 
and small indels increase markedly in rate beyond the trunk of the tumour (figure 2.17 and 2.18). 
In patient 3, the rate of rearrangement acquisition can be seen to vary subclonally too, as the clade 
of the tree that had acquired TP53 mutations had far more rearrangements than the clade that had 
not.  
The fact that the genomic landscape of the trunk of the tumour phylogenies resembles that 
of normal colorectal stem cells indicates that there was nothing particularly special about the 
mutational processes of the cell-of-origin of cancers. It suggests that cancers derive from cells that 
were exposed to normal mutational processes for much of life until an event, such as one or more 
driver mutations, caused a change in the active mutational processes. In patient 1, the trunk of the 
tumour contains almost no signatures of mismatch repair deficiency-associated processes 
(although there was an increase in indels), despite the fact that all organoids have hypermethylated 
the MLH1 promoter, and so this event presumably did occur in the trunk of the tumour. This 
suggests that the acquisition of aberrant mutational processes was rapidly followed by intratumoral 
growth and diversification. It could be that both are a result of the BRAF V600E mutation, given 
that Ras pathway mutations are associated with growth (see introduction to this chapter) and that 
this particular mutation frequently coincides with mismatch repair deficiency (Fearon 2011). 
To understand the transition from normal to cancer, we attempted to time the onset of the 
cancer-specific mutational signatures (Methods). This analysis requires several assumptions, as 
we can only time mutations relative to signature 1 and cannot relate them directly to real time. As 
there is more signature 1 in tumour samples than in normal samples, it cannot be used as a real-
time clock in the tumour, although we use it in this way in the normal organoids. To estimate the 
onset of cancer-specific mutational signatures, we assumed that the rate of signature 1 started 
increasing at approximately the same time as the onset of new mutational signatures. This may be 
valid if both were associated with the acquisition of driver mutations. In all three patients, signature 
18 seemed to be the first cancer-specific mutational signature to become operative. Using the ratio 
of signature 1 to signature 18 in the next branch after our first timepoint (branches after the most 
recent common ancestor (MRCA) in patients 1 and 3, and the branch between the WGD and the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16. Phylogenies of colonic organoids. For each 
patient, the anatomical location in the colon of the tumour is 
shown, with the phylogeny underneath. White circles represent 
organoids derived from normal tissue, while filled coloured 
circles represent organoids derived from tumour, with the colour 
matching the colour of the biopsy site in the schematic above the 
phylogeny. Phylogenies are depicted as in figure 2.12 with 
branch lengths proportional to numbers of mutations, and 
signature contributions overlaid as stacked barplots. 
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Figure 2.17. Phylogenies of colonic organoids showing indel 
burden. Phylogenies are shown as in figure 2.16, but showing 
indels only as figure 2.16 was dominated by substitutions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.18. Phylogenies of colonic organoids showing 
rearrangement burden. Phylogenies are shown as in figure 
2.16, but showing rearrangements only as figure 2.16 was 
dominated by substitutions. 
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MRCA in patient 2) we calculated the number of signature 1 mutations present in the cell when 
signature 18 started. Assuming a linear acquisition of signature 1 in the trunk of the tumour at the 
same rate as in the normal samples, we could translate this signature 1 burden into the age at which 
signature 18 began. As the ratio of other signatures to signature 1 increases down the tree it is 
likely that that the rate of acquisition of signature 18 relative to signature 1 increases over time. If 
this is the case, the estimates that we obtain can be seen as a lower bound of age. Following this 
line of reasoning, in patient 1 (aged 67) signature 18 began in the last 24 years, in patient 2 (aged 
68) in the last 20 years, and in patient 3 (aged 56) in the last 22 years.  
 
 
Summary of results in this chapter 
 
Our understanding of the process of somatic mutation, and its consequences, in normal 
cells remains rudimentary. This has largely been because of the difficulties of detecting somatic 
mutations in normal cells. A protocol to sequence individual colonic crypts isolated by laser 
capture microdissection was derived and applied to sequence hundreds of crypts from 42 different 
individuals. We characterised the genomic landscape of these normal cells, quantifying their 
mutation burden, the signatures of the mutational processes that have affected them, and the 
spectrum of driver mutations found in the colons of healthy people. 
Putative driver mutations were found to occur in approximately 1% of crypts, and so 
number in the hundreds of thousands in the colons of middle-aged healthy individuals. The 
spectrum of driver mutations was different to that observed in cancers, with some of the most 
common colorectal cancer driver mutations absent from our data. Caution should be exercised with 
these estimates, however, as we are limited by a low frequency of driver mutations and variable 
coverage within and between genes; further studies (guided by this initial estimate) will be required 
to establish the frequency of driver mutations more accurately. 
Striking variability in somatic mutation rates in normal cells was found between different 
people and between different cells within the same person. This was due both to variation in the 
number of mutations due to ubiquitous mutational processes and to the presence of sporadic 
mutational processes that only affected certain individuals or certain crypts within one individual. 
One novel signature, which quintupled the normal mutation burden, could be linked to a previous 
 195 
exposure to chemotherapy. Others were of unknown aetiology, but accounted for thousands of 
mutations in focal patches of the colons of children. APOBEC mutations, which have never 
previously been reported in normal cells, were found in a small subset of crypts.  
The genomes of colorectal cancers show mutational signatures that were not found even in 
a large cohort of normal cells. Those mutational processes that were found in all normal cells are 
universally accelerated in cancer. Phylogenetic analysis of the genomes of cancer cell-derived 
organoids reveals that the cell ancestral to the cancer was for most of its life subject to the same 
mutational processes as its neighbours that did not transform. In the process of transformation to 
cancer, this clone both accelerated normal mutational processes and acquired novel ones.  
These findings will be discussed in the Discussion chapter. 
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DISCUSSION 
 
 
 
In this dissertation, I have presented two case studies of somatic evolution. One investigates 
clonal dynamics, and the other somatic mutations, using blood and colon respectively as the model 
tissues. Here, I will discuss how this work informs our understanding of somatic evolution, 
drawing out future perspectives for how their extension, and the development of the field more 
broadly, might change the way in which we manage diseases that stem from natural selection 
within a multicellular organism. 
 
 
1. Discussion of findings 
 
1.a. The clonal dynamics of blood 
 
 Our study is the first to investigate haematopoiesis in an unperturbed healthy human using 
spontaneous somatic mutations. Our method is analogous to lineage tracing experiments in animal 
models, but we were able to use thousands of nested markers, detecting clones that arose at 
different times throughout life. We provide proof-of-concept that somatic mutations are a powerful 
tool to dissect the stem cell dynamics of normal tissues, as they have been used to study population 
dynamics and cancer evolution. 
 There is no previous ab initio estimate of the number of blood stem cells in a human in 
steady state. The value that we derive of 97,000 (90% CI 45,000−215,000) stem cells contributing 
to granulopoiesis will require validation by studying a large number of individuals. A more precise 
estimate could be obtained by whole genome sequencing a larger number of cells and, probably 
more importantly, developing a method of error corrected sequencing that would enable us to 
detect rarer mutations with high confidence. Methods related to duplex sequencing (Schmitt et al. 
2012, Kennedy 2014, Hoang et al. 2016) may provide such an opportunity. 
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 Quantification of the number of haematopoietic stem cells is an important biological 
insight and is also crucial to our understanding of the development of malignancy. As stem cells 
are believed to be at risk of transformation (General Introduction) each one may represent a 
potential cancer. In their discussion of cancer risk, Tomasetti and Vogelstein estimate a number of 
blood stem cells that is two orders of magnitude greater than ours (Tomasetti and Vogelstein 2015, 
General Introduction). Other factors, such as microenvironmental changes (General Introduction), 
are likely to be involved in determining the probabilities of mutant clones arising and 
outcompeting their neighbours, but our estimate provides a step on the road to a quantitative model 
of cancer development. 
 It remains to be shown precisely how the cells that we define as stem cells based on their 
long-term self-renewal in vivo map onto those at risk of malignant transformation. Our observation 
of granulocyte-B cell restricted clones in adults indicates that the cells that we are counting have 
both lymphoid and myeloid potential. Our study could be expanded to all phenotypically distinct 
cell types, resolving the clonal contribution of stem cells to each. We would, in theory, be able to 
build a quantitative map of the differentiation hierarchy of blood, calculating the number of stem 
cells responsible for maintaining each cell type. The gamut of haematological malignancies could 
be investigated, revealing the clone that gave rise to the neoplasm, and the lineage restriction of 
the line-of-descent that predates transformation. As clonal haematopoiesis is a common feature of 
ageing it could be followed prospectively, tracking its emergence from a normal clone through 
longitudinal blood draws. The method could further be applied to bone marrow failure syndromes, 
inflammatory conditions, and ageing. 
 
 
1.b. Somatic mutations in normal colon 
 
1.b.i. Driver mutations 
 
 We investigated the landscape of somatic mutations in hundreds of normal cells from 42 
people. Due to the large number of crypts investigated, we were able to capture infrequent events, 
such as driver mutations. Despite sequencing over 1,000 crypts, driver mutations are so rare that 
assaying even more crypts will be necessary to develop an accurate estimate of the frequency of 
 199 
each individual mutation in normal colon. Studies in mice and humans have begun to quantify the 
selective advantage that mutations confer in competition within the crypt and between crypts 
(Results Chapter 2, section I.5.). The laser capture microdissection method developed here would 
allow these studies to be extended to all driver mutations in humans. Ultimately, the selective 
advantage of every mutation, in different genetic and microenvironmental contexts, would allow 
us to chart all the possible paths to cancer and their respective probabilities, indicating the best 
points to intervene. It might be that early ‘clonal purging’ is the best approach. For example, the 
presence of PIK3CA mutations in normal colorectal mucosa, combined with a recent successful 
trial of a PIK3CA inhibitor in patients with an overgrowth syndrome as a result of an early 
embryonic somatic mosaic PIK3CA mutation (Venot et al. 2018), indicates that it would be 
possible to intervene pharmacologically in somatic evolution in the normal colon. The ERBB2 and 
ERBB3 mutations that we found may also represent druggable targets. 
Caution should be exercised, however, as not all mutations that confer a selective 
advantage in normal mucosa need promote cancer development. Though STAG2 loss confers a 
selective advantage in normal colon (Results Chapter 2 section I.5. and R.4.), it is rare in colon 
cancers. Similarly, in the skin and oesophagus, NOTCH family mutations are, if anything, more 
frequent in normal epithelia than in the cancers that derive from them (Martincorena et al. 2015, 
Inigo Martincorena personal communication). It seems, therefore, that some mutations provide a 
selective advantage without conferring the hallmarks of cancer (Hanahan and Weinberg 2000). In 
the colon, where the progression to malignancy is well described, a distinction could be drawn 
between potentially innocuous mutations and those that actually cause cancer by repeating the 
experiment along the adenoma carcinoma sequence. 
Although the frequency of driver mutations per colon is high, the frequency of driver 
mutations per crypt is low, certainly in comparison to skin (30% of cells, (Martincorena et al. 
2015)), oesophagus (40% of cells, Inigo Martincorena personal communication). This is despite 
the fact that the incidence of colon cancer is similar to that of oesophageal (5% and 1% lifetime 
risk respectively). We speculate that the difference in driver frequencies between these tissues is 
due in part to the modular structure of glandular epithelium, which determines the strength of 
selection within the crypt and prevents clonal expansions beyond it (General Introduction). Indeed, 
it seems that some colorectal cancer driver mutations promote crypt fission (Results Chapter 2 
section I.5.b.), allowing mutant stem cells to escape the constraint of the gland. Two of the 14 
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driver mutations that we observed were associated with crypt fission events. Recently, somatic 
driver mutations were found at a high frequency in endometrial glands (Suda et al. 2018). PIK3CA 
mutations were reported in 20% of glands, although not all of these need be driver mutations. 
Endometrium may represent an unusual glandular tissue in that it is shed and regenerated on a 
monthly basis during reproductive life. This might provide opportunities for glands harbouring 
mutant stem cells to fission and colonise the epithelium more effectively than in the colon. The 
larger size of endometrial glands, if coupled to a larger number of stem cells per gland, may also 
provide greater opportunities for stem cells that have acquired driver mutations to colonise the 
gland. Further work will be required to establish the frequency of driver mutations in other 
glandular tissues and their basis in terms of the rate of acquisition of somatic mutations, their 
selective advantage, and the constraints on clonal expansion.  
 
 
1.b.ii. Mutational signatures 
 
 We observe a surprising diversity of mutational processes active across the normal colons 
of different people. Many of these processes had previously been reported, but the size of our 
cohort and the low complexity of normal genomes allowed us to investigate how their rates vary 
across and within different people and reveal differences between sites in the colon. Intriguingly, 
rates of common mutational processes were higher on the right side of the colon than on the left, 
which is the opposite trend to cancer incidence. We also confirm the finding that mutation rates 
are similar between the colon and the ileum (Blokzijl et al. 2016), despite the former developing 
cancers more frequently. Part of this discrepancy may be due to the number of stem cells per crypt 
and differences in selection pressures.  
 We found signatures that have not been detected in the PCAWG analysis of tens of 
thousands of cancers (Alexandrov et al. 2018). These novel signatures may not have been 
described in cancers simply because they are specific to the colon and fewer colorectal cancer 
genomes have been sequenced than we have sequenced normal crypts. Alternatively, these 
processes may be present in cancer genomes, but obscured by the panoply of additional mutational 
processes. Some novel signatures have an explanation, such as SBSN1 which is found in a patient 
who had been exposed to a cocktail of chemotherapies. It is sobering that chemotherapy could 
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cause so many mutations all around the colon. Nevertheless, during this patient’s colonoscopy, 
which occurred 17 years after his first chemotherapy, only one adenocarcinoma and one adenoma 
were found, which is not a particularly rare finding in a 66 year-old man. Furthermore, although 
the increase in mutations is likely to have affected many other tissues too, this individual survived 
for 19 years after his first chemotherapy. Some signatures were of unknown cause, such as SBSN2 
and SBSN3. These seem to be active early in life, and their features suggest that they are caused 
by extrinsic mutational processes. They warrant further investigation as they may represent 
preventable exposures that account for thousands of somatic mutations in a high proportion of 
people. 
 A comparison of the mutational processes in tumours and normal tissues reveals that the 
process of transformation is associated with both an increase in the rate of normal mutational 
processes and the acquisition of additional ones, even in non-hypermutated cancers. Ostensibly, 
they allow an accelerated evolution of the cancer and contribute to the subclonal diversity within 
the tumour that allows some cells to survive chemotherapy. The origin of many of these aberrant 
mutational processes is unknown; one can hope that the identification of their aetiologies might 
indicate ways to intervene in tumour evolution. 
 
 
2. A comparison of the somatic evolution of blood and colon 
 
A brief comparison of blood and colon highlights the diversity of the forces that govern 
somatic evolution across the human body.  
Stem cell numbers appear to be quite different between the two tissues. Assuming seven 
functional stem cells per crypt and 15 million crypts per colon, there are approximately 100 million 
stem cells per human colon. This is 1,000 times larger than our estimate of the number of active 
blood stem cells. This is a striking difference given that the number of mature blood cells produced 
per day is larger than the number of colonocytes. Presumably, the optimal number of stem cells 
per tissue has been determined over the course of species evolution in part by balancing the 
requirement to produce large numbers of differentiated cells against the risk of malignancy. Why, 
then, should there be so many more colorectal stem cells than blood stem cells? We speculate that 
 202
the colon can have far more stem cells than blood without a substantially increased cancer risk5 
because of the organisation of colonic stem cells into crypts, which reduces the effect of mutations 
that confer a selective advantage (General introduction, section 3.c.). We might predict from this 
that most mutations that are known to cause colorectal cancers confer a stronger selective 
advantage than those that are known to cause blood cancers, since even a weak driver mutation 
can, over time, sweep through the relatively unstructured blood stem cell pool. The presence of 
common and indolent blood clones that rarely (or, at least, slowly) progress to malignancy supports 
this view. Recent evidence indicates that clonal haematopoiesis is likely to be responsible for age-
related morbidities beyond cancer (General Introduction, section 4). The very liquidity of blood 
and the recirculation of blood stem cells, which must limit architectural controls on clonal 
competition, can perhaps be considered to be partly responsible for these diseases. 
 Mutation burdens and processes are different across the two tissues, as a colonic stem cell 
has approximately three times as many mutations as a blood stem cell of the same age. Although 
only 140 blood stem cells from one individual were sequenced, it seems that there is more 
variability in the mutational processes and mutation burden across the colon than in blood. Some 
of the sporadic mutational processes in the colon are likely to be caused by mutagens, a likely 
corollary of the exposure of intestinal stem cells to the luminal contents of microflora and dietary 
carcinogens. Blood stem cells, in contrast, are maintained in a more homogeneous environment. 
 Both variation and selection are therefore different in blood and colon, and are likely to 
vary across all tissues. Indeed, cancers from different organs have a different incidence, repertoire 
of mutational signatures, and predilection for particular driver mutations. Every tissue will have to 
be studied in order to build up a holistic view of somatic evolution across the human body. 
 
 
3. Perspective on managing the diseases of somatic evolution  
  
Somatic evolution is inevitable in a multicellular organism with a long lifespan and 
imperfect DNA replication and repair. Nonetheless, an understanding of the forces of variation 
                                                 
5 Colorectal cancer incidence is approximately four times that of all leukaemias combined (Cancer Research 
UK), but this excess is probably largely a result of recent dietary changes (chapter 2, section I.3.), and the 
disease mostly affects the elderly. Throughout the course of much of human evolution it seems probable 
that colorectal cancers were not a significantly more frequent cause of premature death than leukaemias. 
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and selection in each tissue provides clues as to how we can manage the diseases that stem from 
it.  
 First, the description of mutational signatures across tissues and the identification of their 
causes may provide opportunities to decrease the mutation rate. Extrinsic mutagens may be 
avoided, and protective drugs may be discovered. For example, low-dose aspirin decreases the risk 
of bowel cancer (Brenner et al. 2014), and it has been suggested that this effect of non-steroidals 
on cancer incidence may be through reducing the mutation rate (Kostadinov et al. 2013). Studying 
the mutational signatures of normal colonic crypts of those who have and have not taken aspirin 
would reveal whether or not this was the case. Some mutational processes, such as polymerase 
slippage in normal DNA replication, will always, however, be unavoidable. Measuring a person’s 
normal mutation rate may allow patient stratification: those with higher mutation rates might 
receive more regular screening tests than those with lower ones.  
 Second, clonal dynamics might be monitored. It has recently been shown that it is possible 
to predict which patients with clonal haematopoiesis are at high risk of progression to acute 
myeloid leukaemia (Abelson et al. 2018). By developing a good understanding of healthy clonal 
dynamics, it will be possible to detect a departure from normality and quantify the risk of 
progression to malignancy or another disease. This would be easiest in blood, but one can imagine 
that a similar approach might be possible for other tissues, such as through circulating DNA (Wan 
et al. 2017) or other methods of randomly sampling epithelium (Lao-Sirieix and Fitzgerald 2012).  
This could inform risk stratification and treatment. 
 Finally, as discussed above, judicious ‘clonal purging’ of mutations associated with a high 
risk of progression might remove clones early, before they can grow large enough that they contain 
sufficient genetic diversity to be resistant to drugs.  
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4. Conclusion 
 
It is interesting to contemplate an entangled bank, clothed with many plants of many kinds, with 
birds singing on the bushes, with various insects flitting about, and with worms crawling through 
the damp earth, and to reflect that these elaborately constructed forms, so different from each other, 
and dependent on each other in so complex a manner have all been produced by laws acting around 
us. These laws, taken in the largest sense, being Growth with Reproduction; Inheritance which is 
almost implied by reproduction; Variability from the indirect and direct action of the external 
conditions of life, and from use and disuse; a Ratio of Increase so high as to lead to a Struggle for 
Life, and as a consequence to Natural Selection, entailing Divergence of Character and the 
Extinction of less-improved forms. 
(Charles Darwin, On the Origin of Species) 
 
 
 A slide of cancer histology presents a comparable richness and diversity to Darwin’s 
entangled bank, but on a different scale: cells acquire mutations, creating diversity, and compete 
with one other. Cancers emerge as a result of this struggle for existence. Darwinian theory can be 
applied to somatic tissues: this requires the integration of the fields of cancer genomics, 
evolutionary biology, population genetics, and cell and developmental biology. It is to be hoped 
that such an approach offers opportunities to extend our understanding of health and disease. 
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ABBREVIATIONS AND ACRONYMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABC 
 
Approximate Bayesian computation 
CMP 
 
Common myeloid progenitor 
CRC 
 
Colorectal cancer 
DBS 
 
Doublet base substitution 
GMP 
 
Granulocyte macrophage progenitor 
HDP 
 
Hierarchical Dirichlet process 
HPC 
 
Haematopoietic progenitor cell 
HSC 
 
Haematopoietic stem cell 
HSPC 
 
Haematopoietic stem or progenitor cell 
ID 
 
Insertion or deletion (indel) 
LCM 
 
Laser capture microdissection 
LOH 
 
Loss of heterozygosity 
MEP 
 
Megakaryocyte erythroid progenitor 
MRCA 
 
Most recent common ancestor 
NNMF 
 
Non-negative matrix factorisation 
PCAWG 
 
Pan cancer analysis of whole genomes 
SBS 
 
Single base substitution 
SV 
 
Structural variant 
TCGA 
 
The Cancer Genome Atlas 
VAF 
 
Variant allele fraction 
WGS Whole genome sequencing 
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APPENDIX A 
 
MYELOID LEUKAEMIA AND CLONAL HAEMATOPOIESIS 
MUTATION HOTSPOT LOCI INCLUDED IN BAIT-SET FOR 
TARGETED SEQUENCING OF PERIPHERAL BLOOD 
 
 
Gene Mutation Position 
NRAS Q61 1:115256530-115256531 
NRAS G12 1:115258748-115258748 
CD58 G210 1:117078587-117078587 
GNB1 K57 1:1747229-1747229 
MPL W515 1:43815009-43815009 
CBL Y371 11:119148892-119148892 
CBL C381 11:119148922-119148922 
CBL R420 11:119149251-119149251 
PTPN11 A72 12:112888199-112888200 
PTPN11 G503 12:112926888-112926888 
KRAS G12 12:25398285-25398285 
FLT3 D835 13:28592642-28592642 
FLT3 N676 13:28602341-28602341 
IDH2 R172 15:90631839-90631839 
IDH2 R140 15:90631935-90631935 
CREBBP R1446 16:3788618-3788618 
STAT3 D661 17:40474420-40474420 
STAT3 Y640 17:40474482-40474482 
PPM1D S468 17:58740498-58740498 
PPM1D Q520 17:58740655-58740655 
CD79B Y196 17:62006799-62006799 
SRSF2 P95 17:74732960-74732960 
TP53 R273C 17:7577121-7577121 
TP53 R248Q 17:7577539-7577540 
TP53 R175G 17:7578407-7578407 
TP53 H168R 17:7578428-7578428 
RPS15 P131 19:1440415-1440415 
JAK3 R657 19:17945970-17945970 
JAK3 A572 19:17948010-17948010 
JAK3 M511 19:17949108-17949108 
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CNOT3 E20 19:54646887-54646887 
CNOT3 E70 19:54647435-54647435 
SF3B1 K700 2:198266834-198266834 
SF3B1 K666 2:198267361-198267361 
IDH1 R132 2:209113113-209113113 
DNMT3A P904 2:25457177-25457177 
DNMT3A R882 2:25457243-25457243 
DNMT3A W860 2:25458595-25458595 
DNMT3A R771 2:25463182-25463182 
DNMT3A S770 2:25463184-25463184 
DNMT3A F752 2:25463239-25463239 
DNMT3A R749 2:25463248-25463248 
DNMT3A R736 2:25463287-25463287 
DNMT3A F732 2:25463299-25463299 
DNMT3A R729 2:25463308-25463308 
DNMT3A S714 2:25463541-25463541 
DNMT3A I705 2:25463569-25463569 
DNMT3A G699 2:25463587-25463587 
DNMT3A G685 2:25464460-25464460 
DNMT3A R635 2:25466800-25466800 
DNMT3A R598 2:25467083-25467083 
DNMT3A L547 2:25467436-25467436 
DNMT3A G543 2:25467449-25467449 
DNMT3A P385 2:25469614-25469614 
DNMT3A W330 2:25470484-25470484 
DNMT3A R326 2:25470498-25470498 
DNMT3A R320 2:25470516-25470516 
DNMT3A P307 2:25470554-25470554 
ASXL1 R404 20:31021211-31021211 
ASXL1 R417 20:31021250-31021250 
ASXL1 Y591 20:31022288-31022288 
ASXL1 G642 20:31022439-31022439 
ASXL1 R693 20:31022592-31022592 
GNAS R201 20:57484422-57484422 
U2AF1 Q157 21:44514777-44514777 
U2AF1 S34 21:44524456-44524456 
SF3A1 E75 22:30742471-30742471 
EP300 D1399 22:41565529-41565529 
STAG2 R305 23:123184056-123184056 
BCORL1 R784 23:129149098-129149098 
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PHF6 R274 23:133549137-133549137 
STAG1 A116 3:136287655-136287655 
PIK3CA H1047 3:178952086-178952086 
MYD88 L265 3:38182641-38182641 
TET2 R550 4:106156747-106156747 
TET2 Q916 4:106157845-106157845 
TET2 W954 4:106157961-106157961 
TET2 R1261 4:106164914-106164914 
TET2 G1288 4:106180835-106180835 
TET2 Y1337 4:106182972-106182972 
TET2 A1381 4:106190863-106190863 
TET2 R1465 4:106193931-106193931 
TET2 S1486 4:106193995-106193995 
TET2 I1873 4:106197285-106197285 
FBXW7 R505 4:153247289-153247289 
FBXW7 R479 4:153247367-153247367 
FBXW7 R465 4:153249385-153249385 
KIT V559 4:55593610-55593610 
KIT D816 4:55599322-55599322 
NPM1 L287 5:170837543-170837545 
BRAF V600 7:140453137-140453137 
EZH2 Y646 7:148508728-148508728 
CARD11 R1092 7:2946461-2946461 
CARD11 E626 7:2963931-2963931 
CARD11 D401 7:2976811-2976811 
CARD11 D230 7:2979559-2979559 
RAD21 A480 8:117864217-117864217 
JAK2 V617 9:5073772-5073772 
 
 
 
 
 
 
 
 
 
 
 229 
 
APPENDIX B 
 
COLORECTAL CANCER GENES INCLUDED IN BAIT-SET 
FOR TARGETED SEQUENCING OF COLONIC CRYPTS 
 
 
Gene 
ACVR1B 
ACVR2A 
APC 
ARID1A 
ARID2 
ASXL1 
ATM 
ATR 
ATRX 
AXIN2 
BCOR 
BRAF 
BRCA2 
CARD11 
CBL 
CDC73 
CDH1 
CDK12 
CREBBP 
CTNNB1 
EGFR 
ELF3 
EP300 
ERBB2 
ERBB3 
EZH2 
AMER1 
FBXW7 
FGFR1 
FGFR2 
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FLT1 
GATA3 
GNAS 
H3F3A 
H3F3B 
JAK2 
KDM6A 
KDR 
KIT 
KRAS 
MET 
MGA 
MLH1 
KMT2D 
KMT2C 
MSH2 
MSH6 
NF1 
NF2 
NRAS 
PDGFRA 
PIK3CA 
PIK3R1 
POLE 
PTCH1 
PTEN 
PTPN11 
RB1 
RBM10 
RET 
RNF43 
SETD2 
SMAD2 
SMAD4 
SOX9 
STAG2 
STK11 
TBX3 
TCF7L2 
TGFBR2 
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TP53 
TSHR 
VHL 
WT1 
AKT1 
AXIN1 
B2M 
CDKN1B 
CSF1R 
CUX1 
GRIN2A 
MAP2K1 
MAP2K4 
MAX 
QKI 
RAD21 
ROBO2 
SRC 
TBL1XR1 
UBR5 
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APPENDIX C 
 
CHARACTERISTICS OF INFORMATIVE CRYPTS 
 
crypt site patient sex age VAF Depth cancer.pt 
HLS_1C_30_B5 Right HLS female 60 0.44 12 No 
HLS_1C_30_D5 Right HLS female 60 0.41 10 No 
HLS_1C_30_G5 Right HLS female 60 0.43 12 No 
HLS_1C_30_H5 Right HLS female 60 0.45 9 No 
HLS_2C_30_D6 Right HLS female 60 0.46 8 No 
HLS_2C_30_E6 Right HLS female 60 0.45 9 No 
PD28690bx_2_a5 Right PD28690 male 79 0.4 17 No 
PD28690bx_2_d5 Right PD28690 male 79 0.44 18 No 
PD28690cb_2_g1 Transverse PD28690 male 79 0.38 17 No 
PD28690cb_2_g3 Transverse PD28690 male 79 0.44 16 No 
PD28690cb_2_h1 Transverse PD28690 male 79 0.33 17 No 
PD28690cb_2_h3 Transverse PD28690 male 79 0.42 19 No 
PD34199a_c17 Right PD34199 male 67 0.42 19 No 
PD34199a_c22 Right PD34199 male 67 0.32 16 No 
PD34199a_c27 Right PD34199 male 67 0.39 17 No 
PD34199a_c28 Right PD34199 male 67 0.31 18 No 
PD34199a_c3 Right PD34199 male 67 0.38 19 No 
PD34199a_c31 Right PD34199 male 67 0.36 18 No 
PD34199a_c5 Right PD34199 male 67 0.33 19 No 
PD34199a_c7 Right PD34199 male 67 0.38 19 No 
PD34199a_s13 Left PD34199 male 67 0.4 18 No 
PD34199a_s16 Left PD34199 male 67 0.32 18 No 
PD34199a_s2 Left PD34199 male 67 0.38 18 No 
PD34199a_s27 Left PD34199 male 67 0.32 17 No 
PD34199a_s31 Left PD34199 male 67 0.4 16 No 
PD34199a_s4 Left PD34199 male 67 0.38 18 No 
PD34199a_t14 Transverse PD34199 male 67 0.36 20 No 
PD34199a_t16 Transverse PD34199 male 67 0.42 17 No 
PD34199a_t18 Transverse PD34199 male 67 0.41 18 No 
PD34199a_t22 Transverse PD34199 male 67 0.37 19 No 
PD34199a_t24 Transverse PD34199 male 67 0.42 17 No 
PD34199a_t28 Transverse PD34199 male 67 0.35 17 No 
PD34199a_t31 Transverse PD34199 male 67 0.4 18 No 
 233 
PD34200a_c10 Right PD34200 male 54 0.43 17 No 
PD34200a_c14 Right PD34200 male 54 0.47 14 No 
PD34200a_c15 Right PD34200 male 54 0.46 16 No 
PD34200a_c17 Right PD34200 male 54 0.46 17 No 
PD34200a_c19 Right PD34200 male 54 0.43 16 No 
PD34200a_c23 Right PD34200 male 54 0.45 17 No 
PD34200a_c24 Right PD34200 male 54 0.46 18 No 
PD34200a_c26 Right PD34200 male 54 0.42 19 No 
PD34200a_c31 Right PD34200 male 54 0.44 19 No 
PD34200a_c32 Right PD34200 male 54 0.44 18 No 
PD34200a_c33 Right PD34200 male 54 0.47 17.5 No 
PD34200a_c35 Right PD34200 male 54 0.46 15 No 
PD34200a_c37 Right PD34200 male 54 0.45 17 No 
PD34200a_c41 Right PD34200 male 54 0.39 17 No 
PD34200a_c42 Right PD34200 male 54 0.47 17 No 
PD34200a_c43 Right PD34200 male 54 0.44 17 No 
PD34200a_c47 Right PD34200 male 54 0.43 17 No 
PD34200a_c5 Right PD34200 male 54 0.44 17 No 
PD34200a_c7 Right PD34200 male 54 0.42 16 No 
PD34200a_c8 Right PD34200 male 54 0.42 15 No 
PD34200a_i21 Ileum PD34200 male 54 0.38 16 No 
PD34200a_i22 Ileum PD34200 male 54 0.43 15 No 
PD34200a_i33 Ileum PD34200 male 54 0.46 16 No 
PD34200a_i36 Ileum PD34200 male 54 0.43 17 No 
PD34200a_i54 Ileum PD34200 male 54 0.3 17 No 
PD34200a_s10 Left PD34200 male 54 0.41 17 No 
PD34200a_s17 Left PD34200 male 54 0.35 21 No 
PD34200a_s18 Left PD34200 male 54 0.33 20 No 
PD34200a_s2 Left PD34200 male 54 0.36 16 No 
PD34200a_s20 Left PD34200 male 54 0.38 18 No 
PD34200a_s22 Left PD34200 male 54 0.35 19 No 
PD34200a_s27 Left PD34200 male 54 0.33 19 No 
PD34200a_s29 Left PD34200 male 54 0.38 20 No 
PD34200a_s3 Left PD34200 male 54 0.4 18 No 
PD34200a_s4 Left PD34200 male 54 0.37 17 No 
PD34200a_s8 Left PD34200 male 54 0.41 18 No 
PD34200a_t12 Transverse PD34200 male 54 0.41 15 No 
PD34200a_t14 Transverse PD34200 male 54 0.41 20 No 
PD34200a_t15 Transverse PD34200 male 54 0.42 20 No 
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PD34200a_t16 Transverse PD34200 male 54 0.43 18 No 
PD34200a_t20 Transverse PD34200 male 54 0.33 21 No 
PD34200a_t23 Transverse PD34200 male 54 0.41 20 No 
PD34200a_t27 Transverse PD34200 male 54 0.41 17 No 
PD34200a_t28 Transverse PD34200 male 54 0.38 19 No 
PD34200a_t29 Transverse PD34200 male 54 0.39 18 No 
PD34200a_t3 Transverse PD34200 male 54 0.4 18 No 
PD34200a_t33 Transverse PD34200 male 54 0.42 21 No 
PD34200a_t37 Transverse PD34200 male 54 0.39 21 No 
PD34200a_t6 Transverse PD34200 male 54 0.41 18 No 
PD34201a_c1 Right PD34201 male 38 0.42 15 No 
PD34201a_c10 Right PD34201 male 38 0.4 17 No 
PD34201a_c18 Right PD34201 male 38 0.41 16 No 
PD34201a_c20 Right PD34201 male 38 0.4 15 No 
PD34201a_c22 Right PD34201 male 38 0.4 18 No 
PD34201a_c25 Right PD34201 male 38 0.41 17 No 
PD34201a_c27 Right PD34201 male 38 0.35 16 No 
PD34201a_c32 Right PD34201 male 38 0.36 16 No 
PD34201a_c35 Right PD34201 male 38 0.41 16 No 
PD34201a_c38 Right PD34201 male 38 0.39 15 No 
PD34201a_c4 Right PD34201 male 38 0.37 17 No 
PD34201a_c40 Right PD34201 male 38 0.38 18 No 
PD34201a_c41 Right PD34201 male 38 0.35 16 No 
PD34201a_c42 Right PD34201 male 38 0.42 16 No 
PD34201a_c44 Right PD34201 male 38 0.44 17 No 
PD34201a_c48 Right PD34201 male 38 0.36 18 No 
PD34201a_s1 Left PD34201 male 38 0.36 15 No 
PD34201a_s10 Left PD34201 male 38 0.36 15 No 
PD34201a_s11 Left PD34201 male 38 0.35 15 No 
PD34201a_s15 Left PD34201 male 38 0.36 19 No 
PD34201a_s18 Left PD34201 male 38 0.41 17 No 
PD34201a_s2 Left PD34201 male 38 0.4 17 No 
PD34201a_s20 Left PD34201 male 38 0.38 16 No 
PD34201a_s22 Left PD34201 male 38 0.32 19 No 
PD34201a_s24 Left PD34201 male 38 0.36 17 No 
PD34201a_s28 Left PD34201 male 38 0.39 14 No 
PD34201a_s31 Left PD34201 male 38 0.39 24 No 
PD34201a_s36 Left PD34201 male 38 0.38 17 No 
PD34201a_s4 Left PD34201 male 38 0.36 18 No 
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PD34201a_s42 Left PD34201 male 38 0.45 16 No 
PD34201a_s43 Left PD34201 male 38 0.39 18 No 
PD34201a_s44 Left PD34201 male 38 0.37 22 No 
PD34201a_s45 Left PD34201 male 38 0.39 20 No 
PD34201a_s47 Left PD34201 male 38 0.42 19 No 
PD34201a_s6 Left PD34201 male 38 0.43 17 No 
PD34201a_s7 Left PD34201 male 38 0.39 20 No 
PD34201a_t18 Transverse PD34201 male 38 0.42 17 No 
PD34201a_t19 Transverse PD34201 male 38 0.46 15 No 
PD34201a_t20 Transverse PD34201 male 38 0.43 16 No 
PD34201a_t21 Transverse PD34201 male 38 0.41 18 No 
PD34201a_t22 Transverse PD34201 male 38 0.43 18 No 
PD34201a_t23 Transverse PD34201 male 38 0.41 18 No 
PD34201a_t28 Transverse PD34201 male 38 0.42 19 No 
PD34201a_t3 Transverse PD34201 male 38 0.45 17 No 
PD34201a_t30 Transverse PD34201 male 38 0.41 19 No 
PD34201a_t31 Transverse PD34201 male 38 0.43 17 No 
PD34201a_t32 Transverse PD34201 male 38 0.4 14 No 
PD34201a_t34 Transverse PD34201 male 38 0.41 19 No 
PD34201a_t35 Transverse PD34201 male 38 0.43 18 No 
PD34201a_t39 Transverse PD34201 male 38 0.4 21 No 
PD34201a_t41 Transverse PD34201 male 38 0.4 18 No 
PD34201a_t42 Transverse PD34201 male 38 0.43 17 No 
PD34201a_t44 Transverse PD34201 male 38 0.42 19 No 
PD34201a_t45 Transverse PD34201 male 38 0.4 18 No 
PD34201a_t46 Transverse PD34201 male 38 0.41 19 No 
PD34201a_t8 Transverse PD34201 male 38 0.44 17 No 
PD34202a_s12 Left PD34202 male 13 0.35 18 No 
PD34202a_s15 Left PD34202 male 13 0.31 20 No 
PD34202a_s27 Left PD34202 male 13 0.36 12 No 
PD34202a_s41 Left PD34202 male 13 0.38 13 No 
PD34202a_s43 Left PD34202 male 13 0.3 17 No 
PD34202a_s9 Left PD34202 male 13 0.38 16 No 
PD36719a_lo005 Left OO13 male 60 0.42 12 No 
PD36719a_lo008 Left OO13 male 60 0.38 15 No 
PD36719a_lo018 Right OO13 male 60 0.42 20 No 
PD36719a_lo022 Right OO13 male 60 0.42 21 No 
PD36719a_lo034 Transverse OO13 male 60 0.47 13 No 
PD36719a_lo048 Transverse OO13 male 60 0.37 19 No 
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PD36719a_lo049 Left OO13 male 60 0.385 13 No 
PD36719a_lo066 Right OO13 male 60 0.45 13 No 
PD36719a_lo072 Right OO13 male 60 0.44 12 No 
PD36813aa Transverse OO94 female 66 0.46 12 No 
PD36813aa11 Transverse OO94 female 66 0.45 14 No 
PD36813aa12 Transverse OO94 female 66 0.36 17 No 
PD36813aa16 Transverse OO94 female 66 0.35 16 No 
PD36813aa2 Transverse OO94 female 66 0.4 14 No 
PD36813aa7 Transverse OO94 female 66 0.33 15 No 
PD36813ab10 Transverse OO99 male 66 0.39 18 No 
PD36813ab4 Transverse OO99 male 66 0.41 15 No 
PD36813ab5 Transverse OO99 male 66 0.47 15 No 
PD36813ac15 Transverse O251 female 71 0.43 18 No 
PD36813ac18 Transverse O251 female 71 0.39 18 No 
PD36813ac2 Left O251 female 71 0.43 31 No 
PD36813ac4 Left O251 female 71 0.43 28 No 
PD36813ac7 Left O251 female 71 0.4 31 No 
PD36813ad17 Transverse O189 female 62 0.44 22 No 
PD36813ad2 Left O189 female 62 0.38 33 No 
PD36813ad8 Transverse O189 female 62 0.44 17 No 
PD36813ad9 Transverse O189 female 62 0.43 18 No 
PD36813ae Transverse O208 female 68 0.36 15 No 
PD36813ae3 Transverse O208 female 68 0.38 16 No 
PD36813ae7 Transverse O208 female 68 0.37 17 No 
PD36813b4 Right O251 female 71 0.45 12 No 
PD36813b5 Right O251 female 71 0.46 13 No 
PD36813b6 Right O251 female 71 0.44 13 No 
PD36813c Right O208 female 68 0.44 13 No 
PD36813c2 Right O208 female 68 0.45 16 No 
PD36813c3 Right O208 female 68 0.45 13 No 
PD36813d3 Right O189 female 62 0.47 14 No 
PD36813d5 Right O189 female 62 0.47 14 No 
PD36813e Right O187 female 60 0.47 14 No 
PD36813e5 Right O187 female 60 0.43 14 No 
PD36813e6 Right O187 female 60 0.47 14 No 
PD36813g2 Right O162 male 72 0.39 15 No 
PD36813g4 Right O162 male 72 0.42 18 No 
PD36813h Right O132 female 67 0.47 14 No 
PD36813h3 Right O132 female 67 0.45 14 No 
 237 
PD36813h5 Right O132 female 67 0.47 15 No 
PD36813i Right OO99 male 66 0.45 16 No 
PD36813i4 Right OO99 male 66 0.44 13 No 
PD36813i6 Right OO99 male 66 0.48 14 No 
PD36813j Right OO94 female 66 0.46 12 No 
PD36813j3 Right OO94 female 66 0.44 12 No 
PD36813j6 Right OO94 female 66 0.5 11 No 
PD36813k Right OO82 female 64 0.42 16 No 
PD36813k3 Right OO82 female 64 0.41 17 No 
PD36813k5 Right OO82 female 64 0.44 16 No 
PD36813l Right OO35 male 66 0.41 17 No 
PD36813l7 Right OO35 male 66 0.46 13 No 
PD36813l8 Right OO35 male 66 0.47 15 No 
PD36813m3 Right OO23 male 66 0.46 14 No 
PD36813m5 Right OO23 male 66 0.44 15 No 
PD36813m8 Right OO23 male 66 0.33 17 No 
PD36813n Left OO23 male 66 0.44 16 No 
PD36813o2 Left OO82 female 64 0.3 17 No 
PD36813o9 Left OO82 female 64 0.4 17 No 
PD36813p Left OO94 female 66 0.43 17 No 
PD36813q11 Left OO99 male 66 0.35 17 No 
PD36813q14 Left OO99 male 66 0.38 17 No 
PD36813r12 Left O132 female 67 0.46 13 No 
PD36813r14 Left O132 female 67 0.44 16 No 
PD36813s12 Left O162 male 72 0.31 19 No 
PD36813t20 Left O187 female 60 0.39 15 No 
PD36813u2 Transverse O132 female 67 0.43 20 No 
PD36813v4 Transverse O162 male 72 0.32 21 No 
PD36813x15 Transverse O187 female 60 0.44 18 No 
PD36813x16 Transverse O187 female 60 0.46 18 No 
PD36813y13 Transverse OO39 male 68 0.42 16 No 
PD36813y15 Transverse OO39 male 68 0.47 16 No 
PD36813y6 Transverse OO39 male 68 0.47 14 No 
PD36813y7 Transverse OO39 male 68 0.5 12 No 
PD36813z15 Transverse OO82 female 64 0.42 16 No 
PD36813z4 Transverse OO82 female 64 0.4 15 No 
PD36813z5 Transverse OO82 female 64 0.43 15 No 
PD36813z6 Transverse OO82 female 64 0.45 15 No 
PD36813z7 Transverse OO82 female 64 0.35 15 No 
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PD36813z8 Transverse OO82 female 64 0.33 16 No 
PD36814b2 Right OOO7 male 64 0.38 11 Yes 
PD36814b7 Right OOO7 male 64 0.46 15 Yes 
PD36814c2 Right OOO8 female 64 0.45 13 Yes 
PD36814c3 Right OOO8 female 64 0.46 13 Yes 
PD36814c4 Right OOO8 female 64 0.45 11 Yes 
PD36814d5 Right OO10 female 60 0.45 13 Yes 
PD36814d6 Right OO10 female 60 0.43 13 Yes 
PD36814d7 Right OO10 female 60 0.45 11 Yes 
PD36814d8 Right OO10 female 60 0.46 13 Yes 
PD36814e5 Right O174 female 66 0.41 14 Yes 
PD36814e6 Right O174 female 66 0.4 14 Yes 
PD36814e7 Right O174 female 66 0.45 13 Yes 
PD36814e8 Right O174 female 66 0.45 13 Yes 
PD36814f4 Right O176 female 68 0.46 13 Yes 
PD36814f8 Right O176 female 68 0.45 14 Yes 
PD36814g4 Right O193 female 71 0.43 12 Yes 
PD36814g7 Right O193 female 71 0.47 14 Yes 
PD36814g8 Right O193 female 71 0.45 14 Yes 
PD36814h2 Right O225 male 66 0.5 9 Yes 
PD36814h4 Right O225 male 66 0.45 12 Yes 
PD36814i Right O232 male 62 0.47 13 Yes 
PD36814i3 Right O232 male 62 0.45 12 Yes 
PD36814i4 Right O232 male 62 0.46 13 Yes 
PD36814k2 Right O244 male 68 0.45 16 Yes 
PD36814k6 Right O244 male 68 0.47 14 Yes 
PD36814k7 Right O244 male 68 0.47 14 Yes 
PD36814k8 Right O244 male 68 0.5 14 Yes 
PD36814l2 Right O333 female 68 0.5 13 Yes 
PD36814l4 Right O333 female 68 0.47 10 Yes 
PD36814l7 Right O333 female 68 0.47 13 Yes 
PD36814l8 Right O333 female 68 0.5 13 Yes 
PD36814m5 Right O337 male 66 0.45 10 Yes 
PD36814m8 Right O337 male 66 0.45 11 Yes 
PD37226b5 Left OOO8 female 64 0.4 12 Yes 
PD37226b6 Left OOO8 female 64 0.39 12 Yes 
PD37226c5 Left OO10 female 60 0.45 10 Yes 
PD37226c6 Left OO10 female 60 0.46 13 Yes 
PD37226c7 Left OO10 female 60 0.45 15 Yes 
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PD37226c8 Left OO10 female 60 0.44 12 Yes 
PD37226d4 Left O174 female 66 0.36 12 Yes 
PD37226d5 Left O174 female 66 0.33 11 Yes 
PD37226d6 Left O174 female 66 0.38 11 Yes 
PD37226e4 Left O176 female 68 0.39 12 Yes 
PD37226e5 Left O176 female 68 0.42 12 Yes 
PD37226f5 Left O193 female 71 0.42 11 Yes 
PD37226f6 Left O193 female 71 0.38 11 Yes 
PD37226f7 Left O193 female 71 0.33 14 Yes 
PD37226g5 Left O225 male 66 0.41 10 Yes 
PD37226g6 Left O225 male 66 0.44 12 Yes 
PD37226g7 Left O225 male 66 0.42 12 Yes 
PD37226h4 Left O232 male 62 0.47 12 Yes 
PD37226h7 Left O232 male 62 0.43 16 Yes 
PD37226h8 Left O232 male 62 0.38 15 Yes 
PD37226i5 Left O333 female 68 0.45 11 Yes 
PD37226i6 Left O333 female 68 0.42 12 Yes 
PD37226i7 Left O333 female 68 0.43 13 Yes 
PD37226i8 Left O333 female 68 0.38 12 Yes 
PD37226j4 Left O337 male 66 0.31 12 Yes 
PD37226j5 Left O337 male 66 0.38 13 Yes 
PD37226j6 Left O337 male 66 0.45 11 Yes 
PD37226j7 Left O337 male 66 0.47 13 Yes 
PD37226j8 Left O337 male 66 0.38 16 Yes 
PD37226k2 Left O340 male 72 0.4 15 Yes 
PD37226k5 Left O340 male 72 0.37 15 Yes 
PD37226k6 Left O340 male 72 0.38 14 Yes 
PD37226k8 Left O340 male 72 0.37 17 Yes 
PD37226l5 Left O395 male 60 0.36 14 Yes 
PD37226l6 Left O395 male 60 0.42 14 Yes 
PD37226l7 Left O395 male 60 0.4 12 Yes 
PD37226l8 Left O395 male 60 0.4 14 Yes 
PD37226m5 Left O401 male 62 0.41 13 Yes 
PD37226m7 Left O401 male 62 0.42 14 Yes 
PD37226m8 Left O401 male 62 0.4 16 Yes 
PD37226o4 Transverse O337 male 66 0.36 26 Yes 
PD37226o5 Transverse O337 male 66 0.44 23 Yes 
PD37226p7 Left O337 male 66 0.48 19 Yes 
PD37265b Transverse OOO7 male 64 0.47 14 Yes 
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PD37265b7 Transverse OOO7 male 64 0.5 11 Yes 
PD37265c2 Transverse OOO8 female 64 0.42 11 Yes 
PD37265c3 Transverse OOO8 female 64 0.43 13 Yes 
PD37265c5 Transverse OOO8 female 64 0.45 16 Yes 
PD37265d Transverse OO10 female 60 0.44 14 Yes 
PD37265d5 Transverse OO10 female 60 0.44 12 Yes 
PD37265d8 Transverse OO10 female 60 0.5 11 Yes 
PD37265e Transverse O174 female 66 0.43 14 Yes 
PD37265e5 Transverse O174 female 66 0.45 13 Yes 
PD37265f Transverse O176 female 68 0.4 13 Yes 
PD37265f2 Transverse O176 female 68 0.45 13 Yes 
PD37265f4 Transverse O176 female 68 0.46 12 Yes 
PD37265g6 Transverse O193 female 71 0.42 14 Yes 
PD37265g7 Transverse O193 female 71 0.38 14 Yes 
PD37265g8 Transverse O193 female 71 0.42 12 Yes 
PD37265h5 Transverse O225 male 66 0.41 14 Yes 
PD37265h6 Transverse O225 male 66 0.44 14 Yes 
PD37265h8 Transverse O225 male 66 0.45 13 Yes 
PD37265i2 Transverse O232 male 62 0.46 10 Yes 
PD37265i7 Transverse O232 male 62 0.43 12 Yes 
PD37265k Transverse O244 male 68 0.46 10 Yes 
PD37265k2 Transverse O244 male 68 0.45 10 Yes 
PD37265k3 Transverse O244 male 68 0.43 11 Yes 
PD37265l2 Transverse O333 female 68 0.46 12 Yes 
PD37265l6 Transverse O333 female 68 0.46 11 Yes 
PD37265m3 Transverse O337 male 66 0.37 12 Yes 
PD37265m4 Transverse O337 male 66 0.42 12 Yes 
PD37266b_lo0004 Left PD37266 female 67 0.35 20 No 
PD37266b_lo0005 Left PD37266 female 67 0.42 19 No 
PD37266b_lo0006 Left PD37266 female 67 0.38 18 No 
PD37266b_lo0007 Left PD37266 female 67 0.31 20 No 
PD37266b_lo0008 Left PD37266 female 67 0.39 22 No 
PD37266b_lo0017 Left PD37266 female 67 0.46 16 No 
PD37266b_lo0023 Left PD37266 female 67 0.38 13 No 
PD37266c_lo0010 Ileum PD37266 female 67 0.32 18 No 
PD37266c_lo0012 Ileum PD37266 female 67 0.41 19 No 
PD37266c_lo0014 Ileum PD37266 female 67 0.36 18 No 
PD37266c_lo0016 Ileum PD37266 female 67 0.43 19 No 
PD37266c_lo0018 Ileum PD37266 female 67 0.47 13 No 
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PD37266c_lo0023 Ileum PD37266 female 67 0.47 7 No 
PD37266d_lo0002 Right PD37266 female 67 0.5 8 No 
PD37266d_lo0010 Right PD37266 female 67 0.47 11 No 
PD37266d_lo0012 Right PD37266 female 67 0.4 10 No 
PD37266d_lo0014 Right PD37266 female 67 0.43 11 No 
PD37266e_lo0008 Transverse PD37266 female 67 0.45 19 No 
PD37266e_lo0010 Transverse PD37266 female 67 0.46 7 No 
PD37449c_lo0001 Transverse PD37449 female 36 0.46 17 No 
PD37449c_lo0009 Transverse PD37449 female 36 0.44 18 No 
PD37449c_lo0014 Transverse PD37449 female 36 0.45 19 No 
PD37449c_lo0017 Transverse PD37449 female 36 0.43 16 No 
PD37449d_lo0001 Left PD37449 female 36 0.46 17 No 
PD37449d_lo0002 Left PD37449 female 36 0.44 17 No 
PD37449d_lo0003 Left PD37449 female 36 0.42 19 No 
PD37449d_lo0006 Left PD37449 female 36 0.36 19 No 
PD37449d_lo0011 Left PD37449 female 36 0.43 12 No 
PD37449d_lo0012 Left PD37449 female 36 0.39 9 No 
PD37449d_lo0017 Left PD37449 female 36 0.44 16 No 
PD37449e_lo0001 Right PD37449 female 36 0.45 8 No 
PD37449e_lo0002 Right PD37449 female 36 0.44 18 No 
PD37449e_lo0003 Right PD37449 female 36 0.44 19 No 
PD37449e_lo0004 Right PD37449 female 36 0.41 20 No 
PD37449e_lo0006 Right PD37449 female 36 0.46 7 No 
PD37449e_lo0008 Right PD37449 female 36 0.45 20 No 
PD37449e_lo0010 Right PD37449 female 36 0.42 18 No 
PD37449e_lo0014 Right PD37449 female 36 0.44 20 No 
PD37449e_lo0015 Right PD37449 female 36 0.4 8 No 
PD37449f_lo0002 Ileum PD37449 female 36 0.45 17 No 
PD37449f_lo0006 Ileum PD37449 female 36 0.38 17 No 
PD37449f_lo0008 Ileum PD37449 female 36 0.35 13 No 
PD37449f_lo0010 Ileum PD37449 female 36 0.39 17 No 
PD37449f_lo0011 Ileum PD37449 female 36 0.42 13 No 
PD37449f_lo0016 Ileum PD37449 female 36 0.44 16 No 
PD37449f_lo0017 Ileum PD37449 female 36 0.42 16 No 
PD37449f_lo0019 Ileum PD37449 female 36 0.43 16 No 
PD37449f_lo0022 Ileum PD37449 female 36 0.44 19 No 
PD37449f_lo0023 Ileum PD37449 female 36 0.43 15 No 
PD37457b4 Right O395 male 60 0.31 10 Yes 
PD37457c4 Right O401 male 62 0.46 12 Yes 
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PD37457e6 Right O340 male 72 0.45 14 Yes 
PD37457f4 Transverse O340 male 72 0.43 13 Yes 
PD37457f7 Transverse O340 male 72 0.4 9 Yes 
PD37457g5 Transverse O395 male 60 0.45 13 Yes 
PD37457h2 Transverse O401 male 62 0.4 10 Yes 
PD37457h5 Transverse O401 male 62 0.5 12 Yes 
PD37457i4 Transverse O438 female 62 0.47 13 Yes 
PD37457i5 Transverse O438 female 62 0.5 8 Yes 
PD37457j7 Left O438 female 62 0.33 17 Yes 
PD37457j8 Left O438 female 62 0.47 12 Yes 
PD37509b8 Right 300 female 15 0.48 17 No 
PD37509b9 Right 300 female 15 0.47 15 No 
PD37510b4 Left 312 female 11 0.42 8 No 
PD37510b7 Left 312 female 11 0.4 9 No 
PD37510b8 Left 312 female 11 0.37 12 No 
PD37512a11 Left O311 male 68 0.44 18 No 
PD37512a4 Transverse O311 male 68 0.405 18 No 
PD37512a5 Transverse O311 male 68 0.44 17 No 
PD37512b7 Right O311 male 68 0.47 12 No 
PD37513a13 Left O325 male 62 0.33 14 No 
PD37513a2 Transverse O325 male 62 0.45 16 No 
PD37513a20 Left O325 male 62 0.45 14 No 
PD37513a21 Left O325 male 62 0.45 14 No 
PD37513a3 Transverse O325 male 62 0.44 17 No 
PD37513b5 Right O325 male 62 0.43 7 No 
PD37513b7 Right O325 male 62 0.44 12 No 
PD37513b8 Right O325 male 62 0.45 14 No 
PD37514a Transverse O342 male 62 0.4 17 No 
PD37514a2 Transverse O342 male 62 0.43 16 No 
PD37514a3 Transverse O342 male 62 0.41 16 No 
PD37514b3 Right O342 male 62 0.47 11 No 
PD37514b7 Right O342 male 62 0.41 15 No 
PD37514b8 Right O342 male 62 0.45 9 No 
PD37590b_lo0010 Right PD37590 Female 55 0.45 25 No 
PD37590b_lo0015 Right PD37590 Female 55 0.43 23 No 
PD37590b_lo0018 Right PD37590 Female 55 0.43 32 No 
PD37590b_lo0030 Right PD37590 Female 55 0.34 28 No 
PD37590b_lo0033 Right PD37590 Female 55 0.45 16 No 
PD37590b_lo0041 Right PD37590 Female 55 0.41 22 No 
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PD37590b_lo0051 Right PD37590 Female 55 0.42 25 No 
PD37590b_lo0052 Right PD37590 Female 55 0.36 25 No 
PD37590b_lo0053 Right PD37590 Female 55 0.44 23 No 
PD37590b_lo0058 Right PD37590 Female 55 0.41 24 No 
PD37590b_lo0074 Right PD37590 Female 55 0.45 25 No 
PD37590b_lo0075 Right PD37590 Female 55 0.42 31 No 
PD37590b_lo0090 Right PD37590 Female 55 0.43 33 No 
PD37590b_lo0092 Right PD37590 Female 55 0.45 15 No 
PD37590b_lo0107 Right PD37590 Female 55 0.39 32 No 
PD37590b_lo0116 Transverse PD37590 Female 55 0.43 23 No 
PD37590b_lo0117 Transverse PD37590 Female 55 0.42 18 No 
PD37590c_lo0001 Transverse PD37590 Female 55 0.41 27 No 
PD37590c_lo0005 Transverse PD37590 Female 55 0.41 27 No 
PD37590c_lo0009 Transverse PD37590 Female 55 0.43 20 No 
PD37590c_lo0019 Right PD37590 Female 55 0.46 25 No 
PD37590c_lo0021 Transverse PD37590 Female 55 0.45 26 No 
PD37590c_lo0025 Transverse PD37590 Female 55 0.42 23 No 
PD37590c_lo0032 Transverse PD37590 Female 55 0.44 21 No 
PD37590c_lo0034 Transverse PD37590 Female 55 0.35 28 No 
PD37590c_lo0040 Transverse PD37590 Female 55 0.41 26 No 
PD37590c_lo0048 Transverse PD37590 Female 55 0.41 23 No 
PD37590d_lo0012 Left PD37590 Female 55 0.4 26 No 
 
